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1. Abstract 
 
 
1.1. Zusammenfassung 
Seit ihrer erstmaligen klinischen Zulassung für die Krebsbehandlung Ende der 1990er gelten monoklonale 
Antikörper (mAbs) als einer der erfolgreichsten und vielversprechendsten Behandlungsansätze in der 
Onkologie. mAbs, die gezielt auf tumorassoziierte Antigene (TAA) einwirken, und seit neuerem mAbs, 
welche die durch Checkpoints vermittelte Hemmung der T-Zell-Tumorantwort verhindern, haben sich als 
hinsichtlich der Tumorremission bei Krebspatienten wirksam erwiesen (Carter and Lazar, 2018). Dennoch 
gibt es auch in der Entwicklung von mAbs für die Krebsbehandlung Grenzen und viele mAbs kommen 
aufgrund der niedrigen Zulassungsrate nicht in der klinischen Praxis zur Anwendung (Nelson and Reichert, 
2009; Workman et al., 2017). Nach mehr als 20 Jahren der Entwicklung gibt es noch immer relativ wenige 
tumorassoziierte Antigene (TAA) als Targets für die mAbs-Therapie, die für die klinische Therapie 
zugelassen sind. Daher müssen neue Ansätze und Strategien im Prozess der Selektion von mAbs gefunden 
werden, die zur Ermittlung neuer TAA bzw. besserer, neuartiger mAbs für die Krebstherapie führen können 
(Sánchez-Martín et al., 2015). 
Zahlreiche Publikationen haben in den letzten Jahren gezeigt, dass das Vorliegen von tumorinfiltrierenden 
B-Zellen (TIL-B) in den Tumoren eines Patienten mit einem positiven Prognoseeffekt verbunden ist 
(Wouters and Nelson, 2018). Mehrere Veröffentlichungen deuten zudem darauf hin, dass TIL-B aus 
Patientengewebe eine reichhaltige Quelle für tumorbindende Antikörper sein können (Pavoni et al., 2007; 
Novinger, Ashikaga and Krag, 2015). 
In der hier vorgestellten Studie wurden – soweit uns bekannt erstmalig – TIL-B-Antikörper-Repertoires von 
8 Patienten mit kolorektalem Karzinom genutzt, um 2 Hefe-Fab-Oberflächendisplay-Bibliotheken (κ und λ) 
zu erstellen. Die Evaluierung der Bibliotheken anhand von Durchflusszytometrie-Screening im Hinblick auf 
eine Vielzahl von TAA- und Immun-Checkpoint-Molekülen führte zur Ermittlung mehrerer potenzieller 
Bindungspartner für diese Screeningtargets. Danach erfolgte anhand von Durchflusszytometrie eine 
Sortierung im Hinblick auf 4 Targets: CEACAM5, LRP6, LAG3 und OX40L. Dies erlaubte die Selektion 
spezifischer, aber niedrig-affiner humaner Antikörper für diese Targets. Die weitere Evaluierung der 
Bibliotheken umfasste einen neuartigen Ansatz: Dabei erfolgte ein phänotypisches Screening mithilfe einer 
Hefedisplay-Biopanning-Plattform gegen entsprechende aus kolorektalen Karzinomen abgeleitete Zelllinien 
(HCT 116, HT-29 und SW620). Eine hohe Anreicherung der Hefe-Fab-Oberflächendisplay-
Bindungspartner an den aus kolorektalen Karzinomen abgeleiteten Zellen ließ sich innerhalb von nur 3 
Runden Biopanning beobachten. Mithilfe des Biopanning-Verfahrens isolierte Antikörper (HCT 116, HT-
29) zeigten eine selektive Bindung an ähnlichen Epitopen wie sie auf der Zelloberfläche von HCT116- und 
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HT-29-Zellen vorhanden sind, da diese Antikörper dieselbe schwere Kette aufwiesen, obwohl sie aus zwei 
unterschiedlichen Zelllinien selektiert wurden. Die unterschiedlichen leichten Ketten der isolierten 
Antikörper hatten nachweislich Einfluss auf ihre Affinität. Die weitere Charakterisierung eines der isolierten 
Antikörper (TILB-HCT116-B24) ergab einen EC50-Wert von 569 nM bei Bindung an HCT116. Ein 
Zellbindungsassay anhand von Fluoreszenzmikroskopie mit diesem Antikörper an HCT 116-Zellen und 
normalen Fibroblastenzellen aus dem Colon (CCD-18Co) belegte die spezifische Bindung an HCT 116-
Zellen. 
Soweit uns bekannt ist, ist dies die erste Studie, in der Next-Generation Sequencing (NGS) als 
Hochdurchsatz-Sequenzierung für die aus den TIL-B-Zellen der einzelnen Patienten abgeleiteten Klone im 
Hinblick auf die Fab-Hefeoberflächendisplay-Bibliotheken und die Klone aus der Biopanning-Anreicherung 
eingesetzt wurde. Diese NGS-Daten, die auf der klonalen Frequenzanalyse der schweren und leichten 
Kettensequenzen jedes Patienten basieren, können einen Hinweis auf die klonale Expansion von TIL-B 
geben, die im Tumor der Patienten auftritt. Zudem führte die Kombination von Hochdurchsatz-
Sequenzierung und Hefe-Display-Biopanning-Screening zu einer ähnlich selektiven Anreicherung, wie 
wenn Biopanning der Hefe-Bibliothek gegen die aus kolorektalen Karzinomen abgeleiteten Zelllinien HCT 
116 und HT-29 erfolgte. Hierbei fiel das Biopanning-Ergebnis gegen die aus kolorektalen Karzinomen 
abgeleitete SW620-Zelllinie anders aus: Es ergab andere Klone, was auf eine hochspezifische Selektion 
mithilfe des Biopanning-Prozesses schließen lässt. 
So unterstützt die vorgestellte Studie die Hypothese, dass aus TIL-B abgeleitete Bibliotheken ein Antikörper-
Repertoire enthalten, das vorzugsweise an Krebszellen bindet. Die Hefeoberflächendisplay-Biopanning-
Technologie in Kombination mit Hochdurchsatz-Sequenzierung kann ein wirksames Hilfsmittel für die 
Ermittlung von Tumorantikörper-Therapeutika und möglicherweise für die Identifizierung neuartiger 
Tumor-Antigene darstellen. 
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1.2. Abstract 
Since their first clinical approval for cancer therapy in the late-1990s, monoclonal antibodies (mAbs) are 
considered as one of the most successful and promising therapeutic approaches in oncology. mAbs, which  
target tumor-associated antigens (TAA) and more recently mAbs which  prevent checkpoint-mediated 
inhibition of T cell responses against the tumor, proved to be affective for tumor remission in cancer patients 
(Carter & Lazar, 2018). However, the development of mAbs for cancer therapy still has it’s limitations and 
many mAbs do not arrive to the clinic due to low approval rate (A. L. Nelson & Reichert, 2009; Workman, 
Draetta, Schellens, & Bernards, 2017). Over 20 years of development there are still relatively few tumor-
associated antigens (TAA) for mAbs targeting in oncology that are approved for clinical therapy. This raises 
the need for the development of new approaches and strategies in the mAbs selection process that may result 
in finding new TAA and/or better novel mAbs for cancer therapy (Sánchez-Martín et al., 2015). 
In recent years, it was shown in many reports that the presence of infiltrating B cells (TIL-B) in patient’s 
tumors is associated with positive prognostic effect (Wouters & Nelson, 2018). Moreover, several reports 
indicate that TIL-B from patient’s tissue can be a rich source of tumor-binding antibodies (Novinger, 
Ashikaga, & Krag, 2015; Pavoni et al., 2007) 
In the presented study, to our knowledge for the first time, TIL-B antibody repertoires from 8 colon cancer 
patients were utilized to construct 2 yeast Fab surface display libraries (κ and λ). Evaluation of the libraries 
by flow cytometry screening to a variety of TAA and immune checkpoint molecules, revealed potential 
binders to these screened targets. Subsequent flow cytometry sorting to 4 targets: CEACAM5, LRP6, LAG3 
and OX40L resulted in the selection of specific but low-affinity human antibodies to the targets. Further 
evaluation of the libraries involved a novel approach using phenotypic screening by a yeast display biopanning 
platform against corresponded colon cancer derived cell lines (HCT 116, HT-29 and SW620). High 
enrichment of yeast Fab surface display binders to the colon cancer derived cells was observed within only 3 
rounds of biopanning. Isolated antibodies from the biopanning approach (HCT 116, HT-29) demonstrated a 
selective binding to similar epitopes present on the cell surface of HCT116 and HT-29 cells, as these 
antibodies were found to have the same heavy chain though they were selected on two different cell lines. 
The different light chains in the isolated antibodies were found to influence the antibodies affinity. Further 
characterization of one of the isolated antibodies (TILB-HCT116-B24) indicated an EC50 value of 569nM 
binding to HCT116. A cellular binding assay using fluorescence microscopy with this antibody to HCT 116 
cells and normal colon fibroblast cells (CCD-18Co) showed specific binding to HCT 116 cells. 
 
To our knowledge, this is the first study to use next-generation sequencing (NGS) to provide a high-
throughput sequencing for the clones derived from each patients’ TIL-B cells, for the Fab yeast surface display 
libraries and for the biopanning enrichment clones. This NGS data, based on clonal frequency analysis of 
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each patient’s heavy and light chain sequences, may indicate the clonal expansion of the TIL-B that occurs in 
the patients’ tumor.  Moreover, combining high-throughput sequencing and yeast display biopanning 
screening, demonstrated similar selective enrichment occurred when biopanning the yeast library against 
colorectal derived cell lines HCT116 and HT-29. This was different from the biopanning against the 
metastatic colorectal derived SW620 cell line, which gave different clones, indicating high specific selection 
through the biopanning process. 
Hence, the presented study supports the hypothesis that TIL-B derived libraries contain a repertoire of 
antibodies that can bind preferentially to cancer cells. The yeast surface display biopanning technology 
combined with high-throughput sequencing, could be effective tools for the discovery of antitumor 
antibody therapeutics and possibly for identifying novel tumor antigens. 
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2. Introduction 
 
 
2.1. Role of B cells and antibodies in the immune system 
The immune system is the host defense system of the human body which has a dual function:  the first 
is distinguishing the cells, tissues and organs that are a part of the host body from foreign, “nonself,” 
antigens that might be present. The second is to attack and eliminate those “nonself” invaders, such as 
dangerous bacteria or viruses (Beck & Habicht, 1996). In addition, the immune system can recognize, 
and usually eliminate, “altered self” cells or tissues that have been changed by injury or mutation and 
even to eliminate an initial "tumor" from growing into a clinical cancer by a mechanism determined as 
cancer immunosurveillance (Dunn, Bruce, Ikeda, Old, & Schreiber, 2002).  
The immune system can be divided into two arms of defense: the innate and the adaptive immune 
systems. The innate immune system includes the natural killer cells, mast cells, eosinophils, basophils 
that are leukocytes and the macrophages, neutrophils, and dendritic cells that are phagocytic cells. The 
innate immune system is the first line of defense against many common microorganisms, however, it is 
based on invariant receptors recognizing common features of pathogens and can be evaded or overcome 
by many pathogens. In addition, this early innate response does not lead to immunological memory. In 
contrast, the adaptive immune system has the ability to recognize pathogens specifically and to provide 
enhanced protection against reinfection, based on clonal selection of T-lymphocytes and B- 
lymphocytes which bear antigen-specific receptors. Each T and B lymphocyte carries cell-surface 
receptors of a single specificity, generated by random recombination of variable receptor gene segments 
and the pairing of different variable chains. The main distinctions between B- and T-lymphocyte 
receptors are that the immunoglobulin that serves as the T-cell antigen receptor has a single antigen-
recognition site and is always a cell-surface molecule. In this case cells that differentiated to effector 
cells are able to destroy infected cells or activate other cells of the immune system. B-cell antigen 
receptors have two identical antigen-recognition sites and can be secreted when cells differentiate to 
effector cells, called plasma cells. The secreted B-cell antigen receptor is then called an  antibody 
(Janeway, 2001).  
B cells are generated and start to develop in the bone marrow where they differentiate from primitive 
stem cells to progenitor B cells. Then, they proceed through stages called V(D)J somatic recombination, 
which is marked by the sequential rearrangement of the heavy and light immunoglobulin gene segments 
to generate a diverse repertoire of antigen receptors. In the end of this process, once a light chain gene 
is assembled and a complete IgM isotype molecule is expressed on the cell surface, the cell is defined 
as an immature B cell. Immature B cells then undergo selection for self-tolerance and subsequently for 
the ability to survive in the peripheral lymphoid tissues. B cells that survive in the periphery undergo 
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further differentiation to become mature B cells that express IgD isotype in addition to IgM. These cells, 
also called naïve B cells until they encounter their specific antigen, recirculate through peripheral 
lymphoid tissues. In the germinal centers sites within of the lymph nodes or spleen the mature B cell 
activation occurs, by introduction of the antigen to the B cell receptor. This happens mostly by 
interaction with helper T cells and follicular dendritic cells (FDCs) cells.  In the process of maturation, 
the B cells start to proliferate and coding sequences for the variable regions are modified yet again by 
somatic hypermutation aimed at achieving higher affinity. At this time also a class switch recombination 
to heavy chains constant domain isotypes, IgG, IgA or IgE is carried out by the enzyme activation-
induced cytidine deaminase (AID) (Muramatsu et al., 2000). Finally, differentiation to Plasma B 
antibody secreting cells and to memory B cells occur. high-affinity B cells in the germinal center are 
selected on the basis of antigen engagement initiate the plasma cells differentiation, while subsequent 
helper T cells interaction completes their differentiation, In contrast, memory B cells preferentially 
emerge from a low affinity compartment (Suan, Sundling, & Brink, 2017) 
 
2.1.1. Antibody structure and function 
Antibodies are the secreted form of the B-cell receptor. An antibody is identical to the B-cell receptor 
of the cell that secretes it, except for a small portion of the C-terminus of the heavy-chain constant 
region. In the case of the B-cell receptor the C-terminus is a hydrophobic membrane-anchoring 
sequence, and in the case of antibody it is a hydrophilic sequence that allows secretion. The IgG is the 
class of immunoglobulin characterized by γ heavy chains and it is the most abundant class of 
immunoglobulin found in the plasma (Janeway, 2001). An antibody is a Y-shaped protein with a 
molecular mass of 150 kDa that consists of four polypeptide chains, two identical heavy chains (HC) 
with a molecular weight of 50 kDa each and two identical light chains (LC) of 25 kDa each (Figure 1). 
The heavy chains are linked via disulfide bonds and each side light chain is also linked via a disulfide 
bond with its correspond heavy chain. The polypeptide chains can be divided into functional domains. 
The N-terminus of the heavy chain consists of a variable domain (VH) contain three hypervariable 
regions, known as the complementary determining regions (CDR1, CDR2 and CDR3), which are 
flanked by four more conserved regions, known as framework regions (FR1,FR2,FR3 and FR4). The 
VH is linked to three constant domains (CH1, CH2 and CH2) in the C-terminus while CH1 and CH2 
are linked to each other via a flexible hinge region. The light chain consists of a variable domain (VL) 
with same arrangement of CDRs and frameworks as the VH while here there is only one constant 
domain (CL) that can be discriminated by two different classes, lambda (λ) and kappa (κ). The two 
classes of CL have corresponding distinct gene loci and differentiation occurs at early stages in the bone 
marrow. This is in comparison to the IgG heavy chain’s constant domain (γ) which, as mentioned, 
differentiate in the germinal center during B cell activation. During V(D)J somatic recombination the 
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diversity of variable regions encoded by combinatory design of the genetic locus of variable heavy and 
light chain consisting of germline encoded V for variable, D for diversity (VH only) and J for joining 
gene segments.  
Digestion with the cysteine protease Papain (papaya proteinase I) cleaves an IgG molecule at the N-
terminal side of the disulfide bonds in the hinge region and creates three fragments; two identical Fab 
fragments (Fragment antigen binding) and the Fragment crystallizable (Fc) (Fig 1B). These fragments 
can be determined by their functionality: each Fab fragment forms the antigen binding site and the FC 
portion has the ability to activate a number of immunological pathways. These include complement-
dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). The Fc fragment 
contains the epitopes for the Fcγ receptor (FcγR) which is a protein found on the surface of immune 
cells that binds the Fc domain, and by that facilitates the cytotoxic or phagocytic activity of these cells.  
 
   Figure 1: Antibody structure. 
(A) Crystal structure of IgG1 (from PDB: 1hzh). Surface and cartoon model generated by PyMOL v1.7.6.0 .(B) Schematic 
presentation.  Same colors representing same segments in both presentations. Heavy chains segments: VH (Pink), CH1 (gray), 
CH2 (yellow) and CH3 (purple). Light chains segments: VL (light orange) and CL (deep teal). Heavy chain CH1 and CH2 are 
connected with a flexible region, denoted as hinge which contains two disulfide bonds(s-s) between the two heavy chains. The C-
termini of CL and CH1 are also linked by a disulfide bond. Each variable domain contains three hypervariable regions, named 
complementary determining regions (CDRs) of VH and VL building up six loop structures to form the antigen binding site. The 
Fc is involved in effector site activation of a number of immunological pathways such as ADCC and CDC and by containing 
epitopes for the Fcγ receptor (FcγR). 
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2.2. Monoclonal antibodies in cancer therapy 
It’s been more than a century since the Nobel prize-awarded  Paul Ehrlich had suggested that the 
immune system can prevent tumors growth and that antibodies are in a way “magic bullets” that identify 
their target and can function without harming the whole organism (Strebhardt & Ullrich, 2008). 
Currently oncologists see monoclonal (mAb) based cancer therapies as a vital component of state of the 
art cancer care (Weiner, 2015). In 1975, Köhler and Milstein issued a landmark publication outlining 
how to produce mAbs by fusion of isolated B cells from immunized animals with immortalized 
myeloma cells resulting in a hybrid cell called hybridoma (KÖHLER & MILSTEIN, 1975), a discovery 
that led to a Nobel Prize 10 years later. A year after (1986) Muromonab (Orthoclone OKT3), a very 
powerful immunosuppressive drug marketed by Cilag AG was the first monoclonal murine antibody to 
become available for therapy in humans. ORT/OKT3 is an IgG2a immunoglobulin produced by the 
hybridoma technique that recognizes, binds and blocks the CD3 complex of the T-cell receptor 
(Emmons & Hunsicker, 1987). But as a murine immunoglobulin it caused to significant immunological 
side effect in patients (Sgro, 1995). An appreciation of the consequences of an immune response to 
murine antibodies has led to the development of engineered mAb humanization techniques that carry a 
lower risk of immune reactions. The development of humanization approaches was pioneered by Winter 
and colleagues, where  murine Fc and Fv framework regions were replaced by human germline amino 
acids (Riechmann, Clark, Waldmann, & Winter, 1988). Through this technology, lower immune 
responses to antibodies were observed. This technique led to the successful generation of Rituximab 
(Rituxan), a chimeric monoclonal antibody, targeting CD20 on B-cells for non-Hodgkin’s lymphoma 
and Chronic lymphocytic leukemia which is the first monoclonal antibody to be approved for clinical 
use in the therapy of cancer (Grillo-López et al., 1999). Since then, strategies to generate fully human 
antibodies containing only human amino acid sequence derived antibody regions have been developed.  
Antigen specificity is nowadays being selected either in vivo by the use of genetically modified rodents 
or by antibody engineering processes as antibody libraries combined with screening tools such as 
fluorescence-activated cell sorting (FACS) (Hoogenboom, 2005; Lonberg, 2005, 2008).  
Currently to the end of 2018, 31 mAbs have been approved for clinical use for cancer therapy (data 
from FDA). Those successful monoclonal antibody therapeutics have been based on a number of 
mechanisms of action (MoA). Immunoglobulin G (IgG) molecules that bind to target cancer cells can 
mediate antibody-dependent cellular cytotoxicity (ADCC) by immune effector cells or induce 
complement-dependent cytotoxicity (CDC). Some mAbs can mediate the direct signaling-induced 
death of cancer cells such as in the case of  Trastuzumab that binds to HER2 or Rituximab that binds to 
EGFR.  mAbs such as Bevacizumab that binds VEGF ligand can be used to inhibit angiogenesis.  
Antibodies as Ipilimumab that blocks CTL4 or Nivolumab that blocks PD1 or Avelumab that binds 
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PDL-1 can block inhibitory immune checkpoint molecules, thereby resulting in a stronger antitumor T 
cell responses .Radioimmunoconjugates as Ibritumomab tiuxetan deliver radioisotopes to the cancer 
cells, whereas antibody–drug conjugates as Brentuximab vedotin and Trastuzumab emtansine deliver 
highly potent toxic drugs to the cancer cells, while Moxetumomab pasudotox delivers an immunotoxin 
into the tumor.  
mAb variable regions are also used to retarget immune effector cells towards cancer cells through the 
use of bispecific mAbs that recognize cancer cells with one arm and activating antigens on immune 
effector cells with the other arm, as Blinatumomab that binds to CD3 and CD19. Recent years approvals 
also include mAbs targeting new targets such as RNKL, GD2, SLAMF7, PDGFRα and CCR4 mostly 
with MoA of ADCC. A summary of all the approved monoclonal antibodies used for cancer therapy 
with their binding target and MoA are depicted in Table 1. 
 
 
Table 1: Monoclonal antibodies approved for clinical use in cancer therapy. 
List of the monoclonal antibodies approved for clinical use in cancer therapy with the target they bind, mechanism of action, and 
year of first approval. Currently there are 31 approved mAbs targeting 18 different targets with different MoA as described. Data 
adapted  from (Carter & Lazar, 2018). 
 
 
 
Agent Target(s) Proposed MoA Year approved
1 Rituximab (Rituxan, Mabthera) 1997
2 Tositumomab (Bexxar) 2002
3 Ofatumumab (Arzerra,) 2003
4 Obinutuzumab (Gazyva) 2009
5 Ibritumomab tiuxetan (Zevalin) CD20 Radiation from 90Y induces cellular damage 2013
6 Brentuximab vedotin (Adcetris) CD30 Antibody drug cinjugate 2011
7 Blinatumomab((Blincyto) CD3 and CD19 Mediates formation of a T lymphocyte–tumour cell synapse that results in tumour cell lysis 2014
8 Daratumumab (Darzalex) CD38 Depletes target cells by ADCC, CDC and inducing apoptosis 2015
9 Gemtuzumab ozogamicin (Mylotarg) CD33 Antibody drug cinjugate 2017
10 Inotuzumab ozogamicin  (Besponsa) CD22 Antibody drug cinjugate 2017
11 Moxetumomab pasudotox CD22 antibody immunotoxin 2018
12 Trastuzumab (Herceptin) 1998
13 Pertuzumab (Perjeta) 2012
14 Trastuzumab emtansine (Kadcyla) HER2 Antibody drug cinjugate 2013
15 Cetuximab (Erbitux) 2004
16 Necitumumab (Portrazza) 2015
17 Panitumumab (Vectibix) 2006
18 Bevacizumab (Avastin) VEGF ligand Binds and neutralizes ligand 2004
19 Ramucirumab (Cyramza) VEGFR2 Binds and antagonizes receptor 2014
20 Ipilimumab (Yervoy) CTLA-4 Binds and antagonizes receptor; augments T lymphocyte activation and proliferation 2011
21 Nivolumab (Opdivo) 2014
22 Pembrolizumab (Keytruda) 2014
23 Cemiplimab (Libtayo) 2018
24 Atezolizumab (Tecentriq) 2016
25 Avelumab (Bavencio) 2017
26 Durvalumab (Imfinzi) 2017
27 Denosumab (Xgeva) RANKL Binds and neutralizes ligand; decreases bone resorption and increases mass and strength of some bones 2010
28 Dinutuximab (Unituxin) GD2 Depletes target cells by ADCC, CDC and inducing apoptosis 2015
29 Elotuzumab (Empliciti) SLAMF7 Activates NK cells through SLAMF7 pathway and Fc receptors; depletes target cells by ADCC 2015
30 Olaratumab (Lartruvo) PDGFRα Binds and antagonizes receptor; antitumour activity 2016
31 Mogamulizumab (Poteligeo) CCR4 Depletes target cells by ADCC 2018
Binds and neutralizes ligand; releases inhibition of the immune response 

HER2
PD-1
Depletes target cells by ADCC, CDC and inducing apoptosisCD20
Depletes target cells by ADCC, CDC and inducing apoptosis
Depletes target cells by ADCC, CDC and inducing apoptosis
Binds and antagonizes receptor; augments T lymphocyte activation and proliferation 
EGFR
PD-L1
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2.3. In vitro antibody selection by display technologies  
In vitro antibody selection by display technologies is based on four key steps: Initially the generation 
(or cloning) of the antibody genotypic diversity. The sources of the antibody gene pools can be from B 
cell-receptor (BCR) gene repertoires after animal immunization with a specific antigen, naïve 
repertoires derived from peripheral lymphocytes of healthy individuals or synthetic antibody libraries. 
Most immunizations to date are done using transgenic rodents. Use of naïve repertoires or synthetic 
antibody libraries can theoretically yield antibodies against any given target. The second key step is 
linkage between the genotype and phenotype in order to be able to extract the genetic information of a 
selected binder; This is done by fusing the gene encoding the antibody binding fragments with a host 
(e.g. phage, yeast, bacteria) gene, causing the host to "display" by anchoring of antibody fragments (e.g. 
scFv/Fab) on the surface of the host while containing the antibody genes. The third key step is 
application of selective pressure e.g. high-throughput screening and selection using fluorescence 
activated cell sorting (FACS).The final key step is efficient amplification of the host (e.g. phage, yeast, 
bacteria) (Bradbury, Sidhu, Dübel, & McCafferty, 2011) .  
The concept of display technology was pioneered by Smith in 1985 with the generation of a peptides 
phage display library (Scott & Smith, 1990; Smith, 1985). While antibody fragments display was first 
expressed in bacteria (Skerra & Plückthun, 1988), phage display antibody fragment library was first 
described by Winter group (McCafferty, Griffiths, Winter, & Chiswell, 1990). In 2018, Smith and 
winter were rewarded the Nobel Prize for their work. Since its development, phage display is the most 
established in vitro selection technology. To date 6 human antibodies have been discovered or 
developed by phage display that were approved for therapy with, Adalimumab being the first phage 
display derived antibody granted a marketing approval in 2002 (Frenzel, Schirrmann, & Hust, 2016) 
Another popular in vitro antibody selection display technology is the yeast display that was developed 
in 1997 by Boder and Wittrup and has  become an attractive, eukaryotic alternative to phage display  
(Boder & Wittrup, 1997). In contrast to phage display, yeast can present post-translational modifications 
similar to mammalian systems which are  not present in Escherichia coli bacteria that is used in phage 
display. Post-translational modifications with appropriate protein folding in the endoplasmic reticulum 
in the presence of chaperones allow more efficient display of functional library variants (Doerner, Rhiel, 
Zielonka, & Kolmar, 2014). For example, when antibody selection from an HIV-1 immune antibody 
library displayed on yeast was compared to selection from the same library displayed on phage, yeast 
display was shown to sample the immune antibody repertoire considerably better than phage display, 
selecting all the scFvs identified by phage display and twice as many novel antibodies. The conclusion 
from this work was that eukaryotic processing of the scFv is the biggest reason for the difference in 
selected clones from yeast and phage display (Bowley, Labrijn, Zwick, & Burton, 2007) 
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2.3.1. In vitro antibody selection by yeast display 
First introduced by Boder and Wittrup, in vitro antibody selection by yeast display (YSD) is based on 
using the Saccharomyces cerevisiae yeast cells to present the antibody fragments on the cell surface 
(Figure 2). In this technology, antibody fragments (e.g. scFv/Fab)  are fused to the a-agglutinin 
adhesion receptor of Saccharomyces cerevisiae  which is localized on the yeast cell surface allowing 
the antibody repertoire to be screened and selected by fluorescence activated cell sorting (Boder & 
Wittrup, 1997). The A-agglutinin receptor is an adhesion molecule helping to stabilizes cell-cell 
interactions and promotes fusion between an “a” and α haploid cell to obtain a diploid cell in a process 
called yeast mating (Lu et al., 1995). This receptor is composed of the Aga1 and Aga2 proteins. While, 
Aga1 protein is secreted and binds covalently to b-glucan present in the extracellular matrix of the yeast 
cell wall,Aga2 protein binds to Aga1 protein through two disulfide bonds (Boder & Wittrup, 1997). In 
the YSD system, the HC fragments gene repertoire are genetically fused to the C-terminus of the Aga2 
protein which is episomally encoded on a shuttle plasmid, while the Aga1 protein is chromosomally 
encoded in Saccharomyces cerevisiae yeast cells.  Aga1 protein and the Aga2 protein fusion are 
expressed by induction of the galactose 1 promoter (GAL1) with galactose (Gera, Hussain, & Rao, 2013). 
The Aga2 protein-fusion can be flanked by epitope tags that can be used to assess the level of displayed 
antibodies.  
YSD antibody libraries are constructed first by cloning the antibody genes into a yeast display vector. 
After yeast transformation and growth, antibody expression is induced by galactose medium and then 
yeast display the antibodies can be selected using fluorescence-activated cell sorting (FACS) with 
fluorescent ligands to enrich binders of the library. This is the major advantage of yeast display 
technology over phage display, as it allows defining specific parameters to select antibodies displayed 
on the yeast surface and enables high-throughput isolation of engineered clones from large libraries. 
Yeast displaying antibodies can be sorted by binding to a fluorescently-conjugated antigen and it is 
possible to separate clones quantitatively utilizing the different binding affinities of distinct clones. 
Unlike phage, yeast cells can display approximately 104 – 105 fusion proteins on each yeast cell surface, 
and expression range can be evaluated by binding of epitope tags using fluorophore-labeled reagents 
(Doerner et al., 2014). In first years while comparing to phage display technology, the yeast display 
platform had limitation of the library size, due to the lower efficiency of yeast transformation (Boder, 
Raeeszadeh-Sarmazdeh, & Price, 2012). In 2010 efforts to overcome this problem led to the 
improvement of yeast transformation efficiency, allowing the construction of libraries with 108 to 109 
transformants in a single working day (Benatuil, Perez, Belk, & Hsieh, 2010). Moreover, 
saccharomyces cerevisiae haploid yeast cells are capable of mating with haploid cells of the opposite 
mating type (“a” and α) to produce a stable diploid cell. This capability can be harnessed as an additional 
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option to greatly enhance diversity in yeast-based selection approaches. Since Fabs are composed of 
two distinct polypeptide chains HCs and LCs, it is possible to encode the two chains on different vectors 
in different yeast strains. The two chains can then be brought together in a single diploid yeast by 
mating, displaying Fab on the diploid surface cell. This yeast  mating  approach led to chain shuffled 
libraries with diversities up to 5 X 109 (Weaver-Feldhaus et al., 2004). The highest disadvantage of the 
YSD technology is the multivalent display of antibodies on yeast surface which causes the selection by 
FACS to be based on avidity parameters rather than affinity of the displayed clone (Boder et al., 2012; 
Sheehan & Marasco, 2015). This may cause selection of relatively low affinity antibodies.  
Since the technology invention, scFv is the most frequent antibody format displayed on yeast surface 
while other formats such as Fab or single-chain Fab (scFab) were also described (Sheehan and Marasco, 
2015; Böldicke, 2017). Yet, recently it has been suggested that Fab is the most efficient format to 
express functional antibodies by yeast surface display (Sivelle et al., 2018)  
 
Figure 2: Yeast surface display.  
Yeast surface display as described by Boder and Wittrup with scFv fusion protein. The scFv (cyan) is displayed as an Aga2 (pink) 
fusion protein on the surface of yeast. Expression can be detected by using fluorescent antibodies binding to the epitope tags 
(beige), and binding of the scFv to a biotinylated antigen (orange) can be detected using fluorescent avidin (blue). HA, 
hemagglutinin; VL, variable light chain; VH, variable heavy chain; (Gly4Ser)3, flexible peptide linker. Figure adapted from ( Chao 
et al., 2006). 
 
2.4. Phenotypic screening for antibody discovery, cell-based assay screening 
Since the first approval about 20 years ago, most of the antibodies approved for clinical use in cancer 
therapy have been isolated using in vitro antibody selection combined with high throughput target-based 
screening. Although it is considered as one of the most promising strategies for the development of 
cancer therapies, target-based strategies are limited to targets that have been identified previously 
(“known” targets), while the number of tumor-specific molecules “known” for antibody targeting is 
limited. Currently all the 31 approved mAb antibodies approved for clinical use in cancer therapy are 
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directed against a limited number of 18 targets only as shown in table 1. Moreover, while applying 
target-based screening with “known” antigens, it first requires obtaining of a recombinant soluble 
extracellular domain (ECD) of the target, which is not always reachable. In cases were the antigen can 
be produced as a recombinant ECD, screening can result in selection of antibodies that will not bind 
effectively to the target expressed on the intact cell in it’s native conformation. This can be caused for 
example due to incorrect folding of the soluble recombinant protein, different posttranslational 
modifications of the recombinant protein or alteration of the target proteins due to additional tags on 
the recombinant protein (Stern et al., 2016).  
The limitation of the selection process using recombinant ECD protein together with the currently 
limited number of tumor-specific targets renders the search for clinical antibodies to be more 
challenging and the target space increasingly competitive. Alternative strategies, such as phenotypic 
drug discovery or cell based screening where screening is performed on targets in their native 
conformation on intact cell, are gaining favor (Minter, Sandercock, & Rust, 2017) . These approaches 
can lead to the discovery of novel targets in the cancer therapy landscape. Although these strategies 
have not been widely used, Alemtuzumab, the first clinical approved humanized mAb, was discovered 
from a phenotypic screen. Immunization of rats with human T cells followed by hybridoma technology 
identified antibodies that specifically bound T cells. After humanization, the lead antibody was tested 
and  found to effective for chronic lymphocytic leukemia (CLL) by mechanism of T cell depletion while 
the identification of the antigen as CD52 was made only later (Minter et al., 2017; Waldmann & Hale, 
2005) . Phenotypic screening for an antibody targeting cancer can be performed not only following 
immunization. An example for this is the isolation of the BI-505 antibody using the FIRSTTM platform, 
where a naïve antibody phage library panned against intact ramos B lymphoma cells with an initial 
depletion step on membrane vesicles derived from Jurkat T leukemia cells. This attempt led to the 
isolation of an antibody that acts by induction of B lymphoma cells apoptosis named BI-505. Also, in 
this case, just after isolation of the antibody, the target was identified as intercellular adhesion molecule 
1 (ICAM-1). Interestingly, ICAM-1 had never been reported to be involved in apoptosis in B lymphoma 
cells. Further characterization of BI-505 revealed that ICAM-1 are strongly expressed in multiple 
myeloma (MM) and currently the antibody is under phase II clinical trials (Fransson, Tornberg, 
Borrebaeck, Carlsson, & Frendéus, 2006; Gonzalez-Munoz, Minter, & Rust, 2016).   
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2.4.1. Yeast display biopanning screening  
Phenotypic screening using hybridoma and phage display technologies have demonstrated the ability 
to yield successful antibodies targeting cancer antigens. Using the advantages mentioned before for 
yeast display (having the machinery of eukaryotic cells, presenting high copy of protein displayed with 
multivalent display) together with other characteristics such as low binding of the yeast cells to 
mammalian cells and the fact that yeast cells size typically is around ~5 µm allowing it to be observed 
easily under light microscopy without the need of fluorescent tagging,  YSD technology can be 
promising when combined to mammalian cell-based screening for phenotypic selection of antibodies. 
In 2005, a method for yeast display biopanning on mammalian cell monolayers was first introduced by Shusta (Xin 
& Shusta, 2005). Yeast displaying anti-fluorescein scFv mixed with large non-binders yeast cells were panned on 
fluoresceinated endothelial monolayer adherent cells. Just after three rounds of biopanning yeast displaying anti-
fluorescein scFv were enriched and recovered from the background of irrelevant yeast cells. Later attempts in his 
lab led to successful  isolation of antibodies that bind the plasma membranes of rat brain endothelial cells after 5 
biopanning  rounds of an naïve  human scFv yeast library against confluent rat brain endothelial cells (RBE4 cell 
line) (Wang, Cho, & Shusta, 2007). Recently, also in the Shusta lab, biopanning of a naïve yeast antibody library 
against patient-derived Glioblastoma stem-like cells (GSC), led to isolation of clones with differential binding 
against multiple human normal, tumor, and GSC lines. One of the isolated  human GSC-selective antibody was 
validated for use as a research tool for in vivo immunodiagnostics to visualize tumor xenografts (Zorniak et al., 
2017). Other labs also implement the method, biopanning a naïve yeast antibody library against androgen-
dependent prostate cancer cells led to isolation of high affinity and specific binders to those cells (Williams, Hajiran, 
Nayeem, & Sooter, 2014). Also anti-B7-H4-targeting scFv that reversed in vitro inhibition of CD3-stimulated T 
cells, which was isolated by biopanning a yeast display scFv library derived from patients with ovarian cancer 
against C30 ovarian cancer cell line (Dangaj et al., 2013). In 2013 the Shusta Lab published an optimized protocol 
for biopanning with an additional method for antibody characterization and antigen identification using cell lysate 
and yeast display (Tillotson, Cho, & Shusta, 2013). Illustration of the biopanning method steps are depicted in 
Figure 3.  
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Figure 3: Yeast antibody surface display biopanning process. 
(1) Yeast surface antibody display ,after induction, incubated on an adherent monolayer negative cell line in order to deplete “non-
wanted” binders (optional step).  (2) Yeast that do not bind the negative cell line are transferred and incubated on an adherent 
monolayer cancer cell line (positive cell line) (3) Non-binders are removed by washing. (4) Yeast-cell binders together with the 
mammalian adherent cells are removed. (5) Yeast cells are amplified and induced for the next biopanning round. (6) After several 
rounds of biopanning, enrichment can be observed by light microscopy.   
 
2.5. Tumor infiltrating immune cells and tumor infiltrating B cells (TIL-B) 
Although the phenomenon of infiltration of the immune cells into the tumor tissue is already known for 
over 150 years (Underwood, 1974) and the correlation  between high density of infiltrated immune cells 
and better clinical outcome in breast cancer patients was documented in a clinical cohort as early as 
1922 (Sistrunk & Maccarty, 1922), the research of the phenomenon in clinical and therapy aspects has 
only progressed in the last decade together with cancer immunotherapy research (Pagès et al., 2010). 
The immune cells that infiltrate into solid tumors are heterogeneous between tumor types and are very 
diverse from patient to patient in their occurrence, density and their location in the tumor tissue. All the 
immune cell types can infiltrate into the tumor including macrophages, dendritic cells, mast cells, 
natural killer (NK) cells. T and B lymphocytes that infiltrate to the tumor are defined as “Tumor 
infiltrating lymphocytes” (TILs) and these including memory, naïve and plasma B cells, effector T cells 
including various subsets of T cell: T helper cells, T helper 1 (TH1) cells,TH2 cells, TH17 cells, 
regulatory T (TReg) cells, T follicular helper (TFH) cells and cytotoxic T cells. These immune cells can 
be located in the core (the center) of the tumor, in the invasive margin or in the adjacent tertiary 
lymphoid structures (TLS) (Fridman, Pagès, Sautès-Fridman, & Galon, 2012). Among the infiltration 
the dominant cell population is usually T cells which are strongly associated with patient survival in a 
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wide variety of human cancers. Less is known about tumor infiltrating B cells and their role in the 
immune response to cancer is not fully understood (B. H. Nelson, 2010). 
 
2.5.1. Tumor infiltrating B Cells (TIL-B)  
Tumor infiltrating B cells with high density were observed in many cancer types as melanoma, breast 
cancer, non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer and prostate cancer 
(Flynn, Somasundaram, Arnold, & Sims-Mourtada, 2017). As mentioned, their role within the tumor is 
not fully understood and conceivably complex. There are many factors which may influence TIL-B infiltration, 
as tumor type and stage, the location, subset and activation status of B cells and interaction with other immune 
cells present within the tumor microenvironment. A large number of studies and clinical trials tried to describe 
the positive and negative functions of B lymphocytes in a tumor environment, suggesting B cells can promote 
anti-tumor immunity by different functions such as: differentiate into plasma cells and function as antibody 
generators, antigen-presenting cells (APCs), producing stimulatory cytokines and chemokines for enhancement 
of T-cell responses or as direct killers. Additionally B cells can perform immunosuppressive functions by 
regulatory B cells that can act together with regulatory T cells (Shen et al., 2016). Recently, a review was published 
of 96 studies representing 19 cancers types with cohorts of 50 or more cases in which the prognostic value of TIL-
B was assessed by immunohistochemistry and/or gene-expression analysis. The data indicated that 50.0% of the 
studies reported a positive prognostic effect for TIL-B within the tumor, whereas the remainder found a neutral 
(40.7%) or negative (9.3%) effect. Additionally, 21 studies showed that when the presence of TIL-B were 
analyzed by gene-expression, a large majority reported positive prognostic effect. (Wouters & Nelson, 2018). 
 
2.5.2. TIL-B as an efficient source of highly specific immunoglobulins recognizing 
tumor membrane proteins 
Early in the 1980s together with the hybridoma technology development, a first indication that tumor 
infiltrating B lymphocyte (TIL-B)-derived antibodies are able to secrete tumor-specific antibodies were 
obtained by production of human hybridomas derived from TIL-B of cancer patients (Sikora, Alderson, 
Ellis, Phillips, & Watson, 1983; Sikora, Alderson, Phillips, & Watson, 1982). Later, B cell expansion 
of TIL-B derived from patient tumor biopsies showed IgG reactivity with autologous tumor targets 
(Punt et al., 1994) and  also B cell expansion of melanoma-derived TIL-B followed by cloning of the 
scFv antibody showed binding of the specific scFv with different melanoma cell lines (Zhang et al., 
1995). Also subcutaneous transplantation of human lung cancer tissue with infiltrated B cells in 
immunodeficient mice resulted in obtaining secreted IgG derived from TIL-B that highly bound to 
membrane antigens of autologous cancer cells (Yasuda et al., 2002). 
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The occurrence of reactive antibodies to tumor specific antigens can be explained by the induction of 
the immune response in the tumor microenvironment. The elements that stimulate the immune response 
in the tumor microenvironment is the same as by infection diseases while in the last one a pathogen 
molecule is recognized by immune receptors present on the surface of lymphocytes, and in cancer the 
antigens are  self-molecules that are created during oncogenesis  (Dunn et al., 2002; Goodnow, Vinuesa, 
Randall, MacKay, & Brink, 2010). Those “self” tumor associated antigens may lose their 
immunological tolerance by many causes as tolerance defects, downregulation of regulatory T cells, 
inflammation in the tumor, overexpression of the tumor antigen at levels high enough to exceed the 
engaged TCR threshold required for CD4+ T cell activation, aberrant expression site of the tumor 
antigen or altered protein structure like neoepitope exposure mutation and different post-translational 
modifications. The antibodies that are generated against these antigens can be referred to as 
autoantibodies  (Zaenker, Gray, & Ziman, 2016).   
Tumor antigens that drain to the near local tumor-draining (sentinel) lymph node (SN) are introduced 
to naïve B cells in the lymph node germinal centers where they differentiate into memory B cells or 
plasma cells that now can  circulate back and infiltrate into the tumor (Meeusen, Lim, & Mathivanan, 
2017). This adaptive immune response can occur also in the  Tertiary lymphoid structures (TLS) within 
the tumor stroma (Dieu-Nosjean, Goc, Giraldo, Sautès-Fridman, & Fridman, 2014). Recently, a study 
published by Novinger analyzing heavy and light chain immunoglobulin sequences, from breast cancer 
patient’s infiltrating B cells and B cells present in the tumor-draining lymph node indicated they 
antibodies are functional and derived from the same clones. This study was the first to report a shared 
B cell lineage in two different locations in the same breast cancer patient. More than that, by 
constructing scFv phage display libraries from the patient’s tumor infiltrating B cells, tumor-draining 
sentinel lymph node and peripheral blood followed by enrichment with panning on autologous tumor 
lysates, an increasing clonal relationship between tumor and lymph node in both the heavy and light 
chain populations could be detected. This indicates that the relationship shared between tumor and 
lymph node B cells in this patient may be characterized by selection for tumor-associated antigens. It 
was also found that replacement mutations were enriched over silent mutations in the CDR regions 
compared to the framework regions of light chains in the tumor and lymph node libraries, suggesting 
antigen-mediated selection. In addition, the study showed the after panning, the top 25% of all scFV 
clone binders to BT474 breast cancer cells were TIL-B and lymph node derived clones and not 
peripheral derived clones. Further binding analysis on tissues, indicated  that multiple phage-displayed 
antibodies bound specifically to the tumor tissue and not to corresponding normal breast tissue from the 
same patient (Novinger et al., 2015).  
In addition to Novinger’s study indicated that phage antibody libraries derived from infiltrating B cells 
of patients with breast cancer can be a rich source of tumor-binding antibodies, previous reports 
2. Introduction 18 
 
 
 
 
indicated isolation of antibodies from scFv phage display libraries derived from sentinel lymph node 
were binding  common tumor targets, such as CEA and HER2 (Ayat et al., 2013a; Belimezi, 
Papanastassiou, Merkouri, Baxevanis, & Mamalaki, 2006) and antibodies binding to cancer cell lines 
have been isolated from libraries derived from TIL-B cells (Pavoni et al., 2007; Rothe et al., 2004) also 
Antibodies that bind ganglioside D3 in a tumor have been identified from libraries constructed from 
TIL-B cells in a medullary carcinoma (Kotlan et al., 2005) 
 
2.4. Aim of this study 
The presented work aims to generate yeast Fab display libraries representing the immunoglobins of B cells 
infiltrating into colon cancer tumors followed by evaluation of the libraries as a source for antibodies 
targeting cancer associated antigens. Using traditional yeast display technology and target-based screening 
by fluorescence-activated cell sorting (FACS) and by using emerging technologies as deep sequencing 
(NGS) and yeast display biopanning phenotypic screening on mammalian cancer cell lines, we will try to 
better understand the role of B cell infiltration into tumors.  This research may lead to finding improved 
mAbs for therapy, finding new tumor-associated antigens that can be targeted for cancer therapy or reveal 
new mechanism of action to fight tumor growth.  
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3. Material 
 
 
3.1. Tissues 
Tissues were collected at Rambam Health Care Campus (Haifa, Israel) according to a protocol approved by 
the hospital “Helsinki” Committee, tissues were obtained from a patient with colon cancer at the time of 
surgical treatment 
 
3.2. Bacterial strains, yeast strains and human cell lines 
Bacterial strains 
E. coli   One   Shot   Mach1 chemically   competent   cells  ( #C862003,   Life   Technologies,  Karlsruhe, 
Germany); Genotype: lacZ∆M15 hsdR lacX74 recA endA tonA 
 
Yeast strains  
 
S. cerevisiae EBY100 (ATCC®, Manassas, VA, USA) 
Genotype: MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2-delta200 his3-delta200 pep4::HIS3 
prbd1.6R can1 GAL 
 
S. cerevisiae BJ6454 (ATCC®, Manassas, VA, USA) 
Genotype: MATalpha ura3-52 trp1 leu2-delta1 his3-delta200 pep4::HIS3 prb1-delta1.6R can1 GAL 
 
 
Mammalian cell lines 
All mammalian cell lines were cultivated at 37°C,5% or 10% CO2. Cells were obtained from the American 
Type Culture Collection (ATCC®, Manassas, VA, USA), or companies as summarized in the following 
table (Table 2). 
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Table 2: List of mammalian cell lines. 
Cell type and cell origin are listed for each cell line: 
 
 
Cell line Cell type Origin 
A431 human epidermoid carcinoma ATCC® CRL 1555TM 
A549 human lung carcinoma ATCC® CCL 185TM 
CHO-S1 Chinese hamster ovary 
Life Technologies, Darmstadt, 
Germany  (1119775) 
CCD-18Co human normal colon fibroblast ATCC® CRL-1459™ 
HEK 293 EBNA human embryonic kidney ATCC® CRL-10852™ 
HT-29 Human colorectal adenocarcinoma ATCC® HTB-38™ 
HCT 116 human colorectal carcinoma ATCC® CCL-247™ 
MDA-MB-468 
human breast adenocarcinoma 
(mammary gland) 
ATCC® HTB 132TM 
MKN45 human gastric adenocarcinoma DSMZ ACC 409 
MCF7 
human breast adenocarcinoma 
(mammary gland) 
ATCC® HTB-22™ 
NCI-H1975 human lung adenocarcinoma ATCC® CRL-5908™ 
NTERA-2 cl.D1 human testis carcinoma ATCC® CRL-1973™ 
SK-BR-3 
human breast adenocarcinoma 
(mammary gland) 
ATCC® HTB-30™ 
SW620 
human dukes' type C, colorectal 
adenocarcinoma 
ATCC® CCL-227™ 
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3.3. Plasmids 
In the following Figure 4 depicts the composition of the yeast used plasmids. 
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Figure 4: Schematic structure of plasmids used for library construction. 
All plasmids (A,B,C) were used for the yeast library construction are derivatives of the pYD1 vector (Invitrogen/Life 
Technologies, Darmstadt, Germany).All of the plasmids contains the CEN6/ARS4: Yeast origin of replication. pUC ori: Bacterial 
origin of replication. pGal1: Gal1/10 promotor region. Mat α TT: MAT alpha transcription termination region. Plasmid for the 
heavy chain (A) contain signal peptide: AGA2 gene for soluble protein secretion. MCS with bases homologous to the flanking 
VH gene for gap reaper homologous recombination.CH1: Gene sequence of the CH1 domain of human IgG .Aga2p: Gene 
encoding for Aga2 protein of the a-agglutinin receptor. Trp1: Gene sequence for the phosphoribosylanthranilate isomerase 
(auxotrophic marker) and AmpR: Coding sequence for β-lactamase for ampicillin resistance. Plasmid for the light chain kappa 
(B) contain app8:  Secretory leader for soluble protein secretion. MCS with bases homologous to the flanking VL kappa gene for 
gap reaper homologous recombination. CL: Coding gene for the constant domain of the human IgG light chain kappa. Leu2: 
Coding sequence for the β- isopropylmalate dehydrogenase (auxotrophic marker) and coding sequence for kanamycin resistance. 
Plasmid for the light chain lambda (C) contain app8:  Secretory leader for soluble protein secretion. MCS with bases homologous 
to the flanking VL kappa gene for gap reaper homologous recombination. CL: Coding gene for the constant domain of the human 
IgG light chain lambda. Leu2: Coding sequence for the β- isopropylmalate dehydrogenase (auxotrophic marker) and coding 
sequence for kanamycin resistance. Arrows indicate the orientations of genetic elements. The plasmids maps were created with 
SnapGene Viewer ver. 4.2.6. 
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In the following Figure 5 depicts the composition of the mammalian expression plasmids. 
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Figure 5: Schematic structure of plasmids used for subcloning. 
All plasmids (A,B,C) were used for subcloning the variable region of heavy and light chain DNA from selected clones with the 
yeast expression vectors (pYD) into the mammalian expression vector as IgG1 antibody. Construction are derivatives of pTT5 
mammalian expression vectors (Expresso® CMV system, Lucigen, Middleton, WI, USA) and designed with bases homologous 
to the flanking of the variable regions insertion. EBV oriP: Origin of replication in human cells. AmpR: Coding sequence for β-
lactamase. pMB1 ori: Bacterial origin of replication. pCMV: Promotor region. TPL:Tripartite leader sequence. MLP: Adenoviral 
enhancer element. Signal peptide: Gene encodes the secretory leader and RGB polyA: rbGlob polyA for terminating transcription. 
Plasmid for the heavy chain (A) contain leader and gene sequence of the CH1:CH2:CH3 domain and hinge of human IgG1 with 
bases homologous to the flanking VH gene for homologous recombination. Plasmid for the light chain kappa (B) contain leader 
and. CK: Coding gene for the constant domain of the human IgG light chain kappa with bases homologous to the flanking VK 
gene for homologous recombination. Plasmid for the light chain lambda (C) contain leader and CL: Coding gene for the constant 
domain of the human IgG light chain kappa with bases homologous to the flanking VL gene for homologous recombination. 
Arrows indicate the orientations of genetic elements. The plasmids maps were created with SnapGene Viewer ver. 4.2.6. 
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3.4. Enzymes and proteins 
 
 AccuPrime™ Taq DNA Polymerase Thermo Fisher Scientific, Carlsbad,USA 
Recombinant Human 5T4 (His) Merck, Darmstadt, Germany 
Recombinant Human B7-H3-(2Ig) (Avi-His) EMD,Billerica,MA,USA 
Recombinant Human B7-H3-(4Ig) (Avi-His) EMD,Billerica,MA,USA 
Recombinant Human CD200 (His) EMD,Billerica,MA,USA 
Recombinant Human CEACAM1 (His) Merck, Darmstadt, Germany 
Recombinant Human CEACAM5 (His) Merck, Darmstadt, Germany 
Recombinant Human CEACAM6 (His) Merck, Darmstadt, Germany 
Recombinant Human C-Met  (His) Merck, Darmstadt, Germany 
Recombinant Human CTLA4-Fc  EMD,Billerica,MA,USA 
Recombinant Human DLK-1 (His) Merck, Darmstadt, Germany 
Recombinant Human EGFR (His) EMD,Billerica,MA,USA 
Recombinant Human GRP78  (His) Merck, Darmstadt, Germany 
Recombinant Human HER-2  (His) EMD,Billerica,MA,USA 
Recombinant Human LAG3 (His) EMD,Billerica,MA,USA 
Recombinant Human LRP6 (E3:E4) (His) Merck, Darmstadt, Germany 
Recombinant Human OX40L (His) R&D Systems Inc,Minneapolis, MN,USA 
Recombinant Human PD-1 (His) Novoprotein Scientific,Summit, NJ ,USA 
Recombinant Human PDL1 (His) EMD,Billerica,MA,USA 
Recombinant Human TEM1  (His) R&D Systems Inc,Minneapolis, MN,USA 
Recombinant Human TIM3 (His) Novoprotein Scientific,Summit, NJ ,USA 
Ribonuclease A from bovine pancreas Sigma-Aldrich,St louise,MO,USA 
Streptavidin - DyLight 633 conjugate  Thermo Fisher Scientific, Carlsbad,USA 
Streptavidin Allophycocyanin (APC) conjugate  Biolegend,San Diego, CA,USA 
Streptavidin-Phycoerythrin(PE) conjugate  Biolegend,San Diego, CA,USA 
Taq Ready Mix (2x) Hy-Labs,Rehovot,Israel 
TrypLE™ Express Enzyme Life Technologies,Grand Island,NY,USA 
 
 
3.4.1. Antibodies 
Reference antibodies 
 Cetuximab (Erbitux®) Merck, Darmstadt, Germany 
Anti- human CEACAM5 Merck, Darmstadt, Germany 
Anti- human LAG-3 EMD,Billerica,MA,USA 
Anti- human LRP6 (E3:E4) Merck, Darmstadt, Germany 
mouse anti human OX40L R&D Systems Inc,Minneapolis, MN,USA 
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Detection antibodies for flow cytometry 
 
Goat F(ab')2 Anti-Human Kappa-PE conjugate Southern Biotech, Birmingham, AL,USA 
Goat F(ab')2 Anti-Human Lambda-PE conjugate Southern Biotech, Birmingham, AL,USA 
Donkey F(ab')2 Anti-Human IgG, Fcγ fragment 
-Alexa Fluor® 488 conjugate 
Jackson ImmunoResearch, Cambridgeshire, UK 
 
Detection antibodies for Microscopy  
 
Goat F(ab')2 Anti-Human IgG, Fcγ fragment 
 -Alexa Fluor® 488 conjugate 
JacksonImmunoResearch, Cambridgeshire, UK 
 
3.4. Oligonucleotides 
Oligonucleotides were obtained from Merck Sigma-Aldrich, Rehovot, Israel. 
 
Primers for VH amplification (1stPCR): 
 
MHVH1_f CAGGTBCAGCTGGTGCAGTCTGG  
MHVH1/7_f CARRTSCAGCTGGTRCARTCTGG  
MHVH2_f CAGRTCACCTTGAAGGAGTCTGG  
MHVH3_f1 SARGTGCAGCTGGTGGAGTCTGG  
MHVH3_f2 GAGGTGCAGCTGKTGGAGWCYSG  
MHVH4_f1 SARGTGCAGCTGGTGGAGTCTGG  
MHVH4_f2 CAGSTGCAGCTRCAGSAGTSSGG  
MHVH5_f GARGTGCAGCTGGTGCAGTCTGG  
MHVH6_f CAGGTACAGCTGCAGCAGTCAGG  
MHIgGCH1_r  GACCGATGGGCCCTTGGTGGA 
 
Primers for VK amplification (1stPCR): 
 
MHVK1_f1 GACATCCAGATGACCCAGTCTCC   
MHVK1_f2 GMCATCCRGWTGACCCAGTCTCC   
MHVK2_f GATRTTGTGATGACYCAGWCTCC   
MHVK3_f GAAATWGTGWTGACRCAGTCTCC   
MHVK4_f GACATCGTGATGACCCAGTCTCC   
MHVK5_f GAAACGACACTCACGCAGTCTCC   
MHVK6_f GAWRTTGTGMTGACWCAGTCTCC   
Kappa1stPCR_r  GACAGATGGTGCAGCCACAGT   
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Primers for VL amplification (1stPCR): 
 
MHVL1_f1 CAGTCTGTGCTGACTCAGCCACC 
MHVL1_f2 CAGTCTGTGYTGACGCAGCCGCC 
MHVL2_f CAGTCTGCCCTGACTCAGCCT 
MHVL3_f1 TCCTATGWGCTGACWCAGCCACC 
MHVL3_f2 TCTTCTGAGCTGACTCAGGACCC 
MHVL4_f1 CTGCCTGTGCTGACTCAGCCC 
MHVL4_f2 CAGCYTGTGCTGACTCAATCRYC 
MHVL5_f CAGSCTGTGCTGACTCAGCC 
MHVL6_f AATTTTATGCTGACTCAGCCCCA 
MHVL7_8_f CAGRCTGTGGTGACYCAGGAGCC 
MHVL9_10_f CAGSCWGKGCTGACTCAGCCACC 
Lambda1stPCR_r AGAGGASGGYGGGAACAGAGTGAC 
 
Primers for addition of VH gap repair DNA flanking oligonucleotides (2nd PCR): 
 
Xpress-Liker-MHVH1_f GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTcaggtbcagctggtgcagtctgg  
Xpress-LikerMHVH1/7_f GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTcarrtscagctggtrcartctgg  
Xpress-LikerMHVH2_f GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTcagrtcaccttgaaggagtctgg  
Xpress-LikerMHVH3_f1 GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTsargtgcagctggtggagtctgg  
Xpress-LikerMHVH3_f2 GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTgaggtgcagctgktggagwcysg  
Xpress-LikerMHVH4_f1 GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTsargtgcagctggtggagtctgg  
Xpress-LikerMHVH4_f2 GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTcagstgcagctrcagsagtssgg  
Xpress-LikerMHVH5_f GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTgargtgcagctggtgcagtctgg  
Xpress-LikerMHVH6_f GCAGGGGATCTGTACGACGATGACGATAAGGGTGGTGGTGGTTCTcaggtacagctgcagcagtcagg  
CH1-VHJ1_r GGAGGAGGGTGCCAGGGGGAAGACCGATGGGCCCTTGGTACTAGctgaggagacggtgaccagggttcc 
CH1-VHJ2_r GGAGGAGGGTGCCAGGGGGAAGACCGATGGGCCCTTGGTACTAGctgaggagacggtgaccgtggtccc 
CH1-VHJ3_r GGAGGAGGGTGCCAGGGGGAAGACCGATGGGCCCTTGGTACTAGctgaggagacrgtgaccagggtscc 
CH1-VHJ4_r GGAGGAGGGTGCCAGGGGGAAGACCGATGGGCCCTTGGTACTAGctgaagagacggtgaccattgtccc 
 
Primers for addition of VK gap repair DNA flanking oligonucleotides (2nd PCR): 
APP8-MHVK1_f1 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgacatccagatgacccagtctcc 
APP8-MHVK1_f2 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgmcatccrgwtgacccagtctcc 
APP8-MHVK2_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgatrttgtgatgacycagwctcc 
APP8-MHVK3_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgaaatwgtgwtgacrcagtctcc 
APP8-MHVK4_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgacatcgtgatgacccagtctcc 
APP8-MHVK5_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgaaacgacactcacgcagtctcc 
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APP8-MHVK6_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAgawrttgtgmtgacwcagtctcc 
 Kappa2ndPCR_r AGCTGTACCAGACTTCAATTGTTCGTCAGATGGTGGAAAAATGAAgacagatggtgcagccacagt 
 
Primers for addition of VL gap repair DNA flanking oligonucleotides (2nd PCR): 
 
APP8-MHVL1_f1 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagtctgtgctgactcagccacc 
APP8-MHVL1_f2 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagtctgtgytgacgcagccgcc 
APP8-MHVL2_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagtctgccctgactcagcct 
APP8-MHVL3_f1 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAtcctatgwgctgacwcagccacc 
 APP8-MHVL3_f2 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAtcttctgagctgactcaggaccc 
APP8-MHVL4_f1 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGActgcctgtgctgactcagccc 
APP8-MHVL4_f2 GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagcytgtgctgactcaatcryc 
APP8- MHVL5_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagsctgtgctgactcagcc 
APP8- MHVL6_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAaattttatgctgactcagcccca 
App8-MHVL7_8_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagrctgtggtgacycaggagcc 
APP8-MHVL9_10_f GCCAGCATTGCTGCTAAAGAAGAAGGGGTACAACTCGATAAAAGAcagscwgkgctgactcagccacc 
Lambda2ndPCR_r ACTGATGAGACACACCAGTGTGGCCTTGTTGGCTTGAAGCTCCTCagaggasggygggaacagagtgac 
 
Primers for amplification of VH gap repair DNA flanking oligonucleotides (3rd PCR): 
 
HC3rdPCR_f GCAGGGGATCTGTACGACGATG 
HC3rdPCR_r GGAGGAGGGTGCCAGGGGGAAGAC 
 
Primers for amplification of VK gap repair DNA flanking oligonucleotides (3rd PCR): 
 
kappa3rdPCR_f GCCAGCATTGCTGCTAAAGA 
kappa3rdPCR_r AGCTGTACCAGACTTCAATT 
 
Primers for amplification of VL gap repair DNA flanking oligonucleotides (3rd PCR): 
 
lambada3rdPCR_f GCCAGCATTGCTGCTAAAGA 
lambada3rdPCR_r ACTGATGAGACACACCAGTG 
 
Primers for sequencing: 
 
pTT5_VH_r TCTTGTCCACCTTGGTGTT
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pTT5_VL_r TCTCGACACCAGCCTTGAC
 pTT5_VK_r GCGTTATCAACTTTCCATT
  
 
3.5. Chemicals and supplements 
 
Ampicillin sodium salt  Sigma-Aldrich,St louise,MO,USA 
2-Mercaptoethanol Sigma-Aldrich,St louise,MO,USA 
Bovine serum albumin (BSA) Equitech-Bio, Kerrville, USA 
Calcium chloride (CaCl2) Sigma-Aldrich,St louise,MO,USA 
D-(+)- Galactose Sigma-Aldrich,St louise,MO,USA 
D-(+)Glucose Sigma-Aldrich,St louise,MO,USA 
Dako Fluorescence Mounting Medium Agilent Technologies,Santa Clara,CA, 
 DDT in ddH2O Sigma-Aldrich,St louise,MO,USA 
Disodium hydrogen phosphate (Na2HPO4*2H2O) Merck, Darmstadt, Germany 
DO Supplement –Leu Clontech,Mountain View,CA,USA 
DO Supplement –Leu/–Trp Clontech,Mountain View,CA,USA 
DO Supplement –Trp Clontech,Mountain View,CA,USA 
Eagle Minimal Essential Medium (MEM) Sigma-Aldrich,St louise,MO,USA 
EDTA (ethylenediaminetetraacetic acid) Sigma-Aldrich,St louise,MO,USA 
Ethanol Sigma-Aldrich,St louise,MO,USA 
EX-CELL® 293 Serum-Free Medium Sigma-Aldrich,St louise,MO,USA 
EZ-Link NHS-PEG4-Biotin, No-Weigh Format Thermo Fisher Scientific,Waltham,USA 
Fibronectin bovine plasma Sigma-Aldrich,St louise,MO,USA 
Gel loading dye (6×) New England Biolabs, Ipswich, MA, USA 
Gibco® Dulbecco’s modified eagle medium(DMEM) Life Technologies, Darmstadt, Germany 
Gibco® Fetal bovine serum (FBS) Life Technologies, Darmstadt, Germany 
Gibco® L-glutamine Life Technologies, Darmstadt, Germany 
Gibco® sodium pyruvate Life Technologies, Darmstadt, Germany 
Giboc® RPMI 1640 medium Life Technologies, Darmstadt, Germany 
Giboco®  DMEM/F-12 (1:1) Life Technologies, Darmstadt, Germany 
Giboco®  FreeStyle™ 293 Life Technologies, Darmstadt, Germany 
Glycerol Sigma-Aldrich,St louise,MO,USA 
Glycine Merck, Darmstadt, Germany 
Guava instrument cleaning fluid (ICF) Merck, Darmstadt, Germany 
Hoechst 33342 Sigma-Aldrich,St louise,MO,USA 
Hydrochloric acid smoking 37% (HCl) Merck, Darmstadt, Germany 
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Kinetics buffer (X10) Pall ForteBio LLC, Menlo Park, CA, USA 
LB + ampicillin plates  Hy-Labs,Rehovot,Israel 
LB Broth  Hy-Labs,Rehovot,Israel 
Lithium acetate Sigma-Aldrich,St louise,MO,USA 
Magnesium sulfate heptahydrate (MgSO4) Sigma-Aldrich,St louise,MO,USA 
Minimal SD Agar Base Clontech, Mountain View, CA, USA 
Minimal SD-Base Gal/Raf Clontech, Mountain View, CA, USA 
Paraformaldehyde 16%  aqueous solution EMS,Hatfield,PA,USA 
Pepton from casein Merck, Darmstadt, Germany 
Potassium chloride (KCl) Sigma-Aldrich,St louise,MO,USA 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich,St louise,MO,USA 
Potassium di-hydrogen phosphate (KH2PO4) Merck, Darmstadt, Germany 
ProCHO 5 serum-free media  Lonza,Basel, Switzerland 
ProCHO5 medium Lonza, Basel, Switzerland 
Quick-Load® 100 bp DNA Ladder New England Biolabs, Ipswich, MA, USA 
S.O.C. medium NEB,Ipswich, MA,USA 
Salmon sperm DNA Thermo Fisher Scientific, Carlsbad,USA 
SeaKem® LE Agarose Lonza,Basel, Switzerland 
Sodium chloride (NaCl) Sigma-Aldrich,St louise,MO,USA 
Sodium dehydrogen phosphate monohydrate(NaH2PO4 
H2O) 
Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium phosphate dibasic (Na2HPO4 2H2O) Merck, Darmstadt, Germany 
Sorbitol Merck, Darmstadt, Germany 
TAEx50 buffer Hy-Labs,Rehovot,Israel 
Tris Base Merck, Darmstadt, Germany 
Yeast Nitrogen Base w/o Amino acids  Sigma-Aldrich,St louise,MO,USA 
YPD agar plate  Hy-Labs,Rehovot,Israel 
YPD broth Hy-Labs,Rehovot,Israel 
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3.6. Cell culture media 
Mammalian  
 
A431, NTERA-2cl.D1, SK-BR-3 DMEM, 10% (v/v) FBS 
SW620, CHO-S (adherent) DMEM/F-12 (1:1), 10% (v/v) FBS 
A549,MDA-MB-468,HT-29,HCT116, 
MKN45,MCF7, NCI-H1975 
RPMI 1640, 10% (v/v) FBS, 2 mM L-glutamine, 
1 mM sodium pyruvate 
CCD-18Co MEM Eagle, 10% (v/v) FBS, 2 mM L-glutamine 
CHO-S ProCHO5, 4 mM L-glutamine, Gibco®  
HT Supplement (1:50) 
HEK 293 EBNA(growth) EXcell-293  
HEK 293 EBNA(expression) FreeStyle 293,0.5% (v/v) FBS 
 
Yeast (S. cerevisiae) 
 
SD -Trp, SD -Leu, SD -Trp/-Leu 6.7 g/L Yeast Nitrogen Base w/o Amino acid, 
20g/L D-(+)Glucose, 12.1 g/L NaH2PO4×H2O, 
2.1 g/L Na2HPO4, one of the dropout 
supplements (0.74 g/L DO-mix -Trp, 0.69 g/L 
DO-mix -Leu, 0.64 g/L DO-mix -Trp/- Leu) 
SG-Trp/-Leu + Pepton 37 g/L minimal SD-Base Gal/Raf, 8.56 g/L 
NaH2PO4×H2O, 20.6 g/L Na2HPO4, 
0.64 g/L DO-mix -Trp/-Leu, 50 g/L Pepton from 
casein 
SD -Trp plates, SD - Leu plates, SD -Trp/-Leu plates  46.7 g/L minimal SD agar base, one of the 
dropout supplements (0.74 g/L DO-mix -Trp, 
0.69 g/L DO-mix -Leu, 0.64 g/L DO-mix - Trp/-
Leu) 
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3.7. Solutions, media and buffer 
 
Phosphate buffered saline (PBSx1) 140 mM NaCl, 3 mM KCl, 
8 mM Na2HPO4 x 2H2O, 2 mM KH2PO4, pH 
 PBMCMA (biopanning washing buffer)  PBSx1, 0.9 mM CaCl2, 0.49 mM MgCl21 
g/l BSA 
Washing buffer (Yeast, flow cytometry analysis) PBSx1, 0. 5% (w/v) BSA,2mM EDTA 
Binding buffer (Mammalian, flow cytometry 
analysis) 
PBSx1, 1% (w/v) BSA,2mM EDTA 
LB- Ampicillin LB Broth, 0.1%(v/v) Ampicillin  
LB-glycerol  LB-Ampicillin,30%(v/v) glycerol 
PA SpinTrap binding buffer 2g/L H2NaO4P,1.2g/L Na2HPO4 x 2H2O, 
  PA SpinTrap Elution buffer 0.1M Glycine/HCl  pH 2.7 
PA SpinTrap Neutralizing buffer 1M Tris/HCl pH 7 
Yeast lysis buffer  20 nM NaOH, 5µg/ml Ribonuclease A  
Yeast library freezing solution 15% (v/v) glycerol, SD -Trp/ SD -Leu/ SD 
-Trp/-Leu 
Yeast transformation buffer 1 M sorbitol, in dH2O 
 
 
3.8. Kits and laboratory materials 
 
6/12 Well cell culture plate sterile  Greiner Bio-one, Frickenhausen, Germany 
96 well polypropylene black microplates F-Bottom Greiner Bio-one, Frickenhausen, Germany 
Amicon® Ultra-15 and 0.5 ml centrifugal filter units 
10k 
Merck, Darmstadt, Germany 
Erlenmeyer Flask- Baffled Base 2L, 1L, 500ml, 
250ml, 125ml TriForestLabware,Irvine, CA, USA 
Falcon® 96-well Clear Round Bottom plates Cornning,NY,USA 
FortéBio tips (AHC,AMC,Streptavidin,  Pall ForteBio LLC, Menlo Park, CA, USA 
Gene Pulser cuvette 0.2cm Bio-Rad, Hercules, CA, USA 
Ingenio® Electroporation Kit  Mirus Bio,Madison,WI,USA 
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MicroAmp™ Optical 96-Well Reaction Plate  Thermo Fisher Scientific,Waltham,USA 
Nunc™ Cell Culture Treated Flasks with Filter Caps T-
80 Thermo Fisher Scientific,Roskilde,Denmark 
Petri dish 90mm  Hy-Labs,Rehovot,Israel 
Protein A HP SpinTrap GE Healthcare,Buckinghamshire,UK 
Qiaquick pcr purification kit Qiagen, Hilden, Germany 
RNA ScreenTape kit  Agilent Technologies,Santa Clara,CA, USA 
RNeasy® Midi kit Qiagen, Hilden, Germany 
SuperScript™ III Reverse Transcriptase Thermo Fisher Scientific, Carlsbad,USA 
TaqMan Gene Expression Assay  
(CD19,CD20,RPLP0) Applied Biosystems ,Foster City,CA,USA 
 
3.9. Equipment 
 
Analytical balance New Classic MF MS3002S Mettler Toledo, Giessen, Germany 
Agilent 2200 TapeStation Agilent Technologies,Santa Clara, USA 
Analytical balance New Classic MF MS3002S Mettler Toledo, Giessen, Germany 
Applied Biosystems ViiA™ 7 Real-Time PCR System  Thermo Fisher Scientific, Waltham, MA ,USA 
BD FACSAria™ III cell sorter BD Biosciences,San Jose,CA,USA 
Bio RS-24, Mini-rotator Biosan,Riga, Latvia 
CCD microscope camera Leica DFC3000 G  Leica,Wetzlar, Germany 
Cell counter Vi-CELL® XR Beckmann Coulter, Brea, CA, USA 
Circulating Bath  PolyScience,Niles,IL,USA 
Class II, Type A2 Biosafety Cabinets Labconco Corporation,Kansas City, MO,USA 
Electrophoresis  chambers Bio-Rad, Hercules, CA, USA 
Elite Dry Bath Incubator Major Science , Saratoga, CA, USA 
Flow cytometer Guava easyCyte HT 2L Merck, Darmstadt, Germany 
FortéBio Octet RED Pall ForteBio LLC, Menlo Park, CA, USA 
Gene Pulser Xcell™ Electroporation Systems Bio-Rad, Hercules, CA, USA 
Heracell CO2 Incubator Thermo Fisher Scientific, Waltham, MA ,USA 
Heraeus Multifuge X3R Thermo Fisher Scientific, Waltham, MA ,USA 
Heraeus™ Fresco™ 17 Microcentrifuge Thermo Fisher Scientific, Waltham, MA ,USA 
Incubation shaker Multitron Standard Infros HT, Bottmingen, Switzerland 
Mini horizontal gel unit Scie-Plas Ltd,Cambridge,UK 
MiniBIS Pro - DNR Bio Imaging System DNR,Neve Yamin,Israel 
MultiSUB™ horizontal gel electrophoresis unit Cleaver Scientific Ltd,Warwickshire,UK 
NanoDrop™ 1000 Spectrophotometer Thermo Fisher Scientific, Waltham, MA ,USA 
NanoDrop™ 2000 Spectrophotometer Thermo Fisher Scientific, Waltham, MA ,USA 
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Pannoramic MIDI II 3DHISTECH,Budapest,Hungary 
Power supply PS500X DC Hoefer,Holliston, MA,USA 
Rotor-Stator TH Tissue Homogenizers 
 
Omni International,Kennesaw,GA,USA 
SterilGARD® III Advance  Safety Cabinets The Baker Company,Sanford, Maine,USA 
Veriti™ 96-Well Thermal Cycler Thermo Fisher Scientific, Waltham, MA ,USA 
 
 
Further equipment comprised common laboratory instrumentation. 
 
 
3.10. Software 
 
Agilent 2200 TapeStation analysis ver A.01.09   Agilent Technologies,Santa Clara,CA, USA 
Agilent 2200 TapeStation conroler  ver A.01.09   Agilent Technologies,Santa Clara,CA, USA 
BD FACSDIVA™ software ver 1.1.3 BD Biosciences,San Jose,CA,USA 
cellSens Entry Imaging  ver  v4.7 Olympus,Tokyo,Japan 
Clone Manager professional ver 9.51  Scientific & Educational Software ,Denver, 
CO, USA 
FCS Express 6 ver 6.06.0014 De Novo Software,Glendale, CA,USA 
FortéBio octet data acquisition ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
FortéBio octet data analysis ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
GraphPad Prism verV6.07 GraphPad Software, La Jolla, CA, USA 
GuavaSoft ver 3.1 Merck, Darmstadt, Germany 
Jalview ver 2.10.4 http://www.jalview.org 
Leica application suite  ver v4.7 Leica,Wetzlar, Germany 
Mendeley Desktop ver.1.19.2 Mendeley Ltd,London,UK 
Microsoft Office 2016 Microsoft Corp., Redmond, WA, USA 
Panoramic Viewer  ver 1.15.4 3DHISTECH,Budapest,Hungary 
PyMOL ver.vl.1.7.6.0 Schrodinger LLC, San Diego, CA, USA 
QuantStudio™ Real-Time PCR  ver.1.3 Applied Biosystems ,Foster City,CA,USA 
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4. Methods 
 
 
 
4.1. Molecular biological methods 
4.1.1. Total RNA isolation from patients’ tissues  
Total RNA was Isolated separately for each patient’s tissue using the RNeasy® Midi kit (chapter 3.8) 
according to the manufacturer’s instruction. Samples were taken out from storage in liquid nitrogen and 
immediately placed in a bucket with liquid nitrogen until weighting of the samples. The weighed tissues 
were placed in a suitably 15 ml centrifuge tube followed by immediately adding of 6 ml lysis buffer 
(6ml buffer RLT+ 60µl β-Mercaptoethanol) and homogenized immediately using a conventional rotor–
stator homogenizer (chapter 3.8) for 45 sec until the samples were uniformly homogeneous. The tissue 
lysates were centrifuged (4500xg, 10 min) and the lysate supernatants were transferred to a new 15 ml 
tube by pipetting. Subsequently, only the lysate supernatants were used. one volume of 70% ethanol 
was added to the homogenized lysates and were mixed immediately by shaking vigorously. The lysates 
of each sample were divided and applied on three RNeasy® Midi columns placed in a 15 ml centrifuge 
tube and were centrifuged (4500xg, 5 min). The flow-through were discarded. Followed by pipetting 2 
ml buffer RW1 into the RNeasy® Midi columns. The columns were centrifuged (4500xg, 5 min) and 
the flow-through were discarded. 160 µl of DNase I incubation mix (20 µl + 140 µl buffer RDD) were 
directly added to the RNeasy® Midi columns silica-gel membrane and were placed on the benchtop for 
15 min at 25°C.Then, 2 ml of buffer RW1 were added into the RNeasy® Midi columns and placed on 
the benchtop for 5 min at 25°C. The columns were centrifuged (4500xg, 2 min) and the flow-through 
were discarded. For washing, 2.5 ml of buffer RPE were added to RNeasy® Midi columns. The columns 
were centrifuged (4500xg, 2 min) and the flow-through were discarded. This step was repeated 2 times. 
For elution the RNeasy® Midi columns were transferred to new 15 ml tubes and 150 µl of RNase-free 
water were added directly onto the RNeasy® Midi columns silica-gel membrane and placed on the 
benchtop for 1 min at 25°C. The elution steps were repeated once as describe above. RNA concentration 
was photometrically determined (cf. chapter 4.1.2). 
4.1.2. Determination of DNA/RNA concentration 
The nucleic acid concentration in aqueous solutions was measured by a UV spectrophotometer, Nanodrop 
ND1000 (chapter 3.9) applying 1.5 µl of sample. The underlying physical principals are the law of 
Lambert-Beer and the absorption of aromatic nucleobases within the DNA/RNA at the wavelength 260 
nm. The ratios A260/A280 and A260/A230 can be used as a quality criterion for the purity of the DNA/RNA. 
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For DNA ratios should be around 1.8 and 2.0-2.2, respectively. For RNA ratios should be around 2 and 
2.0-2.2, respectively. 
4.1.3. Determination of RNA integrity number 
The determination of quality of the total RNA isolated from the patient’s tissues were measured using the 
2200 TapeStation system electrophoresis bioanalyzer (chapter 3.9) using the RNA ScreenTape kit 
according to the manufacturer’s instruction by applying 1 µl of RNA from each sample. The RNA 
integrity number equivalent (RINe) provides an independent quality score for total RNA was analyzed by 
the Agilent 2200 TapeStation Software (chapter 3.10) . 
4.1.4. Polymerase chain reaction 
DNA can be exponentially and specifically amplified by the polymerase chain reaction (PCR) employing 
DNA flanking, complementary oligonucleotides or primers (Mullis et al., 1986).  
PCRs for library contraction  
For each patient heavy and light chain variable region amplification (1st PCR), 2 µl of cDNA template 
(cf. chapter 4.1.5) were mixed with 5 µl AccuPrime™ reaction mix, 0.2 µM forward and reverse 
primers(chapter 3.5) 0.5 µl 2.5 U/µl AccuPrime™ Pfx DNA Polymerase (chapter 3.4), and dH2O in a 
final volume of 50 µl. After initial denaturation at 95°C for 60 sec, 30 cycles of amplification were 
performed for each 15 sec at 95°C for denaturation, 30 sec at 55°C for annealing, and 45 sec at 68°C 
for extension followed by a final extension for 10 min at 68°C.DNA was recover and purified from gel 
(cf. chapter 4.1.7). For addition of gap repair DNA flanking oligonucleotides (2nd PCR) was performed, 2 
µl of 1st PCR DNA clean-up product were mixed with 5 µl AccuPrime™ reaction mix, 0.2 µM forward and reverse 
primers (chapter 3.5), 0.5 µl 2.5 U/µl AccuPrime™ Pfx DNA Polymerase, and dH2O in a final volume of 50 µl. 
After initial denaturation at 95°C for 60 sec, 30 cycles of amplification were performed for each 15 sec at 95°C 
for denaturation, 30 sec at 55°C for annealing, and 45 sec at 68°C for extension followed by a final extension for 
10 min at 68°C. For amplification of 2nd PCR products in sufficient amount for Gap Repair (3rd PCR), 6 µl of 2st 
PCR DNA clean-up product were mixed with 10 µl AccuPrime™ reaction mix, 0.2 µM forward and reverse 
primer (chapter 3.5), 0.5 µl 2.5 U/µl AccuPrime™ Pfx DNA Polymerase, and dH2O in a final volume of 100 µl. 
After initial denaturation at 95°C for 60 sec, 30 cycles of amplification were performed for each 15 sec at 95°C 
for denaturation, 30 sec at 55°C for annealing, and 45 sec at 68°C for extension followed by a final extension for 
10 min at 68°C. DNA was recover and purified from gel (cf. chapter 4.1.7) 
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PCRs for subcloning 
In order to subcloning the variable region of heavy and light chain DNA from selected clones with the 
yeast expression vectors (pYD) into the mammalian expression vector (pTT5). 2 µl of yeast lysis (cf. 
chapter 4.2.3) were mixed with 5 µl AccuPrime™ reaction mix, 0.2 µM forward and reverse primer, 0.5 
µl 2.5 U/µl AccuPrime™ Pfx DNA Polymerase, and dH2O in a final volume of 50 µl. After initial 
denaturation at 95°C for 60 sec, 30 cycles of amplification were performed for each 15 sec at 95°C for 
denaturation, 30 sec at 55°C for annealing, and 45 sec at 68°C for extension followed by a final extension 
for 10 min at 68°C. 
Colony PCRs  
To verify the insertion for the mammalian expression vector (pTT5) after transformation (cf. chapter 
4.2.1) colony PCR were performed using Taq Ready Mix (chapter 3.4). Small amount of colony was 
mixed with 10 µl Taq Ready Mix (2X), 0.1 µM forward and reverse primer and dH2O in a final volume 
of 50 µl. After initial denaturation at 95°C for 60 sec, 33 cycles of amplification were performed for each 
15 sec at 95°C for denaturation, 30 sec at 58°C for annealing, and 45 sec at 68°C for extension followed 
by a final extension for 10 min at 68°C. 
4.1.5. Reverse transcriptase to synthesize first-strand cDNA 
cDNA was synthesized from each patient’s isolated total RNA using SuperScript™ III Reverse 
Transcriptase kit (chapter 3.9) according to the manufacturer’s instruction. Briefly, 4 µg of total RNA 
template   were mixed with 200 ng/μl random hexamers primer, 4 μl of 10 mM dNTP Mix and sterile 
distilled dH2O in a final volume of 40 µl. The mixture was heated to 65°C for 5 min and incubated on ice 
for at least 1 min. Followed by brief centrifugation and mixing with, 2 μl 10X First-Strand Buffer, 1 μl 
0.1 M DTT, 1 μl 40 U/μl RNaseOUT™ Recombinant RNase Inhibitor, 2 μl 200 U/μl SuperScript™ III 
RT. The mix was incubated at 25°C for 5 min followed by incubation at 50°C for 50 minutes for cDNA 
synthesis, and 15 min at 70°C for inactivation.  
4.1.6. Real time PCR for quantitative gene expression analysis 
Expression of CD19 and CD20 genes in the cDNA templates synthesized from patient’s RNA (cf. chapter 
4.1.5) was performed  using the Applied Biosystems TaqMan Gene Expression Assay (chapter 3.9) 
according to the manufacturer’s instruction with the ViiA 7 Real-Time PCR System (chapter 3.10). 
Briefly, cDNA templets from the patients were diluted 1:2 with DEPC water. For each reaction 5 µl 
master mix (enzyme),0.5µl assay mix (TaqMan probe and primers) and 4.5μl were mixed in a well of 
MicroAmp® optical 96-well reaction plate (chapter 3.9). The samples were analyzed using the QuantStudio™ 
Real-Time PCR Software (chapter 3.11) applying the comparative cT assay.  
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4.1.7. Purification of DNA and gel extraction 
DNA fragments were purified after PCR amplification or from agarose gel bands excised with a clean 
scalpel. PCR amplifications were cleaned and purified using the QIAquick PCR Purification kit (chapter 
3.9) according to the manufacturer’s instructions. The recovery of DNA from agarose gel was done by 
using the Zymoclean Gel DNA Recovery kit (chapter 3.9) according to the manufacturer’s instructions. 
DNA was eluted in 30 µl dH2O. DNA concentration was photometrically determined (cf. chapter 4.1.3). 
4.1.8. Gel electrophoresis  
With the help of agarose gel electrophoreses, linear DNA fragments can be separated in an electric field 
based on their length. In general, 1-2% (w/v) agarose gels were prepared in TAE buffer (X1) (chapter 
3.6) supplemented with SeaKem® LE Agarose (chapter 3.6). DNA premixed with 6x loading dye were 
loaded on gels along with 10 µl Quick-Load® 100 bp DNA Ladder (0.1-15 kbp) for determination of 
size and isolating of separated DNA (chapter 3.6) . Fragments on gels were run for 45 min at 100 V. DNA 
bands were visualized by UV light using the DNR Bio Imaging System, MiniBIS Pro (chapter 3.10). 
4.1.9. Sanger DNA sequencing 
Isolated plasmid DNA (15 µl with 50-100 ng/µl) or alternatively yeast clones were transferred to HyLabs 
(Rehovot, Israel) and sequenced using primers listed in (chapter 3.5). 
4.1.10. Next-generation sequencing 
Yeast clones were transferred to Dr. Thomas Clarke, EMD Merck (Billerica, USA) the clones VH and 
VL were sequenced and analyzed using the Illumina MiSeq System. 
 
4.2. Microbiological methods 
4.2.1. Transformation and cloning in E. coli  
Transformation and cloning were carried out with One Shot® Mach1™-T1R Chemically Competent 
E. coli (chapter 3.2) by heat shock. The genes of interest (heavy or light chain variable region) were 
amplified using specifically designed primers which are flanked with additional 15-20 base pairs of 
non-annealing 5’-tail (chapter 3.5) that carries the homology to the insertion site in the specific pTT5 
mammalian expression plasmid. The linearized plasmids pTT5 IgH/pTT5 IgK/ pTT5 IgK provided by 
Lucigen Corporation (chapter 3.3) were transformed together with the PCR amplicon (cf. chapter 4.1.4) 
into the competent E.coli strain while the recombination occurred in vivo. 25 ng PTT5 plasmid and 1 
µl of   purified PCR amplicon were incubated with 10 µl One Shot® Mach1™-T1R Chemically 
Competent E. coli, which were thawed on ice, for 30 min. Heat-shock was performed for 30 sec at 42°C 
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followed by incubation on ice for 2 min. Then, transformed cells were shaken in 175 µl S.O.C. medium 
for 1 h at 225 rpm and 37°C followed by plating on LB-A selective agar (chapter 3.6)  and incubation 
overnight at 37°C.  
4.2.2. Extraction of pure plasmid DNA from bacterial cultures 
The pTT5 plasmids with the insertion of the selected clones after colony PCR verification (cf. chapter 
4.2.1) were extracted and purified using the AccuPrep® Plasmid Mini Extraction kit (chapter 3.9) 
according to the manufacturer’s instructions. DNA was eluted in 50 µl dH2O. DNA concentration was 
photometrically determined (cf. chapter 4.1.3). 
4.2.3. Lysis of the yeast cells  
In order to isolate the heavy and the light chain variable regions from each selected clone by PCR (cf. 
chapter 4.1.4), crude lysate of the cytoplasmic fluids were done. The lysates contained, among other, the 
heavy and light yeast expression vector. These lysates were used as template for the PCRs for the isolation 
of the variable regions of the antibodies for cloning into specific pTT5 mammalian expression plasmid. 
Large glob of cells from freshly growing yeast on an agar plate were mixed with 50 µl lysis buffer (chapter 3.7), 
incubated for 2 min at 100°C and centrifuged (21000xg, 2 min, RT). The lysate supernatants were collected by 
pipetting. 
4.2.4. Generation and transformation of competent S. cerevisiae 
Electrocompetent S. cerevisiae cells were prepared for the electroporation with pYD derived plasmids 
that enable covalent cell surface display of heterodimeric antibody Fab fragments. Fresh electrocompetent 
cells were prepared prior to electroporation (Benatuil et al., 2010). Briefly, one colony of S. cerevisiae 
BJ5464 or EBY100 yeast cells from YPD agar plate were grown in YPD medium to stationary phase 
overnight at 30 °C, 250 rpm and an aliquot of cells was used for inoculation of 400 ml YPD at an initiate 
0.3 OD600 (3x106 cells per ml). An absorbance value of 1 at 600 nm corresponded to approximately 1 × 
107 cells per ml, measured with the Vi-CELL XR cell counter (chapter 3.9). Cells were cultivated at 30 
°C ,225 rpm until 1.5 OD600. The culture was chilled on ice for 15 min and cells were harvested by 
centrifugation (1600×g, 5 min, 4 °C). The cell pellets were washed three times in 30 ml ice cold dH2O 
following by resuspension in 50ml 1M sorbitol/1M CaCl2 solution (chapter 3.4) following by 
centrifugation (1600×g, 5 min, 4 °C), twice. The cell pellets were suspended with 50ml cold 1 M sorbitol 
solution (chapter 3.5) following by centrifugation (1600×g, 5 min, 4 °C). The cell pellets than were 
resuspend with 1 M sorbitol solution in concentration of 16.25x108 cells per ml. Aliquots with 0.4 ml cell 
suspension were prepared in 1.5 ml tubes and stored at ice until transformation. The transformations were 
done immediately after preparation of the electrocompetent cells. For each patient’s gap repair 
transformations of vHC or vLC fragments one aliquot of competent yeast cells were used. Cells were washed 
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once with 1ml of 1 M sorbitol solution followed by centrifugation (4100×rpm,1min,4°C). The pellets 
were resuspended with 400 µl 1 M sorbitol solution to give approximately 1.6 × 109 cells/ml   and with 2 
µg respective linearized plasmid HC or LC (chapter 3.3) and 6 µg of respective vHC or vLC DNA 
fragments. The suspensions were mixed by pipetting and transferred to a pre-chilled cuvette. Cells were 
electroporated with 1.5 kV, 25 μF and 200 Ω (time constants ranged from 3-4.5 ms). Directly after 
electroporation, cells were diluted with 1 ml of ice-cold 1.0 M sorbitol. For expansion each of the transformed 
cells were inoculated with appropriate 300 ml selective SD media for 48hr at 30°C,225 rpm. The cells 
were harvested (1600×g, 10 min, RT) and re-inoculated in appropriate 300 ml selective SD media 
(chapter 3.7) for 5 hr at 30°C,225 rpm. Cells then were harvested (1600×g, 10 min, RT) and resuspend in 
selective SD solution with final 15% glycerol (chapter 3.7) in concentration of 1x109cells per ml. For 
transfection efficiency and library size evaluation, same appropriate dilution of cells was plated onto 
selective respective SD and YPD plates after transformation and after inoculation and were allowed to 
grow for 72 h at 30 °C. Cells were count and transfection efficiency and library size evaluation were 
calculated respectively. 
4.2.5. Construction of Fab libraries by mating of S. cerevisiae cells    
In order to construct the Fab yeast displayed libraries, yeast mating was performed. After construction of 
heavy and light chain plasmids encoding regions VH-CH1 and VL-CL, respectively, via homologous 
recombination in haploid EBY100 (VH-CH1) and BJ5464 (VL-CL) yeast strains. The haploid yeast cells 
were combined into diploid cells that display functional Fabs on their surface after mating. For Fab library 
generation, 1x 109 of each 8 patients’ (VH-CH1) EBY100 transformed yeast cells (MATα strain) were 
thawed and mixed into 400 ml SD-TRP selective media and were inoculated for 12 hr at 30 °C ,225 rpm. 
Respectively, 1x 109 of each 8 patients’ (VL-CL) kappa or lambda BJ5464 transformed yeast cells (MATa 
strain) were thawed and mixed into 400 ml SD-LEU selective media (chapter 3.7) and were inoculated 
for 12 hr at 30 °C ,225 rpm. 1 x 109 of each culture were mixed together, (VH-CH1) EBY100 with (VL-
CL) kappa or lambda BJ5464. Cells then were harvested (1600×g, 5 min, RT) and the pellet was 
resuspended in 300 µl YPD broth. The mixed cells were then spotted (50µl) in the center of a prewarmed 
30 °C YPD plate. The plates were incubated at 30 °C for 19 hr. The yeast colonies were scrapped off 
from the plates into tube contained selective SD-Trp/-Leu media (chapter 3.7). Mated cells then of both 
libraries kappa and lambda were transferred to 1.4 L of SD -Trp/-Leu medium at concentration of 2.5 x 
106 cells per ml and cultivated for 48 h 25 30 °C and 225 rpm. Immediately after mating and after 
inoculation cells were taken for serial dilution for plating onto SD -Trp/- Leu SD- Trp and SD -Leu 
(chapter 3.7). Cells were allowed to grow for 72 h at 30 °C to and library size was calculated by the 
number of independent clones that were grown. Mating efficiency were calculated by relatively by 
subtraction of clone numbers that were grown on the control plates.  
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4.2.6. Cultivation, induction of Fab surface expression and storage of S. cerevisiae cells 
Cultivation of S. cerevisiae yeast cells were performed for propagation as well as to induce cell surface 
display of antibody fragments on yeast cell surface. Propagation of cells carrying pYD-VH-CH1 and/or 
pYD-VL-CK, pYD-VL-CL constructs was done in minimal SD media, supplemented with drop out 
supplements to confirm auxotrophic phenotypes and to select transformants towards their episomally 
encoded marker genes (chapter 3.3) 
For this, cells from plate, glycerol stoke, flow cytometry sorting or bio-panning were transferred into 
selective SD medium. Expansion of the culture was carried out for 24-72 h at 30 °C and 225 rpm until 
stationary phase was reached (OD600 of approximately 4-6). For induction and expression of antibody 
fragments, cells of a stationary phase SD culture were harvested and transferred to SG-Trp-Leu+50 gr/ml 
peptone medium (chapter 3.7) to an initiate OD600 of 1, followed by cultivation for 48 h at 20 °C and 
225 rpm. Culture volumes typically varied between 10-50 ml. For storage of single clone yeast cells, cells 
of stationary SD cultures were centrifuged and resuspended in selective SD solution with final 15% 
glycerol (chapter 3.7) at 4-6 × 108 cells/ml. Aliquots with 1.5 ml cell suspension were prepared in 2 ml 
cryogenic vials and stored at -70 °C. 
4.2.7. Flow cytometry binding assays using yeast surface display  
Flow cytometric binding analysis was carried out at a Guava easyCyte HT cytometer or BD FACSARIA 
III cytometer (chapter 3.9) using corresponding software Guava ExpressPro or BD FACSDIVA™ 
software respectively (chapter 3.10). Flow cytometry was performed for evaluation of different 
recombinant cancer associated antigens binding and surface presentation of antibody Fab fragments of 
the yeast cells from the libraries. Briefly, cells were induced for Fab expression  in 10 ml SG-Trp-Leu+50 
gr/ml peptone medium (chapter 3.7 )  in 50 ml filtered tube at 20 °C for 48 hr. 5x106 cells were taken into 
2 ml tube and washed with 1 ml of cold D-PBS + 0.5 % BSA (chapter 3.7)  followed with centrifugation 
(4500×rpm,3 min,4°C). The pellets were resuspended with 50 µl DPBS with the respective concertation 
of biotinylated antigen, followed by incubation with rotation on RT for 20 min and on ice for 10 min. 
Then cells were washed with 1 ml of cold D-PBS + 0.5 % BSA (chapter 3.4 ) followed with centrifugation 
(4500×rpm,3 min,4°C). The pellets were resuspended with 50 µl with 5 µg/ml anti LC Kappa or lambda 
PE conjugated and 4 µg/ml SA APC conjugated (chapter 3.4.1) fluorescents markers. Followed by 
incubation with rotation on RT for 20 min and on ice for 10 min. Then cells were washed with 1 ml of 
cold D-PBS + 0.5 % BSA (chapter 3.7)  followed with centrifugation (4500×rpm,3 min,4°C) twice . The 
cells were then resuspended with 0.5 ml DPBS and were taken for the FACS analysis. For control, yeast 
cells were labeled without the biotinylated antigen.  
For high-throughput screening of individual clones, individual clones were grown with streaking on SD-
Trp/-Leu selective plates. Each individual clone was transferred to 96 deep well plate (chapter 3.8) filled 
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with 0.9 ml SG-Trp-Leu+50 gr/ml peptone medium. The plate was incubated for 48 hr at 20 °C ,450 rpm 
with 80 % humidity. Then, 100 µl of yeast cells were transferred from the deep well plats into u-bottom 
well plates. The plates were centrifuged (3000×g,3 min) supernatant were removed by inversion of the 
plate. The plates were washed with 150 µl per well of cold D-PBS + 0.5 % BSA. Followed by 
centrifugation (3000×g,3 min) and the supernatants were removed by inversion of the plate. The pellets 
in each well was resuspended with 50 µl DPBS with the respective concertation of biotinylated antigen, 
followed by incubation on ice for 30 min. Then, the plates were centrifuged (3000×g,3 min) supernatant 
were removed by inversion of the plate. The plate washed with 150 µl per well of cold D-PBS + 0.5 % 
BSA, followed by centrifugation (3000×g,3 min) and the supernatant were removed by inversion of the 
plate. The pellets on each well were resuspended with 50 µl DPBS and anti LC Kappa or lambda PE 
conjugated and 4 µg/ml SA APC conjugated fluorescents markers. Followed by incubation on ice for 30 
min. Then, the plates were centrifuged (3000×g,3 min) supernatant were removed by inversion of the plate 
and the plates washed with 150 µl per well of cold D-PBS + 0.5 % BSA. Followed by centrifugation 
(3000×g,3 min) and the supernatant were removed by inversion of the plate. The cells then resuspend with 
150 µl per well DPBS and were taken for the GUAVA analysis. For control individual yeast clones were 
labeled without the biotinylated antigen.  
4.4. Cell biological methods 
4.2.8. Flow cytometry sorting for isolating high binders using yeast surface display  
In order to sort high yeast binders from the libraries to different recombinant cancer associated antigens. 
Flow cytometric sorting assay was carried out at the FACS Aria III (chapter 3.9) using corresponding 
Diva softer (chapter 3.10). The binding of the yeast cells expressed Fab on their surface preformed as 
described in chapter 4.27 with exception of all the process performed under sterile condition and the 
amount of yeast cells for binding and sorting were between 100-250 x106 cells. After binding were 
performed the pellet resuspend with 1.5-3 ml respectively and were taken for the FACS Aria III for 
sorting. The sort was performed in 2 steps, the gated population with the top PE and APC fluorescent 
cells respectively were sorted. Immediately after the sort, re-sort was performed while again the gated 
population with the top PE and APC fluorescent cells respectively were sorted. After the re-sort the sorted 
cells were transferred into 50 ml filtered tube containing 5 ml SD/Trp-Leu for inculcation 24-72 h at 30 
°C and 320 rpm until stationary phase was reached. In addition, appropriate diluted amount of yeast cells 
was plated on a selective SD-Trp/-Leu selective agar plate for clone streaking.  Incubate at 30 0C, 320 
rpm.          
4.2.9. Bio-Panning on cancer derived cell lines using yeast surface display  
In order to isolate high yeast binders from the libraries, targeting the surface displayed antigens on 
cancer derived cell lines, biopanning assay was carried out. Briefly, adherent cell line cultures were 
prepared in T80 flasks. In the first bio-panning round, 4 flasks from each cell line were seeded with 
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5x106 cells per flask in the appropriate growth medium (chapter 3.6) and incubated for 3 days at 37 °C 
with 5% CO2 until more than 80% confluency were reached. The flasks where washed twice with 
washing buffer (PBSCMA) (chapter 3.6) to remove all unattached cancer cells immediately before 
adding the yeast cells. 
2x109 yeast cells of the kappa library were induced for Fab expression in 200 ml SG-Trp-Leu+50 gr/ml 
peptone medium (chapter 3.6) in 2L filtered tube at 20 °C for 48 hr. The yeast cells were reached a total 
number of ~ 20x109 cells. The cells were washed with washing buffer (PBSCMA) (chapter 3.4) 
followed with centrifugation (2500×g,3 min). The pellets were resuspended with 40 ml washing buffer 
and 10 ml (5x109 cells) were transfer to each flask with the attached negative derived cell line culture 
(depletion). The overlaid yeast cells, were incubated for 2 hr at 20 °C. Then the unbonded yeast cells 
were removed and transferred respectively to 4 flasks with the specific cancer cell line culture(positive 
binding). Followed by incubation for 2 hr at 20 °C. After incubation the cells that didn’t bind were 
discarded and the flasks were washed 3 times with washing buffer and 3 times with DPBS. After 
washing, pictures of the cancer derived cells and the yeast binders were taken using the CCD 
microscope camera Leica DFC3000 G (chapter 3.9) and the corresponding software Leica application 
suite software (chapter 3.10 ).The cancer derived cells and the yeast binders were removed from the 
flasks using 2.5 ml of 0.48 mM EDTA per flask. Cells were washed out with SD/Trp-Leu medium, 
centrifuged (2500×g,3 min) and the pellet were transferred into 50 ml filtered tube in 5 ml SD/Trp-Leu 
medium for inculcation 24-72 h at 30 °C and 320 rpm until stationary phase of the yeast cells were 
reached. In the next bio-panning rounds only 1 flask was used for the bio-panning rounds containing 
1x109 yeast cells per flask. In the 4th round only 1x108 yeast cells were used.   
 
4.4.1. Cultivation of mammalian cells 
All mammalian cell lines (chapter 3.2) were cultivated in tissue culture flasks of appropriate sizes (chapter 
3.8), T80 or alternatively Erlenmeyer flask using the recommended media formulations (chapter 3.6) 
under sterile conditions at 37°C, 5% or 10% CO2 under humidified atmosphere. Cells were certified 
mycoplasma-free and never exceeded passage 25. 
 
Adherent cells were detached by 2.5ml TrypLE™ Express Enzyme (chapter 3.4) for 2-3 min at 37°C after 
washing with DPBS+1%BSA to remove residual serum components for cell analysis or with appropriate 
medium for cultivation. Cell number and viability of detached adherent cells or unprocessed suspension cells 
were measured by the cell counting device Vi-CELL® XR (chapter 3.9) by calculating the average of 50 
images of trypan blue treated cells. For analysis, after cell pelleting (250xg, 10 min, RT), supernatants were 
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discarded, and cells were diluted in DPBS+1%BSA yielding appropriate cell numbers (dependent on cell 
line). Cell lines were testified mycoplasma free and cell culture conditions were standardized.  
4.4.2. Transfection of mammalian cells and antibody expression 
Antibodies were expressed by transient co-transfection of antibody chains in HEK293-EBNA cells 
(chapter 3.2) by electroporation using the Ingenio Electroporation kit (chapter 3.6 and 3.8) according to 
the manufacturer’s instruction. Briefly, HEK293-EBNA cells were cultivated with starting 
concentration of 0.6x 106/ml cells in growth medium in Erlenmeyer flasks at 37°C, 5% CO2 and 125 
rpm orbital shaking for 2 days. Then, cells were counted and 40x106 viable cells per transfection were 
taken. Cells were pelleted (800xrpm,5min) washed with DPBS and pelleted again (800xrpm,5min). The 
pellet was resuspended with 0.25 ml Ingenio electroporation buffer per transfection and were 
transferred to 1.8 ml tube for each transaction. For small scale expression, 5 µg DNA (plasmid ratio: 1:1 
HC:LC) and 15 µg UltraPure™ Salmon Sperm DNA Solution were added as a carrier. The suspensions 
were mixed by pipetting and transferred to 4mm cuvette. Cells were electroporated with 1 pulse 250V 
and 25msec. Immediately after electroporation 1 ml of FreeStyle 293 expression medium +0.5%FBS were 
added to the cuvette and cells were transferred to 20ml expression medium +0.5%FBS respectively to final 
concentration of 2.0x106 cells/ml. Then the transfected cells were incubated 37°C, 5% CO2 and 125 
rpm orbital shaking for 4 hours then the temperature were reduced to 32°C for 5 days. Supernatants were 
harvested 5 days post transfection by centrifugation (1600xrpm, 5 min) and sterile filtration through 0.22 
µm Steriflip devices.  
4.4.3. Flow cytometry for cellular binding assay  
Flow cytometric cellular binding analysis for the reformatted to IgG Abs was carried out at a BD 
FACSARIA III cytometer (chapter 3.9) using corresponding software BD FACSDIVA™ (chapter 
3.10). Adherent human cell lines were detached at 70-80% confluency with TrypLE™ Express 
Enzymeand suspension cells were directly subjected to assays (chapter 3.4). Cells were counted with the 
ViCELL® XR (chapter 3.10). For the determination of antibody binding to cellular targets by flow 
cytometry, 1x106 viable cells were washed with DPBS +1% BSA pelleted at 2500xrpm (4°C, 3 min) 
and incubated with the appropriate concentration of crude or purified Abs (50-2000 nM) for 1 hr on ice. 
After washing with 1 ml DPBS +1% BSA pelleted at 2500xrpm (4°C, 3 min), antibody binding was 
detected via Alexa flour 488 conjugated F(ab')₂ donkey anti-human Fcγ specific pAb (chapter 3.4.1) 
after washing with DPBS +1% BSA pelleted at 2500xrpm (4°C, 3 min) cells were resuspended in 0.4 
ml DPBS and analyzed  in the cytometer . All incubation steps were carried out in DPBS +1% BSA 
buffer (chapter 3.7). For geometric mean fluorescence intensity (MFI) values, background 
autofluorescence values of cells treated with medium only were subtracted. For EC50 value analysis,  
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MFI values were plotted versus logarithm of mAb concentration and fitted by a 4PL model using 
GraphPad Prism 6 (chapter 3.10). 
4.4.4. Fluorescence microscope for cellular binding imaging on slides  
Cellular binding on cells attached to slides for the reformatted to IgG Abs and the imaging was carried 
out with the Olympus BX43 upright fluorescence microscope together with the Olympus DP74 color 
camera for fluorescence (chapter 3.9) using corresponding software cellSens Entry (chapter 3.10). 
Adherent human cell lines were detached at 70-80% confluency with TrypLE™ Express Enzymeand 
suspension cells were directly subjected to assays (chapter 3.4). Cells were counted with the ViCELL® 
XR (chapter 3.9). For the determination of antibody binding to cellular targets by fluorescence 
microscope imaging. 0.25-0.5x106 cells were seeded on preincubated 20 µg/ml fibronectin round 
coverslip per well with the appropriate medium in 6 well plate (chapter 3.8) for 24 hr to 70-80% 
confluency. Medium were removed, and wells were washed with DPBS. Cells were then incubated for 1 
hr on ice with the respective Ab (50-500 nM). Then, cells were washed with DPBS +1% BSA. After 
washing, 0.5 ml paraformaldehyde (4%) were added to each well for 20 min incubation at RT. After incubation, 
paraformaldehyde was aspirated, and cells were washed immediately with DPBS +1% BSA twice. Then, 0.5 ml 
of 0.1M glycine were added to each well for 10 min incubation at RT. After incubation, glycine was aspirated, 
and cells were washed immediately with DPBS +1% BSA twice the cells. For blocking, cells were incubated 
with 1 ml DPBS+3%BSA per well for 1 hr at RT and washed once with 1 ml DPBS +1% BSA. Antibody 
binding was detected via Alexa flour 488conjugated F(ab')₂ goat  anti-human Fcγ specific pAb, and 
nuclei were stained with 0.5 µg /ml Hoechst stain solution (chapter 3.5), cells were incubated with 
mixed of the solutions for 40 min at RT at dark. After incubation cells were washed twice with DPBS 
and coverslips with the cells were attached to microscope slide with one drop of mounting medium per 
each coverslip. The slides were kept O.N at dark box till drying. Binding and cell nuclei staining were 
observed in the fluorescence microscope and imaging were taken.  
 
4.3. Biochemical and Biophysical methods 
4.3.1. Tissue procurement and tissue immunohistochemistry 
Tissues were collected at Rambam Health Care Campus (Haifa, Israel) according to a protocol approved 
by the hospital “Helsinki” Committee, tissues were obtained from a patient with colon cancer at the 
time of surgical treatment. Small portion of the tissue were formalin-fixed, and the rest were flash frozen 
and stored until used at liquid nitrogen. For selecting tissues with high density of infiltrating B cells, 
formalin-fixed tissues first stained with hematoxylin and eosin for demonstrating the presence of 
lymphocytes within tumor tissue. Then the tissues presented high lymphocyte were stained with mouse 
anti-CD20 for selecting the tissues presenting high B cell density. The staining preformed at Rambam 
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Health Care Campus by Dr. Yaniv Zohar. The sections were scanned using the Pannoramic MIDI II i 
automatic digital slide scanner (chapter 3.9) at the Technion Biomedical Core Facility, Haifa, Israel.  
4.3.2. Determination of protein concentration 
Protein concentration were photometrically determined either by absorption at 280 nm (A280) according 
to the law of Lambert-Beer’s, by applying the UV spectrophotometer Nanodrop ND2000 (cf. chapter 
3.9) while the concentration was calculated to the respective molecular weight (in kDa) and molar 
extinction coefficient (M-1 cm-1) of the protein 
4.3.3. Protein  biotinylation 
Biotinylation was performed with the EZ-LinkTM NHS-PEG4-Biotin, No-Weigh Format Kit (chapter 
3.8) according to the manufacturer’s instructions. Incubating 0.5-1 mg protein with a 20-fold molar 
excess of EZ-LinkTM NHS-PEG4-Biotin reagent in PBS. Residual reagent was removed by ZebaTM  
Desalt Spin columns (chapter 3.8). 
4.3.4. Protein A affinity purification  
For purification of antibodies from supernatants of small-scale productions (25 ml, chapter 4.4.2) 
purification was carried out with Protein A HP SpinTrap columns (chapter 3.8) according to 
manufacturer’s instructions using recommended buffers binding buffer, elution buffer and 
neutralization buffer (chapter 3.7) as well as centrifugation (100xg, 30 sec per step) after the 
supernatants were concentrated in a centrifuge using the Amicon® Ultra-15 centrifugal filter device 
with 10,000 molecular weight cut-off (MWCO; 4000xg, ~30 min) (chapter 3.8)  (4000xg,RT) until 
reaching volume of 600 µl. Briefly, Protein A HP SpinTrap columns were equilibrated with binding 
buffer and 600 µl supernatants were applied on the columns followed by incubation 4 min in RT while 
gently mixing. Followed by two washing steps with binding buffer. Elution was carried out with 400 µl 
elution buffer in tubes containing 30 µl neutralization buffer in 2 steps. Eluates were concentrated and 
dialyzed with DPBS using Amicon® Ultra-15 centrifugal filter device with 10,000 molecular weight 
cut-off (MWCO; 3000xg, ~20 min) 3 times. 
4.3.5. Biolayer interferometry 
Biosensor experiments using biolayer interferometry were performed on an Octet Red96 platform using 
Octet Data Acquisition and Analysis software (cf. chapter 3.9 and 3.10) at 30°C using 1000 rpm orbital 
sensor agitation in a volume of 200 µl in black 96-well microplates. The physical principal of biolayer 
interferometry is based on the optical detection of changes within the layer thickness on biosensor tips 
by association and dissociation of molecules resulting in a shift in the interference pattern of reflected 
light. White light is thereby directed through the biosensor and is reflected once by a reference layer 
within the biosensor tip and secondly by the tip surface . (Rich & Myszka, 2007)  
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For determining the concentration of produced reformatted IgG antibodies, Dip and Read™ Anti-hIgG Fc 
Capture biosensor (chapter 3.8) were used. Biosensors were equilibrated in 10mM Glycine and kinetics buffer 
(chapter 3.8) and in  the medium or buffer, in which the mAb is present, for 30 sec. Then, loading of 
mAbs is evaluated for 300 sec at 1000 rpm. Based on standard curves of mAbs of known concentration in 
the respective medium, the concentration can be calculated. For this, binding rates were calculated with 
the analysis software based on four parameter fitting (4PL unweighted) using the initial slope the “R 
equilibrium” after 300 sec. 
4.3.6. Determination of mAbs  binding to antigens ECD 
Dip and Read™ Anti-hIgG Fc Capture biosensor were equilibrated 5 sec in 10 mM Glycine followed by 5 sec 
in kinetics buffer 5 times. Then, 5 µg/ml antibodies diluted in kinetics buffer were  immobilized on 
biosensor tips for 300 sec, a baseline was recorded for 60 sec in kinetics buffer (KB) followed by stepwise 
association and dissociation of the analyte (serial dilution in KB) for 600 sec and 900 sec, respectively. 
Buffer controls were subtracted as background and binding parameters were calculated assuming a 1:1 
Langmuir binding model performing global fitting algorithm provided by the Octet data analysis software. 
4.3.7. Determination of mAbs binding to biotinylated antigens ECD 
For evaluating binding of mAbs with the avidity affect, streptavidin biosensors were equilibrated with 
kinetics buffer for 300 sec. Then, 5 µg/ml biotinylated antigen ECD were captured on the streptavidin 
biosensor tips for 900 sec, a baseline was recorded for 60 sec in kinetics buffer (KB) followed by 
stepwise association and dissociation of mAbs (200nM) in kinetics buffer for 600 sec and 900 sec, 
respectively. As controls, the non-related isotype control mAb were implemented to exclude unspecific 
binding.
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5. Results 
 
 
5.1. Construction of yeast display antibody libraries derived from tumor infiltrating B cells of 
colon cancer patients 
In the recent years several publications reported on constructions of tumor infiltrating B cells derived 
libraries, most of which are phage display libraries (Novinger et al., 2015). In this work, for the first 
time to our knowledge, we construct yeast display libraries from infiltrating B cells antibodies 
repertoire. In order to construct the libraries, RNA from tumor tissues of 8 colon cancer patients was 
extracted. RNA was then subjected to cDNA synthesis by RT PCR. Hypervariable V(D)J antibody 
regions amplification was done by PCR from cDNA templates using site-specific primers. Yeast display 
antibody (Fab) libraries were created utilizing the hypervariable V(D)J antibody region DNA 
amplification by yeast transfection and mating. A standardized protocol for collection of tissue samples 
procurement was developed together with pathologists from the Rambam Health Care Campus that 
allows the cancer tissue from a single patient to be used both as a source of high-quality RNA and also 
as tissue for subsequent histological analysis. 
 
5.1.1. Selection of colon cancer tissues from patients demonstrating high B cells infiltration 
Previous publications related high density of lymphocyte infiltration to the tumor with better survival 
(Wouters & Nelson, 2018). Therefore, in this work only tissues with high B cell infiltration were used 
as a source for the construction of libraries. From 40 formalin-fixed tissue specimens of colon cancer 
patients, which were obtained during surgical treatment at the Rambam Health Care Campus, only 8 
demonstrated high immunohistochemistry staining by anti-CD20 marker. These tissues were selected 
as source of infiltrated B cells for libraries construction. Scans of the formalin-fixed histological 
sections of the 8 colon cancer patients with high B cell infiltration to the tumor are depicted in Figure 
6. Patient demographic and clinical data of the selected tissues show diversity in gender, age, colon 
section and tumor grade, as summarized in Table 3. 
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  Figure 6: Anti-CD20 Immunohistochemistry staining of patients’ tissue specimens with high tumor infiltrating B cells. 
Formalin-fixed histological sections of the 8 colon cancer patients with high B cell infiltration to the tumor. The sections were 
immunohistochemistry stained with mouse anti-CD20 (Brown). Patient’s reference number is represented in the left bottom corner 
of each image. Sections were scanned using a Panoramic MIDI digital slide scanner. Visualizations were performed using the 
Panoramic Viewer software. Scale bar = 5000 µm.   
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  Table 3: Patients’ demographic and clinical data of the compatible selected tissues.  
P-21955T tissue section was used as a control tissue, as it showed no tumor B cell infiltration. All samples were snap frozen with 
liquid nitrogen within one hour post surgical treatment. 
 
5.1.2. RNA isolation from tissues 
RNA degradation is the main concern when performing extraction of mRNA from tumor specimens which 
were removed during surgical procedure. Several reports indicate that up to one hour post surgery is an 
adequate time to maintain non-degraded mRNA(Grizzle, Bell, & Sexton, 2011). In this work a standardized 
protocol for collection of tissue samples was developed together with pathologists from the Rambam Health 
Care Campus. Hence, successful maintaining was achieved, including rapid tissue acquisition to prevent 
RNA degradation (Table 3), together with acquisition of separate tumor pieces for subsequent histological 
analysis. Tissues were stored in liquid nitrogen until RNA isolation. To isolate RNA, tissues were thoroughly 
homogenized with a conventional rotor–stator homogenizer and further purified with a QIAGEN RNeasy 
Midi kit. The total RNA yields obtained from each patient’s tissue are summarized in Table 4. The weights 
of tissue specimens of all patients were adequate for good total RNA yields. Absorbance ratios 260/280 and 
260/230 of all extracted total RNA yields indicated relatively high purity of total RNA in all samples 
(Matlock, 2015). RNA yields were adequate for subsequent processing.  
 
 
 
 
 
Patient ref 
Number 
Age Gender  
Primary 
Tumor(T) 
[stage] 
 
Colon section 
Intertumoral 
Lymphocyte 
Response 
CD20 
Staining 
Freezing time 
after surgery 
[min.] 
 
 
P-20055T 75 F T2 Transverse colon or right colic flexure + + 35 
P-20066T 50 M T1 Right flexure + + 22 
P-20116T 85 F T1 Sigmoid colon + + 40 
P-20671T 63 F T3 Cecum + + 35 
P-20829T 76 M T3 Cecum + + 40 
P-21548T 89 F T3 Ascending colon + + 34 
P-21574T 69 M T2 Descending colon or transverse colon + + 37 
P-22017T 67 M T2 Cecum + + 28 
P-21955T 52 F T3 Ascending colon - - 35 
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Table 4: Specimen weights, yield and purity of the total RNA obtained from patients’ tissues. 
Total RNA yields obtained from each patient’s tissue. Tissues were thoroughly homogenized with a conventional rotor–stator 
homogenizer and further purified with a QIAGEN RNeasy Midi kit. Weights of each patient’s tissue were taken for better RNA 
isolation efficiency. Absorbance ratios 260/280 and 260/230 of all extracted total RNA yields indicated relatively high purity of total 
RNA in all samples (Matlock, 2015). RNA yields were adequate for subsequent processing.  
 
5.1.3. Extracted total RNA quality, RNA Integrity Number (RIN) score 
As the source of RNA in this work are tissues taken from patients during surgical treatment. Since RNA 
degradation may occur during the acquisition process it is important to ensure the quality of the extracted 
RNA and further the expression of the representing B cells repertoire genes (Grizzlea, Bella, & Sextonb, 
2012). The integrity of RNA molecules is of paramount importance for experiments that try to reflect the 
snapshot of gene expression at the moment of RNA extraction. The RNA integrity number equivalent (RINe) 
provides an independent quality score for total RNA (Schroeder et al., 2006). The RINe score of each 
patient’s isolated RNA was analyzed by the Agilent 2200 TapeStation. The RINe score for each patient 
together with a gel-like image of the analysis are depicted in Figure 7. The data analysis confirms that all 
the extracted RNA samples from patients partially degraded during the acquisition process (RINe score 4.6-
7.9) but no substantial degradation with a low RINe score were observed. As a control, RNA was extracted 
from a Raji cell line and revealed a score of 8.4 RINe, with a score above 8 considered good RNA quality.    
 
 
 
 
 
 
 
 
Patient ref 
number 
Weight 
(mg) 
Absorbance ratios Total RNA 
(ng/µl) 
Total Volume 
(µl) 
RNA Yield 
(µg) 260/280 260/230 
P-20055T 102 2.04 2.23 425 430 183 
P-20066T 54 2.06 2.16 550 440 242 
P-20116T 161 2.07 2.26 550 430 237 
P-20671T 121 2.05 2.25 450 400 180 
P-20829T 70 2.02 2.25 400 430 172 
P-21548T 64 2.03 2.23 425 430 183 
P-21574T 94 2.05 2.31 220 430 95 
P-22017T 47 2.03 2.24 325 430 140 
P-21955T 153 2.07 2.27 1582 400 632 
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Figure 7: Analysis of total RNA integrity gel-like image. 
Gel-like image of total RNA integrity, by the Agilent 2200 TapeStation, showed partial degradation in RNA extractions of all 
patients. Many degradation products appear between the two ribosomal bands and below the 18S band (line A-I). The control Raji 
cell RNA extraction sample showed high-quality total RNA with the 18S and 28S subunits as two distinct bands.         
 
5.1.4. cDNA synthesis by RT PCR and real-time PCR for CD19 and CD20 gene expression  
In order to amplify hypervariable V(D)J antibody regions site-specific primers by PCR were use. cDNA 
templates for each patient’s tissue RNA were synthesized using the Invitrogen SuperScript™ III Reverse 
Transcriptase kit. Due to the partial RNA degradation during the acquisition process (chapter 5.1.3), 
expression levels of B cell marker genes were analyzed by real time PCR applying the comparative cT assay 
(Livak & Schmittgen, 2001) to verify adequate expression for further hypervariable V(D)J antibody regions 
amplification. cDNA from all patients and from the control sample (low B cells infiltration) were analyzed 
for gene expression of the B cells markers CD19 and CD20 and the house keeping RPLP0 gene was used as 
control gene for overall gene expression. In comparative cT assay in real time PCR, the cT values are inverse 
to the amount of target nucleic acid and correlate with the number of target copies in the sample. Lower cT 
values, typically below 29 cycles, indicate high amounts of the target sequence. Higher cT values, above 38 
cycles, mean lower amounts of the target nucleic acid. As depicted in Figure 8 there is a correlation between 
gene expression of CD19 and CD20 and the cT values which indicate high amount of the gene expression. 
The control sample showed the lowest expression of CD19 and CD20, as expected. Expression of the 
housekeeping gene RPLP0 was very high in all patients’ cDNA (~ cT 15), as expected. Interestingly, there 
was no correlation found between expression of the B cells markers (CD19 and CD20) genes and the RPLP0. 
The correlation between the cT values and the RINe scores of all patient’s samples are depicted in Figure 9. 
The graph shows a negative correlation between the RINe scores and the cT values (when one is low the other 
is high, and the other way around), which indicates a decrease in the expression of the housekeeping gene as 
a result of the RNA degradation. However, as there is no correlation between the RPLP0 expression with the 
CD19 and CD20 expression, it may indicate less RNA degradation of the B cells that infiltrated into the 
tumor relatively to the surrounding tumor tissue itself.  
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Figure 8: Real time PCR cT mean of B cells and the housekeeping RPLP0 marker genes.   
cT mean from the comparative cT real time PCR assay of CD19, CD20 and the housekeeping gene RPLP0 expression of each patient’s 
cDNA. No correlation between the expression of CD19 and CD20 genes to the RPLP0 gene is observed. CD19 and CD20 cT values indicate 
high gene expression. The control sample shows the lowest expression of CD19 and CD20, as expected.  
 
 
 
 
Figure 9: RINe score value Vs cT mean of RPLP0 gene. 
A correlation between the cT value and the RINe score of each patient’s sample. The graphs show a “mirror” picture: when the 
RINe score is low the cT value is high. This may indicate a decrease in the expression of the housekeeping gene, as a result of the 
RNA degradation. 
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5.1.5. Hypervariable V(D)J antibody region amplification by PCR 
Using amplification of antibodies hypervariable region from peripheral lymphocytes of healthy individuals 
in order to create antibody libraries with Naïve repertoires is an established method in the recent years (Hust 
& Dübel, 2010). Here, tumor infiltrating B cells were derived from the patients as a source for the antibody 
gene pool. Amplification of VH and VL was conducted in a nested PCR approach using AccuPrime™ Taq 
DNA Polymerase. Antibody gene repertoire was amplified in three steps. In the first step, VH and VL were 
amplified using a set of subfamilies framework 1 forward primers and IgG1, kappa and lambda constant 
domain reverse primers. The second PCR reaction was performed to incorporate 5′ and 3′ overhangs for gap 
repair cloning into the pYD derived plasmids. In the third step, amplification of the second PCR was 
performed in order to obtain enough DNA material for the gap repair cloning reaction. Imaging of the first 
PCR products separated on agarose gel are depicted in Figure 10. Amplification of most VH and VL (kappa 
and lambda) subfamilies from all patients can be observed, excluding rare subfamilies that showed low 
amplification in all patients. 
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Figure 10: Agarose gel electrophoresis of first PCR VH and VL subfamilies amplification.   
(A) Agarose gel electrophoresis of VH subfamilies - first PCR amplification. (B) Agarose gel electrophoresis of VL kappa subfamilies - 
first PCR amplification. (C) Agarose gel electrophoresis of VL lambda subfamilies - first PCR amplification. Each gel represents a patient 
with the reference number. Each line represents amplification with a specific subfamily primer. In general, it can be observed that most of 
VH and VL subfamilies were amplified, excluding rare subfamilies that showed low amplification in all patients.   
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5.1.6. Antibody yeast display libraries generation 
Generation of the yeast display (YSD) antibody libraries in this work was based on the a-agglutinin 
system, initially developed by Boder and Wittrup (Boder & Wittrup, 1997). Modified pYD1 yeast 
surface display vectors were used: vectors for heavy chain (pYD1-VH-CH1) and light chain expression 
(pYD1-VL-CK or pYD1-VL-CL) were used for surface expression of Fab1-fragments, both under 
control of a galactose-inducible GAL1 promoter (chapter 3.3). A linkage to the yeast cell wall was 
conducted by a genetic fusion of Aga2p to the C-terminus of the CH1 domain, allowing for the covalent 
surface display of the following N-terminal fusion protein: Xpresstag-(G4S)–VH–CH1- (G4S)–His-
(G4S)3-Aga2p. The light chain expression vector encoded an aMFpp8 leader sequence for soluble light 
chain secretion (Rakestraw, Sazinsky, Piatesi, Antipov, & Wittrup, 2009). In order to generate YSD 
libraries for each patient, gap repair cloning by homologous recombination in two yeast strains was 
employed (Bessa, Pereira, Moreira, Johansson, & Queirós, 2012). PCR products and linearized YSD 
plasmids from each out of 8 patients were used for generation of 24 yeast libraries (8 HC, 8 LC kappa 
and 8 LC lambda) (Benatuil et al., 2010). Heavy and light-chain diversities were introduced into the different 
haploid yeast strains, heavy chain to EBY100 (MATa) and light chain to BJ5464 (MATα), with opposite mating 
types, and then combined into diploid cells by yeast mating (Weaver-Feldhaus et al., 2004). Figure 11 
schematically illustrates the yeast surface display expression system of the antibody Fab fragment display on the 
surface of diploid Saccharomyces cerevisiae cells after yeast mating. Patients’ libraries sizes were calculated by 
plating of serial dilutions, using the respective auxotrophic markers selective agar plates (-Trp or -Leu). The size 
of the libraries and the percentage of transfected cells is summarized in Table 5. For yeast mating all 8 patients’ 
HC libraries were mixed as were also the LC kappa libraries and LC lambda libraries. These combined libraries 
were used for yeast mating, resulting in final library sizes of approximately 4.1×108 unique clones for the HC-LC 
kappa library (TIL-B kappa) and approximately 2.5×108 unique clones for the HC-LC Lambda library (TIL-B 
lambda).   
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Figure 11: Schematic illustration of the yeast surface display expression system of the antibody Fab fragment display on the 
surface of diploid Saccharomyces cerevisiae cells after yeast mating.   
As a result of yeast mating, diploid cells were generated, where a surface-anchored heavy chain assembles with the secreted light chain to 
form a Fab fragment. Fab fragments are expressed on the yeast surface as Aga2p fusions with a C-terminal His-tag and N-terminal Xpress-
tag for optional detection of Fab presentation. The two single copy plasmids encode for the antibody heavy chain and the antibody light 
chain which contain the TRP or LEU auxotrophic markers for selection in yeast, respectively. Aga1p is chromosomally encoded by AGA1 
in yeast. The heavy chain of the Fab fragment is C-terminally fused to the a-agglutinin yeast adhesion receptor protein Aga2p which 
assembles with the co-expressed light chain as well as with the Aga1p via two disulfide bonds. Aga1p in turn is covalently linked to β-
glucan of the extracellular yeast cell matrix and anchors the heavy and light chain assembly to the cell wall. Expression of Aga1p as well 
as plasmid encoded proteins are under control of the inducible galactose 1 promotors. 
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Table 5: Patients’ library sizes and percentage of transfected cells.  
Patients’ libraries sizes were calculated by plating of serial dilutions using the respective auxotrophic markers selective agar plates 
SD /-TRP for the HC libraries and SD/-LEU for the LC libraries. All libraries resulted in final library sizes of 1.4-5.6x 107. 
Percentage of transfected cells were calculated relatively to the plating of serial dilutions using non-selective YPD agar plates.        
 
5.2. Yeast display libraries screening for cancer associated antigens and immune checkpoints 
by flow cytometry 
After the constriction of the two tumor infiltrating B cells patients derived YSD antibody libraries were completed 
(TIL-B kappa and lambda), the aim of this work was to evaluate the libraries for binding to the conventional 
researched cancer associated antigens and immune checkpoints. Hence, a panel of an extracellular domain of 
human cancer associated antigens and immune checkpoints were biotinylated with EZ-Link NHS-PEG4-Biotin 
(Chapter 4.3.3) in order to screen the YSD libraries by flow cytometry. Bivariate screening by flow cytometry 
was  performed, including monitoring the binding of biotinylated ECD antigens to the antibody Fab fragments on 
cells by streptavidin Allophycocyanin (APC) conjugate marker and monitoring the display levels of antibody Fab 
fragments on cells by labeled PE antibodies directed against the constant region of the displayed light chain. For 
the screening of associated cancer antigens and immune checkpoints targeting antibodies, screening was 
performed using an antigen concentration of 1μM in order to observe potential high-affinity binders that will 
selected during flow cytometry sorting selection. Approximately 1 × 106 cells after induction were used for each 
antigen analysis. Total mean fluorescence intensity (MFI) of the APC marker from the gated population compared 
to the MFI obtained from yeast-cells labeled without the antigen (background) were chosen to predict potential 
high-affinity binders to some of the antigens in the tested antigen panel. Total MFI obtained from different cancer 
 
 
 
Patient 
ref 
number 
 
 
Heavy chain 
 
 
Light chain kappa 
 
 
Light chain Lambda 
% transfected 
cells 
Library 
size 
% transfected 
Cells 
Library 
size 
%transfected 
cells 
Library 
size 
P-20055T  9.2 % 75.1x10  1.2% 3.9x107  2.9% 4.8X107 
P-20066T  5.2 % 73.6x10  3% 3x107  2.5% 3.6X107 
P-20116T  6.1 % 74.7x10  3.9% 2.4x107  1.9% 5.6X107 
P-20671T  2.8 % 72x10  3.7% 1.5x107  3% 5.4X107 
P-20829T  5.8 % 73.5x10  4% 5.2x107  2.9% 5.1X107 
P-21548T  7.5 % 72.3x10  5.9% 5.8x107  1.6% 5.3X107 
P-21574T  8.5 % 72.2x10  5.4% 1.4x107  2.9% 4.3X107 
P-22017T  11.5 % 73x10  4.9% 2x107  2.1% 4X107 
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associated antigens that were bound to the antibody Fab fragments on cells of the kappa and the lambda libraries 
are depicted in Figure 12. The data indicated that all antigen cancer associated antigens which were tested have 
some binders to the antibody Fab fragments on cells in both libraries (apart from TEM1 in the kappa library). In 
the kappa library h-5T4 and h-LRP6 had strongest total MFI, while in the lambda library h-LRP6 and h-
CEACAM5 had strongest total MFI. The total MFI obtained from immune checkpoints that were bound to the 
antibody Fab fragments on cells of the kappa and the lambda libraries are depicted in Figure 13. The data 
indicated, that most of the immune checkpoints, unlike the antigen cancer associated antigens, which were tested 
had no binders to the antibody Fab fragments on cells in both libraries. In the kappa library only h-LAG-3, h-
OX40L, h-TIM3 and h-CTL4 had total MFI above the background, while in the lambda library only h-OX40L 
and h-TIM3 had significant total MFI above the background. A display of antibody Fab fragments was observed 
in both libraries (data not shown).  
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Figure 12: Screening of the TIL-B kappa and lambda yeast Fab fragments libraries for cancer associated antigens binders 
by flow cytometry. 
(A) Total MFI obtained from different cancer associated antigens that were bound to the antibody Fab fragments on yeast-cells of the 
TIL-B kappa library. (B) Total MFI obtained from cancer associated antigens that were bound to the antibody Fab fragments on yeast-
cells of the TIL-B lambda library. The red line indicates the background level of the total MFI that was obtained from cells labeled 
with a SA-APC marker without the biotinylated antigen.  
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Figure 13: Screening of the TIL-B kappa and lambda yeast Fab fragments libraries for immune checkpoints binders by 
flow cytometry. 
(A) Total MFI obtained from different immune checkpoints that were bound to the antibody Fab fragments on yeast-cells of the TIL-
B kappa library. (B) Total MFI obtained from immune checkpoints that were bound to the antibody Fab fragments on yeast-cells of 
the TIL-B lambda library. The red line indicates the background level of the total MFI that was obtained from cells labeled with a SA-
APC marker without the biotinylated antigen.  
 
 
 
 
 
 
 
 
 
 
5. Results 62 
 
 
 
 
5.3. Selection of cancer associated antigens and immune checkpoints targeting antibodies by 
FACS. 
Previous studies have well established the process of screening antibody repertoires from immunized 
transgenic rats harboring human variable antibody regions against a cancer related antigen by 
fluorescence-activated cell sorting (FACS) of yeast Fab displayed immune libraries (Schröter et al., 
2018). In this work, to our knowledge, we were first to attempt to isolate binders to associated antigens and 
immune checkpoints from YSD libraries constructed based on antibody repertoires from patients’ tumor 
infiltrating B cell repertoire. Based on screening both libraries (kappa and lambda) with a panel of cancer 
associated antigens and immune checkpoints (cf. chapter 5.2) two cancer associated antigens were selected, 
h-LRP6 and h-CEACAM5, as well two immune checkpoint targets, h-OX40L and LAG3, for the process of 
FACS selection. Those targets showed relatively high total MFI in the first screening for binders. This was an 
interesting finding, as LRP6 and CEACAM5 are considered colon cancer associated antigens (Heine et al., 
2011; Rismani et al., 2017) while the libraries B cells source had been derived from colon cancer patients.  
 
5.3.1. Selection of h-OX40L targeting antibodies by FACS sorting 
The TIL-B lambda library was chosen for the sorting selection of h-OX40L targeting antibodies, based 
on the first screening analysis which showed that h-OX40L had relatively high total MFI binding to Fab 
fragments displayed on the yeast-cells surface (cf. chapter 5.2). Bivariate sorting selections by FACS 
were performed. Binding of the h-OX40L to the Fab fragments displayed on the yeast surface was 
detected by the red laser (640 nm) by the second staining step using streptavidin APC or streptavidin 
DyLight 633  conjugates and the display levels of antibody Fab fragments on cells were detected by the 
blue laser (488 nm) by incubation of cells with anti-human lambda light chain-specific goat F(ab′)2 R-
PE conjugate. For that, the human h-OX40L amino acids (Gln51-Leu183) were labeled with EZ-Link 
NHS-PEG4-Biotin (chapter 3.5). N-Hydroxysuccinimide (NHS) esters react efficiently with primary 
amino groups (-NH2) by nucleophilic attack, forming an amide bond and releasing the NHS. The h-
OX40L protein was labelled in the primary amine in the side chain of lysine (K) residues and the N-
terminus of each polypeptide. For the sorting section the TIL-B lambda library was induced for Fab 
fragment surface display with SG–Trp–Leu + peptone  medium at 20ºC for 48 hr. Post induction 1.5 x 
108 cells were incubated with an initial concentration of 1µM biotinylated h-OX40L followed by 
incubation of the cells with SA-APC and the goat F(ab')2 anti-human lambda-R-PE (3.4.1). Cells were 
subjected to FACS (Figure 14). The bivariate dot plot showed that 6.9% (MFI-336) of the library cells 
were positive to h-OX40L and 37.8% (MFI-875) of the library cells were positive to the display antibody 
Fab fragment on surface cells. Top 1.2% of cells positive to h-OX40L and the Fab display were sorted. 
A subsequent re-sort was performed immediately with the sorted cells for better selection of high 
affinity binders. In the re-sort the bivariate dot plot showed that 46% (MFI-500) of the library cells were 
positive to h-OX40L and 67.5% (MFI-823) of the library cells were positive to the display antibody Fab 
5. Results 63 
 
 
 
 
fragment on surface cells. Here, top 25.4% of cells positive to h-OX40L and the Fab display were sorted. 
Then the sorted cells were re-grown in SD–Trp–Leu and utilized for inoculation of SG–Trp–Leu + 
peptone medium for induction of the Fab fragment between all subsequent sorting rounds. In the second 
round of sorting, antigen concentration was reduced to 0.5 µM biotinylated h-OX40L and 1x108 cells 
were taken for the sorting. The bivariate dot plot showed an increase in the amount of the library cells 
that were positive to h-OX40L up to 13.9% (MFI-385) and as well an increase in the display antibody 
Fab fragments on surface cells, up to 48% (MFI-998). Top 1.5% of cells positive to h-OX40L and to 
the Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that 54% (MFI-539) 
of the library cells were positive to h-OX40L and 72% (MFI-822) were positive to the display of 
antibody Fab fragment on surface cells. Here, top 14.4% of positive cells to h-OX40L and Fab display 
were sorted. After the second sorting, binding analysis of yeast-cells labeled with only SA-APC and 
anti-lambda R-PE indicated for yeast-cells that unspecific enriched for binding to the APC marker 
during the sorting rounds with 5.5% yeast-cells (Figure 15). Hence, in order  to eliminate the unspecific 
binders to the APC marker, antigen concentration that was reduced to 0.25 µM biotinylated h-OX40L 
was followed this time with SA-PE and not SA-APC detection for the third sorting. Top 3.4% of positive 
cells to h-OX40L were sorted. In the fourth subsequent round sorting, antigen concentration and number 
of cells were the same as third sorting. The bivariate dot plot showed for increasing of the library cells 
that were positive to h-OX40L up to 48% (MFI-710) and as well increasing in the display antibody Fab 
fragment on surface cells up to 57.6% (MFI-1141). Top 6.1% of positive cells to h-OX40L and Fab 
display were sorted. In the subsequent re-sort the bivariate dot plot showed for 78.9% (MFI-893) of the 
library sorted cells were positive to h-OX40L and 80.9% (MFI-1060) cells were positive to display of 
antibody Fab fragment on surface cells. Here, Top 22.2% of positive cells to h-OX40L and Fab display 
were sorted. In the last subsequent round sorting the detection marker used was SA-DyLight 633 for 
final polishing of the enriched unspecific yeast-cell binders to the APC marker which showed of 6% 
(Figure 15). Antigen concentration and number of cells were the same as the third sorting. The bivariate 
dot plot showed of 25.4% (MFI-344) of the library cells that were positive to h-OX40L and 53.2 % 
(MFI-1065) were positive to the display of antibody Fab fragment on surface cells. Top 2.6% of positive 
cells to h-OX40L and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed 
for 58.2% (MFI-575) of the library cells were positive to h-OX40L and 72.4% (MFI-1007) cells were 
positive to display of antibody Fab fragment on surface cells. Here, Top 23.1% of positive cells to h-
OX40L and Fab display were sorted. After five rounds of FACS sorting, final binding analysis showed 
28.9% of positive yeast-cells binders to h-OX40L (Figure 14) with 1.2% of unspecific binders (Figure 
15). Single cells were plated on SD–Trp–Leu agar plates, and yeast-cell clones were subjected to 
binding analysis by the Guava easyCyte HT cytometer and further sequencing procedure (single colony 
sequencing service at Hay labs) to identify and select clones for sub cloning and expression of full-
length IgG. 
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Figure 14: FACS sorting selection process of the TIL-B lambda library to h- OX40L yeast-cell binders. 
FACS sorting selection process of the TIL-B lambda library. Each round was immediately followed with a re-sort for better yeast 
cell selection. Bivariate plots show yeast-cells labelled with biotinylated h-OX40L, SA-APC and anti-lambda R-PE for detection of 
surface expression display of Fab fragments during round I and II. In round III plots represent yeast-cells labelled with biotinylated 
h-OX40L, SA-PE for elimination of unspecific APC yeast-cell binders. In round IV biotinylated h-OX40L yeast-cells were labelled 
back with SA-APC. In round V sorting was performed using SA-DyLigh 633 for another round of elimination of unspecific yeast-
cells binders to APC. The percentage of yeast-cells taken for each sorting round are presented in each sort gate. The percentage of 
the enriched yeast-cells that were positive to h-OX40L in each sorting round are presented in the right top of the dot plot images. 
Final analysis of the outcome of round V sorting showed 28.9% of positive yeast-cells binders to h-OX40L. 
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Figure 15: Unspecific binding to APC marker during FACS sorting selection process of the TIL-B lambda library to h- OX40L 
yeast-cell binders. 
Bivariate plots of yeast-cells labeled without biotinylated h-OX40L and only with SA-APC and anti-lambda R-PE for detection of 
surface expression display of Fab fragment. The analysis indicated for yeast-cells that unspecific enriched for binding to the APC 
marker during the sorting rounds. Round III and V were performed for elimination of those binders (Figure 14). Analysis of the 
outcome of round V showed unspecific binding of 1.2% yeast-cells. 
 
5.3.2. Selection of h-LRP6 targeting antibodies by FACS sorting 
*Parts of the work in this chapter were done by Svea Becker as part of her Master thesis.  
The TIL-B kappa library was chosen for the sorting selection of h-LRP6 targeting antibodies, based on the 
first screening analysis, which showed that h-LRP6 had relatively high total MFI binding to Fab fragments 
displayed on the yeast surface (cf. chapter 5.2). Bivariate sorting selections by FACS were performed the 
same as described with the h-OX40L sorting (chapter 5.3.1). The human h-LRP6, extracellular homologous 
regions domains E3-E4 was labelled with EZ-Link NHS-PEG4-Biotin same as described before (chapter 
5.3.1). For the sorting section the TIL-B kappa library was induced for Fab fragment surface display with a 
SG–Trp–Leu + peptone  medium at 20ºC for 48 hr. Post induction, 1.5 x 108 cells were incubated with initial 
concentration of 1µM biotinylated h-LRP6 followed by incubation of the cells with SA-APC and the goat 
F(ab')2 anti-human lambda-R-PE (chapter 3.4.1). Cells were subjected to FACS sorting (Figure 16). The 
bivariate dot plot showed that 7.3% (MFI-562) of the library cells were positive to h-LRP6 and 34% (MFI-
2189) were positive to the display of antibody Fab fragment on surface cells. Top 1.4% of positive cells to h-
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LRP6 and Fab display were sorted. A subsequent re-sort was performed immediately with the sorted cells for 
better selection of high affinity binders. In the re-sort the bivariate dot plot showed that  12.5% (MFI-480) of 
the library cells were positive to h-LRP6 and 46.4% (MFI-1718) were positive to the display of antibody Fab 
fragment on surface cells. Here, Top 6.8% of positive cells to h-LRP6 and Fab display were sorted. Sorted 
cells were re-grown in SD–Trp–Leu and utilized for the inoculation of SG–Trp–Leu + peptone medium for 
induction of Fab fragment between all subsequent sorting rounds. In the second sorting round, antigen 
concentration was reduced to 0.5 µM biotinylated h-LRP6 and 1x108 cells were incubated. The bivariate dot 
plot showed  reducing of the library cells that were positive to h-LRP6 up to 3% (MFI-385) with 0.5 µM 
antigen but increasing in the display antibody Fab fragment on surface cells up to 47.6% (MFI-2233). Top 
1.9% of positive cells to h-LRP6 and Fab display were sorted. In the subsequent re-sort the bivariate dot plot 
showed that  49.2% (MFI-524) of the library cells were positive to h-LRP6 and 70.6% (MFI-2225) cells were 
positive to display of antibody Fab fragment on surface cells. Here, Top 13.8% of positive cells to h-LRP6 
and Fab display were sorted. In the third sorting round, antigen concentration was reduced to 0.25 µM 
biotinylated h-LRP6 and again 1x108 cells were incubated. The bivariate dot plot showed  increasing of the 
library cells that were positive to h-LRP6 up to 41.2% (MFI-1003) with 0.25 µM antigen but reducing in 
display antibody Fab fragment on surface cells up to 40.6% (MFI-1685). Top 7.2% of positive cells to h-LRP6 
and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that  78.7% (MFI-1213) 
of the library cells were positive to h-LRP6 and 81% (MFI-1572) cells were positive to display of antibody 
Fab fragment on surface cells. Here, Top 23.7% of positive cells to h-LRP6 and Fab display were sorted. In 
the fourth sorting round, antigen concentration was reduced to 0.1 µM biotinylated h-LRP6 and again 1x108 
cells were incubated. The bivariate dot plot showed  reducing of the library cells that were positive to h-LRP6 
up to 25.9% (MFI-1494) with 0.1 µM antigen and as well reducing in the display antibody Fab fragment on 
surface cells up to 36.7% (MFI-1680). Top 2.1% of positive cells to h-LRP6 and Fab display were sorted. In 
the subsequent re-sort the bivariate dot plot showed that  66.5% (MFI-1313) of the library cells were positive 
to h-LRP6 and 75% (MFI-1572) were positive to display of antibody Fab fragment on surface cells. Here, 
Top 13.4% of positive cells to h-LRP6 and Fab display were sorted. After the second sorting, a binding 
analysis, which  yeast-cells labeled without biotinylated h-LRP6 and only with SA-APC and anti-
lambda R-PE, were indicated for yeast-cells that unspecific enriched for binding to the APC marker 
during the sorting rounds up to 42.2% (Figure 17).Hence, In the last sorting round, order to eliminate the 
unspecific binders to the APC marker,  the detection marker replaced to SA-DyLight 633 for final polishing. 
The antigen concentration and number of cells were the same as forth sorting. The bivariate dot plot showed 
that 16.7% (MFI-1347) of the library cells were  positive to h-LRP6 and 59.4 % (MFI-3065) of the library 
cells were positive display of antibody Fab fragment on surface cells. Top 1.5% of positive cells to h-LRP6 
and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that  55.4% (MFI-1694) 
of the library cells were positive to h-LRP6 and 76% (MFI-1007) of the library cells were positive display of 
antibody Fab fragment on surface cells. Here, top 16.3.1% of positive cells to h-LRP6 and Fab display were 
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sorted. After five rounds of FACS sorting, a final binding analysis showed  51.1% of positive yeast-cells binders 
to h-LRP6 (Figure 16) with 10% of unspecific binders (Figure 17). Single yeast cells were plated on SD–Trp–
Leu agar plates, and yeast-cell clones were subjected to binding analysis by FACS and further sequencing 
procedure (single colony sequencing service at Hay labs) to identify and select clones for sub cloning and 
expression of full-length IgG molecules. 
 
Figure 16: FACS sorting selection process of the TIL-B kappa library to h-LRP6 yeast-cell binders. 
FACS sorting selection process of the TIL-B kappa library. Each round was immediately followed with a re-sort for better yeast cell 
selection. Bivariate plots show yeast-cells labelled with biotinylated h-LRP6, SA-APC and anti-lambda R-PE for detection of surface 
expression display of Fab fragment during round I-IV. In Round V sorting were performed using SA-DyLigh 633 for elimination of 
unspecific yeast-cells binders to APC marker. The percentage of yeast-cells were taken for each sorting round are presented in each 
sort gate. The percentage of the enriched yeast-cells that were positive to h-LRP6 in each sorting round are presented  in the right 
top of the dot plot images. Final analysis of the outcome of round V sorting showed 51.1% of positive yeast-cells binders to h-LRP6. 
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Figure 17: Unspecific binding to APC marker during FACS sorting selection process of the TIL-B kappa library to h-LRP6 
yeast-cell binders. 
Bivariate plots of yeast-cells labeled without biotinylated h-LRP6 and only with SA-APC and anti-lambda R-PE for detection of 
surface expression display of Fab fragment. The analysis indicated for yeast-cells that unspecific enriched for binding to the APC 
marker during the sorting rounds. Round V were performed for elimination of those binders (Figure 16). Final analysis of the 
outcome of round V showed unspecific binding of 1.2% yeast-cells. 
 
5.3.3. Selection of h-LAG3 targeting antibodies by FACS sorting 
The TIL-B kappa library was chosen for the sorting selection of h-LAG3 targeting antibodies, based on the 
first screening analysis, which showed that h-LAG3 had relatively high total MFI binding to Fab fragments 
displayed on the yeast surface (chapter 5.2). Bivariate sorting selections by FACS were performed the same 
as described in previous sorting (chapter 5.3.1). The human LAG3 (Leu23-Leu450) was labeled with EZ-Link 
NHS-PEG4-Biotin as described before (chapter 5.3.1). For the sorting section the TIL-B kappa library was 
induced for Fab fragment surface display with a SG–Trp–Leu + peptone  medium at 20ºC for 48 hr. Post 
induction 1.5 x 108 cells were incubated with initial concentration of 1µM biotinylated h-LAG3 followed by 
incubation of the cells with SA-APC and the goat F(ab')2 anti-Human lambda-R-PE (3.4.1). Cells were 
subjected to FACS sorting (Figure 18). The bivariate dot plot showed that 1.1% (MFI-4639) of the library 
cells were positive to h-LAG3 and 26.8% (MFI-2433) were positive to the display of antibody Fab fragment 
on surface cells. Top 0.5% of positive cells to h-LAG3 and Fab display were sorted. A subsequent re-sort was 
performed immediately with the sorted cells for better selection of high affinity binders. In the re-sort the 
bivariate dot plot showed that  34.2% (MFI-1116) of the library cells were positive to h-LAG3 and 48.1% 
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(MFI-823) were positive to the display of antibody Fab fragment on surface cells. Here, Top 14.8% of positive 
cells to h-LAG3 and Fab display were sorted. Sorted cells were re-grown in SD–Trp–Leu and utilized for the 
inoculation of a SG–Trp–Leu + peptone medium for induction of Fab fragment between all subsequent sorting 
rounds. In the second sorting round, antigen concentration was reduced to 0.25 µM biotinylated h-LAG3 and 
1x108 cells were incubated. . The bivariate dot plot showed  reducing of the library cells that were positive to 
h-LAG3 up to 4.8% (MFI-1029) with 0.25 µM antigen and increasing in the display antibody Fab fragment 
on surface cells up to 51.2% (MFI-2957). Top 3.3% of positive cells to h-LAG3 and Fab display were sorted. 
In the subsequent re-sort the bivariate dot plot showed that  27.8% (MFI-378) of the library cells were positive 
to h-LAG3 and 62.1% (MFI-2379) cells were positive to display of antibody Fab fragment on surface cells. 
Here, Top 8.9% of positive cells to h-LAG3 and Fab display were sorted. In the third sorting round, antigen 
concentration and number of cells that were taken for incubation were the same. The bivariate dot plot showed  
increasing of the library cells that were positive to h-LAG3 up to 10.7% (MFI-1072) with 0.25 µM antigen, 
as well as in display antibody Fab fragment on surface cells up to 58.7% (MFI-3425). Top 4.4% of positive 
cells to h-LAG3 and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that  
58.2% (MFI-649) of the library cells were positive to h-LAG3 and 79.8% (MFI-3025) cells were positive to 
display of antibody Fab fragment on surface cells. Here, Top 7.8% of positive cells to h-LAG3 and Fab display 
were sorted. After three rounds of FACS sorting, a final binding analysis showed 67.4% of positive yeast-
cells binders to h-LAG3 (Figure 18) with 7.9% of unspecific binders (Figure 19). Single cells were plated on 
SD–Trp–Leu agar plates, and yeast-cell clones were subjected to binding analysis by FACS and further 
sequencing procedure (single colony sequencing service at Hay labs) to identify and select clones for sub 
cloning and expression of full-length IgG. 
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Figure 18: FACS sorting selection process of the TIL-B kappa library to h-LAG3 yeast-cell binders. 
FACS sorting selection process of the TIL-B kappa library. Each round was immediately followed with a re-sort for better yeast cell 
selection. Bivariate plots show yeast-cells labelled with biotinylated h-LAG3, SA-APC and anti-lambda R-PE for detection of surface 
expression display of Fab fragment. The percentage of yeast-cells were taken for each sorting round are presented  in each sort gate. 
The percentage of enriched yeast-cells that were positive to h-LAG3 in each sorting round are presented  in the right top of the dot 
plot images. Final analysis of the outcome of round III sorting showed 67.4% of positive yeast-cells binders to h-LAG3. 
 
 
Figure 19: Unspecific binding to APC marker during FACS sorting selection process of the TIL-B kappa library to h-LAG3 
yeast-cell binders. 
Bivariate plots of yeast-cells labeled without biotinylated h-LAG3 and only with SA-APC and anti-lambda R-PE for detection of 
surface expression display of Fab fragment. The analysis indicated for yeast-cells that unspecific enriched for binding to the APC 
marker during the sorting rounds. Final analysis of the outcome of round III unspecific binding indicated for 7.9% yeast-cells. 
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5.3.4. Selection of h-CEACAM5 targeting antibodies by cell biopanning and FACS sorting 
 
In order to improve selectivity of antibodies from the TIL-B library, this time for the h-CEACAM5 
cancer associated antigen, selection of h-CEACAM5 targeting antibodies was performed with a 
combination of two selection processes, cell biopanning and FACS sorting. Yeast display biopanning 
cell-based screening of antibody libraries was previously described to successfully identify antibodies 
targeting cell surface antigens (Tillotson et al., 2013). The CEACAM5 antigen showed relatively high 
total MFI binding to a Fab fragment display on the yeast surface in the first screening analysis (chapter 
5.2). Here, unlike in the previous selection approach only by FACS sorting, the selection was started 
with cell biopanning selection. Here the amount of the TIL-B library yeast-cells that were taken for the 
first-round panning were one-fold grater (~109), compared to the FACS sorting approach when the 
yeast-cells taken for the first run are limited (~108). The human gastric cancer derived cells line MKN-
45 were chosen to be panned on. The MKN-45 cell line was previously shown to have high expression 
of CEACAM5 on the cell surface (Alonso-Camino, Sánchez-Martín, Compte, Sanz, & Álvarez-Vallina, 
2009), which was also found in our internal experiments (data not shown). For depletion of non 
CEACAM5 binders, CEACAM5 CRISPR-Cas9 knockout MKN45 cells that were constructed at our 
labs (ITL) were used. Hence, depletion was conducted on cells that are identical to the selection strain, 
with the elimination of the target itself. The Fab fragment display induced TIL-B lambda yeast library 
(4 x109) were panned first against the confluent CEACAM5 CRISPR-Cas9 knockout MKN45 cells for 
2 hr at RT and then immediately after the washing step the non-binders yeast-cells were panned against 
the confluent MKN-45 cells. After panning yeast-cells were washed and removed using EDTA. Panned 
cells were re-grown in an SD–Trp–Leu medium and utilized for the inoculation of the SG–Trp–Leu + 
peptone medium to induce a Fab fragment between all subsequent biopanning rounds. After five rounds 
of binding, washing, clone recovery and amplification there was clear enrichment in the number of yeast 
cells Fab display binding to the MKN45 cells, as compared to the panning on the depletion cells. This 
is shown in the light microscopy images of each biopanning round (Figure 20). 
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Figure 20: TIL-B lambda library biopanning rounds on MKN5 cell line and depletion rounds on CEACAM5 CRISPR-
Cas9 knockout MKN45 cells.   
(A) Light microscopic analysis of enrichment of the TIL-B lambda library yeast cells after each round against a confluent MKN-45 
monolayer. (B) TIL-B lambda library yeast-cells after each round of depletion against a confluent CEACAM5 CRISPR-Cas9 
knockout MKN45 cells monolayer. Scale bar, 100 µm. Yeast cells are the small objects (~5 µm) residing on the monolayer cells. 
 
To validate the binding of the TIL-B lambda library yeast-surface display to h-CEACAM5 expressed 
on the surface of MKN-45 cells during biopanning rounds, the yeast-cell outputs of each round were 
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screened in a FACS binding analysis. The human CEACAM5 extra cellular domain was labeled with 
EZ-Link NHS-PEG4-Biotin, as described before (chapter 5.3.1). A bivariate binding analysis by flow 
cytometry was performed, as described previously (chapter 5.3.1). Then, screening was performed using an 
antigen concentration of 0.5μM. Approximately 1×106 cells  were subjected to the flow cytometry analysis 48 hr 
post induction with a SG–Trp–Leu + peptone medium at 20ºC. The bivariate dot plot (Figure 21) shows an 
increase in positive yeast-cell binders to h-CEACAM5 from 0.6% in the initial biopanning round to 4.6% in the 
fourth biopanning round. The analysis in round five showed a slight reduction in the positive yeast- cells binders 
but with increased mean fluorescence intensity from the positive yeast cells binders. 
 
Figure 21: FACS binding screening of the yeast-cells outcome of the biopanning rounds.    
Yeast-cells from each biopanning round induced for a Fab fragment display and incubated with 0.5µM biotinylated h-CEACAM5.   
Bivariate plots of yeast-cells labelled with SA-APC for h-CEACAM5 binders and anti-lambda R-PE for detection of surface 
expression display of a Fab fragment show enrichment of yeast- cells from the TIL-B lambda library to h-CEACAM5, up to 4.6 % 
in round IV. Round V showed slight reduction in the positive yeast- cells binders but with an increase in the mean fluorescence 
intensity from the positive yeast cells binders.  
 
After the biopanning selection, while the selection was done to h-CEACAM5 that expressed on MKN-45 cell 
line, yeast-cells outcome from the fifth biopanning round were subjected to FACS selection using the 
biotinylated h-CEACAM5 in order to isolate high affinity binders. For the sorting section the yeast-cells were 
induced for Fab fragment surface display with a SG–Trp–Leu + peptone  medium at 20ºC for 48 hr. Post 
induction 1.5 x 108 cells were incubated with initial concentration of 0.5µM biotinylated h-CEACAM5  
followed by incubation of the cells with SA-APC and the Goat F(ab')2 Anti-Human lambda-R-PE (chapter 
3.4.1). Cells were subjected to FACS (Figure 22). The bivariate dot plot showed that 8.6% (MFI-503) of the 
library cells were positive to h-CEACAM5 and 27.8% (MFI-2433) cells were positive to display of antibody 
Fab fragment on surface cells. Top 2.9% of positive cells to h-CEACAM5 and Fab display were sorted. A 
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subsequent re-sort performed immediately with the sorted cells for better selection of high affinity binders. In 
the re-sort the bivariate dot plot showed that 38.1% (MFI-399) of the library cells were positive to h-
CEACAM5 and 62.5% (MFI-700) cells were positive to display of antibody Fab fragment on surface cells. 
Here, Top 19.3% of positive cells to h-CEACAM5 and Fab display were sorted. Sorted cells were re-grown in 
SD–Trp–Leu and utilized for the inoculation of SG–Trp–Leu + peptone medium for induction of Fab fragment 
between all subsequent sorting rounds. In the second subsequent round sorting, antigen concentration was 
reduced to 0.25 µM biotinylated h-CEACAM5 and 1x108 cells were incubated. The bivariate dot plot showed  
increasing of the library cells that were positive to h-CEACAM5 up to 10.3% (MFI-450) with 0.25 µM antigen 
and increasing in the display antibody Fab fragment on surface cells up to 49.9% (MFI-1115). Top 5.2% of 
positive cells to h-CEACAM5 and Fab display were sorted. In the subsequent re-sort the bivariate dot plot 
showed that  15.6% (MFI-593) of the library cells were positive to h-CEACAM5 and 63.9% (MFI-2379) cells 
were positive to display of antibody Fab fragment on surface cells. Here, Top 7% of positive cells to h-
CEACAM5 and Fab display were sorted. In the third sorting round, antigen concentration and number of cells 
taken for incubation were the same as previous round. The bivariate dot plot showed slight reducing of the 
library cells that were positive to h-CEACAM5 up to 9.7% (MFI-343) with 0.25 µM antigen but increasing in 
display antibody Fab fragment on surface cells up to 54.2% (MFI-1053). Top 4.4% of positive cells to h-
CEACAM5 and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that  27.3% 
(MFI-326) of the library cells were positive to h-CEACAM5 and 71.7% (MFI-597) cells were positive to 
display of antibody Fab fragment on surface cells. Here, Top 5.2% of positive cells to h-CEACAM5 and Fab 
display were sorted. In the fourth subsequent round sorting, antigen concentration and number of cells taken 
for incubation were the same as previous round. The bivariate dot plot showed slight increasing of the library 
cells that were positive to h-CEACAM5 up to 10.2% (MFI-514) with 0.25 µM antigen, but slight reducing in 
display antibody Fab fragment on surface cells up to 52.9% (MFI-975). Top 0.7% of positive cells to h-
CEACAM5 and Fab display were sorted. In the subsequent re-sort the bivariate dot plot showed that  14.8% 
(MFI-724) of the library cells were positive to h-CEACAM5 and 59.5% (MFI-597) cells were positive to 
display of antibody Fab fragment on surface cells. Here, Top 1.2% of positive cells to h-CEACAM5 and Fab 
display were sorted. After four rounds of FACS sorting, a final binding analysis showed   12.1% of positive 
yeast-cells binders to h-CEACAM5 (Figure 22). Single cells were plated on SD–Trp–Leu agar plates, and 
yeast-cell clones were subjected to yeast-cell clones binding analysis by FACS and further sequencing 
procedure (single colony sequencing service at Hay labs) to identify and select clones for sub cloning and 
expression of full-length IgG.  
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Figure 22: FACS sorting selection process of the biopanning on MKN-45 cell line outcome to h-CEACAM5 yeast-cell binders. 
FACS sorting selection process of the yeast-cells biopanning on MKN-45 cell line outcome to h-CEACAM5. Each round 
immediately followed with a re-sort for better selection. Bivariate plots show yeast-cells labelled with biotinylated h-CEACAM5, 
SA-APC and anti-lambda R-PE for detection of surface expression display of Fab fragment. The Percentage of yeast-cells were taken 
for each sorting round are presented  in each sort gate. The percentage of enriched yeast-cells that were positive to h-CEACAM5 in 
each sorting round are presented  in the right top of the dot plot images. Final analysis of the outcome of round IV sorting showed 
12.1% of positive yeast-cells binders to h-CEACAM5. 
 
5.4. Evaluation of sorted individual yeast-cells clones: binding analysis, sequencing, 
formatting as IgG antibody, expression and purification 
After the selection sorting process with the different TIL-B kappa library to antibodies targeting h-LRP6 and 
h-LAG3 and the TIL-B lambda library to antibodies targeting the h-OX40L and h-CEACAM5, single cells 
from the last-round sort were plated on SD–Trp–Leu agar plates and individual yeast-cell clones were picked 
for single yeast-cell clones binding analysis by Guava easyCyte HT cytometer or by flow cytometry binding 
analysis, in order to evaluate high single yeast-cell clones that bind to the antigens. Single yeast-cell clones 
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were induced for a Fab fragment surface display with a SG–Trp–Leu + peptone medium at 20ºC for 48 hr. The 
same labeling procedure, as described previously (chapter 5.2), was applied here. Then the cells were incubated 
with initial concentration of 0.1-0.2 µM biotinylated antigen. After individual clones were confirmed for 
binding to the antigen, the single clones were analyzed by sequencing their variable region frameworks and 
complementary determining region (CDR) diversities within the heavy and light-chain and then analyzed by 
Salsa analysis (Merck). Then a clustering strategy was applied, where sequences with ≥ 90% identical CDR 
residues were allocated to the same cluster for identification of unique clones. Functionality of the heavy and 
the light chain for correct expression was tasted and the heavy or the light chain were removed from subsequent 
analyses if the third complementarity determining region (CDR3) was of indeterminate length, stop codons 
were present, or the amino acid translation was out of frame. Unique clones’ VH and VL regions of IgG 
molecules that showed specific binding to the antigen were subcloned into pTT5 plasmids (chapter 3.3). 
Ligation-free subcloning of VH or VL gene regions was performed by lysis and by PCR application from the 
yeast cell individual clones into pTT5 plasmid to generate pTT5-IgG-HC and pTT5-IgG-CL constructs, using 
the Expresso CMV system (chapter 3.3). This method is based on the system described previously (Bubeck, 
Winkler, & Bautsch, 1993) employing linearized acceptor vectors and target genes that were PCR amplified 
using primers containing 18 bp overlaps with the vector ends. Chemically competent One Shot Mach1™-T1R 
E. coli cells were co-transformed with both a linearized vector and amplified inserts, to allow fusion of the 
PCR product to the vector via homologous recombination. After sequence verification of cloned constructs, 
HEK293-EBNA cells were transiently transfected with expression vectors (chapter 4.4.2). Five days post 
transfection, antibody containing supernatants were harvested and purified by a protein A HP SpinTrap column 
(chapter 3.8). Purified IgG antibodies were analyzed for binding to the antigen with BLI analysis (chapter 
4.3.5). 
 
5.4.1. Evaluation of sorted individual yeast-cells clones targeting h-OX40L 
After the selection sorting process of the TIL-B Lambda library with the h-OX40L immune checkpoint (cf. 
chapter 5.3.1), single cells from the fifth-round sort were plated on SD–Trp–Leu agar plates. Ninety-five 
single yeast-cell clones were picked for the single yeast-cell clones binding analysis by Guava easyCyte HT 
cytometer, in order to evaluate high single yeast-cell clones that bind to the h-OX40L. The 95-single yeast-
cell clones were induced and labelled, as described previously (chapter 5.3.1), and then the cells were 
incubated with an initial concentration of 0.1µM biotinylated h-OX40L and subjected to an analysis in the 
Guava easyCyte HT cytometer. Figure 23 depicts the mean fluorescence intensity (MFI) of the APC marker 
from the 95 yeast-cell clones that bound to the h-OX40L obtained by the Guava easyCyte HT cytometer 
binding analysis. All 95 yeast-cells clones had MFI above the background MFI level (yeast-cells labelled 
without biotinylated h-OX40L) and above the pool that the yeast-cells clones had been isolated from. 
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Figure 23: Binding analysis of single yeast-cell clones to h-OX40L by the Guava easyCyte HT cytometer.  
Binding enrichment of individual yeast-cells clones from the TIL-B lambda library to h-OX40L. Bars represent the total MFI obtained 
from the biotinylated h-OX40L that were bound to the antibody Fab fragments, followed by the SA-APC marker, from the individual 
clones. All yeast-cells clones had higher MFI signal than the background level of the total MFI obtained from the yeast -cell clones 
labeled with a SA-APC marker without biotinylated h-OX40L, and from the pool that the yeast-cell clones had been isolated from. 
 
As all yeast-cell clones bound to the h-OX40L, all single clones were sequenced and clustered as described 
previously (chapter 5.4). Table 6 summarizes the unique clones that were identified by an ID name of a 
representative clone from all the clustered clones, the number of repeats in clustered and clone germline 
diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage from the germline. 
Thirteen unique heavy and light chain combinations were identified and represented as unique functional 
clones. 
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Table 6: Isolated unique binders to h-OX40L with their germline diversity. 
Summary of the sequence clustering analysis for the individual yeast-cell clones that bind to h-OX40L.Clone ID name is a yeast 
clone number representative for the cluster. After clustering, 13 clones out of 95 were identified as unique. The 13 clustered 
sequences were verified for functional expression for both heavy and light chain to generate the functional Fab fragment. Repeats 
of clones in each cluster and germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage 
from the germline are presented.      
  
The 13 unique clones of VH an VL regions of IgG molecules that showed specific binding to the h-OX40L 
were subcloned into pTT5 plasmids, as described previously (chapter 5.4). After expression and purification, 
as described before (chapter 5.4), purified IgG1 antibodies were analyzed for binding to the antigen with BLI 
analysis (chapter 5.5.1).   
 
5.4.2. Evaluation of sorted individual yeast-cells clones targeting h-LRP6 
After the selection sorting process of the TIL-B kappa library with the h-LRP6 E3:E4 domain (cf. chapter 
5.4.2), single cells from the fifth-round sort were plated on SD–Trp–Leu agar plates. This time, because an 
aggressive sorting strategy was applied during the sorting process, only 20 single yeast-cell clones were 
picked for single yeast-cell clones binding analysis. Here, because the unspecific binding analysis (Figure 
17) in the last sorting round showed that 10% of the yeast- cells bound unpacifically, an unspecific binding 
analysis by FACS was performed, as described before (chapter 5.3.1), for each individual clone in order to 
Clone 
ID 
repeats 
VH-region 
identity (%) 
VH gene DH gene JH gene 
VL-region 
identity (%) 
VL gene VJ gene 
A01 4 96 
IGHV6-
1*01 
IGHD6-
19*01 
IGHJ3*02 
92 IGLV1-51*01 IGLJ2*01 
A02 26 90 
IGHV1-
3*01 
IGHD5-
12*01 
IGHJ6*01 
99 IGLV6-57*01 IGLJ2*01 
A03 31 90 
IGHV3-
30*03 
IGHD3-
22*01 
IGHJ6*02 
90 IGLV1-44*01 IGLJ3*02 
A06 1 100 
IGHV6-
1*01 
IGHD5-
24*01 
IGHJ3*01 
95 IGLV2-23*02 IGLJ2*01 
A09 9 97 
IGHV4-
39*07 
IGHD3-
10*01 
IGHJ6*02 
93 IGLV1-40*01 IGLJ3*02 
A10 1 95 
IGHV6-
1*01 
IGHD3-
10*01 
IGHJ3*01 
87 IGLV1-40*01 IGLJ3*02 
A16 1 96 
IGHV6-
1*01 
IGHD3-
10*01 
IGHJ6*02 
91 IGLV3-19*01 IGLJ3*02 
B07 3 91 
IGHV1-
3*01 
IGHD5-
12*01 
IGHJ6*01 
94 IGLV1-44*01 IGLJ3*02 
B13 1 95 
IGHV3-
11*01 
IGHD1-
26*01 
IGHJ6*02 
95 IGLV3-21*02 IGLJ3*02 
B17 1 87 
IGHV4-
31*03 
IGHD5-
24*01 
IGHJ6*02 
85 IGLV1-44*01 IGLJ3*02 
D10 1 93 
IGHV6-
1*01 
 IGHJ4*02 
88 IGLV2-14*01 IGLJ2*01 
D12 1 92 
IGHV3-
30*04 
IGHD6-
19*01 
IGHJ2*01 
76 IGLV1-47*01 IGLJ2*01 
D19 1 87 
IGHV6-
1*01 
IGHD3-
22*01 
IGHJ6*02 
99 IGLV6-57*01 IGLJ3*02 
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eliminate unspecific binder clones for further analysis. Exemplary histograms of relative fluorescence 
intensities are depicted in Figure 24. Only 2 clones exhibited strong binding to the SA-APC marker (A10 and 
A16) and were excluded from further analysis.  
 
 
Figure 24: Unspecific binding analysis of single yeast-cell clones sorted for h-LRP6 binders. 
Twenty individual clones picked from the final h-LRP6 sorting round were incubated without the biotinylated h-LRP6 but only with 
the SA-APC marker followed by flow cytometry. The analysis revealed 2 clones that bound strongly to the SA-APC marker (A10 and 
A16). 
 
The 18 remaining yeast-cell clones were identified with specific binding to the h-LRP6. The single clones 
were sequenced and clustered, as described previously (Chapter 5.4). The cluster analysis revealed two unique 
clones. Table 7 includes the ID name of a representative clone from the clustered clones, the number of 
repeats in clustered, and clone germline diversity of the heavy (VDJ) and light (VJ) gene segments with their 
identity percentage from the germline. 
 
 
Table 7: Isolated unique binders to h-LRP6 with their germline diversity.  
Summary of the sequence clustering analysis for the individual yeast-cell clones that bind to h-LRP6. Clone ID name is a yeast 
clone number representative for the cluster. After clustering, 2 clones out of 18 were identified as unique. The 2 clustered 
sequences were verified for functional expression for both heavy and light chains to generate a functional Fab fragment. Repeats 
of clones in each clustered and germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage 
from the germline are presented.      
 
Clone 
ID 
repeats 
VH-region 
identity (%) 
VH gene DH gene JH gene 
VL-region 
identity (%) 
VL gene VJ gene 
A01 17 95 
IGHV3-
48*01 
IGHD3-
22*01 
IGHJ6*03 75 IGKV1-27*01 IGKJ5*01 
A15 1 90 
IGHV3-
23*04 
IGHD3-
3*01 
IGHJ6*02 94 IGKV2-30*01 IGKJ2*01 
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To confirm specific binding to the h-LRP6 ligand, the 2-unique single yeast-cell clones were induced and 
labelled, as described previously (chapter 5.3.1). Cells were incubated with initial concentration of 0.25µM 
biotinylated h-LRP6 and subjected to flow cytometer for binding analysis, as described before (chapter 5.3.1). 
Exemplary histograms of relative fluorescence intensities are depicted in Figure 25. The 2 clones (A01 and 
A15) exhibited significant binding to the h-LRP6 antigen.  
 
Figure 25: Binding analysis of individual yeast-cell clones sorted to h-LRP6 binding. 
The two individual clones picked from the final h-LRP6 sorting round V were incubated with biotinylated h-LRP6 and labelled by 
the SA-APC marker, followed by flow cytometry. The analysis indicated significant binding of the unique yeast-cells clones to the h-
LRP6 antigen. 
 
The two unique clones of VH and VL regions of IgG molecules that showed specific binding to the h-OX40L 
were subcloned into pTT5 plasmids, as described previously (chapter 5.4). After expression and purification, 
as described before (chapter 5.4), purified IgG1 antibodies were analyzed for binding to the antigen with BLI 
analysis (chapter 5.5.2).   
 
5.4.3. Evaluation of sorted individual yeast-cells clones targeting h-LAG3 
After the selection sorting process of the TIL-B kappa library with the h-LAG3 immune checkpoint. (chapter 
5.4.3), single yeast-cells from the third-round sort were plated on SD–Trp–Leu agar plates. Ninety-four single 
yeast-cell clones were picked for single yeast-cell clones binding analysis by Guava easyCyte HT cytometer, 
in order to evaluate high single yeast-cell clones that bind to the h-LAG3. The 94-single yeast-cell clones 
were induced and labeled as described previously (chapter 5.3.1),and then cells were incubated with initial 
concentration of 0.2µM biotinylated h-LAG3 and subjected to Guava easyCyte HT cytometer. Figure 26 
depicts the mean fluorescence intensity (MFI) of the APC marker indicated from the 94 yeast-cell clones that 
bind to the h-LAG3 obtained by the Guava easyCyte HT cytometer binding analysis. All 94 yeast-cells clones 
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had MFI above the background MFI level (yeast-cells labeled without biotinylated h-LAG3). Sixty-three 
yeast-cells clones had total MFI above the pool that the yeast-cells clones had been isolated from. 
 
 
 
Figure 26: Binding analysis of single clones to h-LAG3 by Guava easyCyte HT cytometer.  
Binding enrichment of individual yeast-cell clones from the TIL-B kappa library to h-LAG3. Bars represent the MFI obtained from 
the biotinylated h-LAG-3 followed by the SA-APC marker that were bind to the antibody Fab fragments on the individual clones. All 
yeast-cells clone indicated for high MFI signal than the background level of total MFI that obtained from yeast-cells labeled with SA-
APC marker without biotinylated h-LAG-3. Sixty-three yeast-cell clones indicated for high total MFI than the pool yeast-cell clones 
were isolated from.  
 
 
As all yeast-cell clones bound to the h-LAG3, all the single clones were sequenced and clustered as described 
previously (chapter 5.4). Table 8 summarizes the 18 unique clones that were identified by an ID name of a 
representative clone from all the clustered clones, the number of repeats in clustered and clone germline 
diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage from the germline. 
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Table 8: Isolated unique binders to h-LAG3 with their germline diversity.  
Summary of the sequence clustering analysis for the individual yeast-cell clones that bind to h-LAG3. Clone ID name is a yeast 
clone number representative for the cluster. After clustering, 18 clones out of 95 were identified as unique. The 18 clustered 
sequences were verified for functional expression for both heavy and light chains to generate functional Fab fragment. Repeats of 
clones in each clustered and germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage 
from the germline are presented.      
 
The 18 unique clones VH an VL regions of IgG molecules that showed specific binding to the h-LAG3 were 
subcloned into pTT5 plasmids , as described previously (chapter 5.4). After expression and purification, as 
described before (chapter 5.4), purified IgG1 antibodies were analyzed for binding to the antigen with BLI 
analysis (cf. Chapter 5.5.3).   
Clone 
ID 
repeats 
VH-region 
identity (%) 
VH gene DH gene JH gene 
VL-region 
identity (%) 
VL gene VJ gene 
A04 5 92 
IGHV3-
30*03 
IGHD4-
17*01 
IGHJ4*02 95 
IGKV2-
30*01 
IGKJ1*01 
A12 11 90 
IGHV3-
9*01 
IGHD5-
24*01 
IGHJ6*02 90 
IGKV3-
20*01 
IGKJ2*01 
A13 3 95 
IGHV3-30-
3*01 
IGHD3-
3*01 
IGHJ6*02 92 
IGKV1-
27*01 
IGKJ2*01 
A17 2 91 
IGHV3-
23*04 
IGHD3-
3*01 
IGHJ6*02 89 
IGKV4-
1*01 
IGKJ2*01 
A22 1 92 
IGHV4-
61*02 
IGHD5-
12*01 
IGHJ4*02 89 
IGKV4-
1*01 
IGKJ2*01 
A23 9 92 
IGHV3-
23*04 
IGHD5-
18*01 
IGHJ1*01 88 
IGKV3-
15*01 
IGKJ4*01 
B06 1 93 
IGHV3-
33*05 
IGHD3-
22*01 
IGHJ3*02 88 
IGKV2-
28*01 
IGKJ5*01 
B23 1 90 
IGHV5-
51*03 
IGHD3-
22*01 
IGHJ6*01 82 
IGKV2-
28*01 
IGKJ5*01 
B24 1 96 
IGHV3-
30*18 
IGHD3-
3*01 
IGHJ6*02 84 
IGKV1-
12*01 
IGKJ4*02 
C02 1 83 
IGHV1-
2*02 
IGHD6-
19*01 
IGHJ5*02 92 
IGKV1-
8*01 
IGKJ1*01 
C06 1 85 
IGHV4-
59*01 
 IGHJ6*03 95 
IGKV2-
28*01 
IGKJ5*01 
C09 35 84 
IGHV3-
21*01 
IGHD4-
17*01 
IGHJ3*01 87 
IGKV3-
11*01 
IGKJ5*01 
C17 2 91 
IGHV3-
30*03 
IGHD4-
17*01 
IGHJ1*01 88 
IGKV3-
20*01 
IGKJ2*01 
D01 1 91 
IGHV3-
48*01 
IGHD3-
22*01 
IGHJ6*02 91 
IGKV1-
9*01 
IGKJ2*02 
D03 1 95 
IGHV3-
64*05 
IGHD3-
22*01 
IGHJ3*01 91 
IGKV1-
39*01 
IGKJ2*01 
D05 1 88 
IGHV4-
34*01 
IGHD3-
22*01 
IGHJ3*01 94 
IGKV1-
9*01 
IGKJ4*01 
D10 1 95 
IGHV6-
1*01 
 IGHJ4*02 91 
IGKV3-
20*01 
IGKJ4*01 
D19 1 93 
IGHV3-
53*01 
IGHD3-
22*01 
IGHJ3*02 95 
IGKV2-
30*01 
IGKJ1*01 
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5.4.4. Evaluation of sorted individual yeast-cells targeting h-CEACAM5  
After the selection sorting process with the TIL-B Lambda library with the h-CEACAM5 ECD (chapter 
5.4.4), single yeast-cells from the fourth-round sort were plated on SD–Trp–Leu agar plates. This time, 
because the selection was started with biopanning on MKN45 cell line followed by selection by FACS sorting 
strategy, only 10 single yeast-cells clones were picked. The single clones were sequenced and clustered as 
described previously (chapter 5.4). Table 9 summarized the two unique clones that were identified by an ID 
name of a representative clone from all the clustered clones, the number of repeats in clustered and clone 
germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage from the 
germline 
 
Table 9: Isolated unique binders to h-CEACAM5 with their germline diversity.  
Summary of the sequence clustering analysis for the individual yeast-cell clones that bind to h-CEACAM5. Clone ID name is a 
yeast clone number representative for the cluster. After clustering, 13 clones out of 95 were identified as unique. The 2 clustered 
sequences were verified for functional expression for both heavy and light chains to generate functional Fab fragment. Repeats of 
clones in each clustered and germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage 
from the germline are presented.      
 
To confirmed specific binding to the h-CEACAM5 ECD, the 2-unique single yeast-cell clones were 
induced and labeled as described previously (chapter 5.3.1), cells were incubated with initial 
concentration of 0.25µM biotinylated h-CEACAM5 and subjected to flow cytometer for binding 
analysis. Exemplary histograms for relative fluorescence intensities are depicted in Figure 27. Clone 
A01 exhibited significant differential binding to h-CEACAM5 compared to clone A03. 
 
Clone 
ID 
repeats 
VH-region 
identity (%) 
VH gene DH gene JH gene 
VL-region 
identity (%) 
VL gene VJ gene 
A01 7 88 
IGHV3-
7*01 
IGHD1-
14*01 
IGHJ4*02 87 IGLV3-19*01 IGLJ5*01 
A03 3 89 
IGHV3-
30*03 
IGHD2-
15*01 
IGHJ4*02 93 IGLV7-46*01 IGLJ3*02 
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Figure 27:Binding analysis of individual yeast-cell clones sorted to h-CEACAM5 binding. 
The two individual clones picked from the final h-CEACAM5 sorting round IV were incubated with the biotinylated h-CEACAM5 
and labeled by the SA-APC marker followed by flow cytometry. The relative MFI indicate for significant binding of the unique yeast-
cells clones A01 than to clone A03 to the h-CEACAM5 antigen. 
 
A01 unique clone VH and VL regions of IgG molecules that showed stronger specific binding to the h-
CEACAM5 antigen were subcloned into pTT5 plasmids, as described previously (chapter 5.4). After 
expression and purification, as described before (chapter 5.4), purified IgG1 antibodies were analyzed for 
binding to the antigen with BLI analysis (chapter 5.4.4). 
   
5.5. Evaluation of re-formatted full-length IgG1 selected mAbs by BLI   
After the selected yeast-clones VH and VL regions sequences were re-formatted into full-length IgG1 
by subcloning into pTT5 mammalian expression vectors and were expressed in the HEK293-EBNA 
cells, the secreted full-length IgG1 antibodies were evaluated for affinity and specificity to the antigen 
which they were selected for. For that, biolayer interferometry (BLI) measurements were performed 
(cf. chapter 4.3.5) utilizing anti human Fc (AHC) biosensor tips and the relevant recombinant antigen 
protein. Antibodies were first captured on the AHC biosensor tips. Afterwards, in the association step, 
binding to the relevant antigen can be measured by incubation of biosensors in relatively high 
concentration (200 nM) of the relevant antigen, to ensure also binding of low affinity antibodies. It 
should be noted that the lowest limit of detection for this biophysical method of kinetic measurements 
is 1 µM (Estep et al., 2013). Hence, in order to measure specificity to the antigen of antibodies with 
affinity lower than 1 µM, BLI measurements were performed utilizing streptavidin (SA) biosensor tips. 
For that, the biotinylated antigen was immobilized on the SA biosensors followed by incubation of the 
biosensors with the relevant antibody in the association step. In this orientation of the BLI measurement 
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the binding rate of the antibodies increased by avidity due the bivalent Fab fragments in the full-length 
IgG1 antibodies that bind to the immobilized biotinylated antigen (Tobias & Kumaraswamy, 2013).  
 
5.5.1. Evaluation of re-formatted full-length IgG1 h-OX40L targeting antibodies 
*Parts of the work in this chapter were done by Svea Becker as part of her Master thesis.  
After sequence verification of the cloned constructs of the heavy and light chain, only 10 clones were 
confirmed with correct sequence for transient transfection to the HEK293-EBNA cells. Five days post 
transfection antibodies were harvested and purified by protein A HP SpinTrap column (chapter 4.3.4) 
according to the manufacturer’s instructions. To evaluate their kinetic parameters the antibodies were 
analyzed by biolayer interferometry (BLI) to assess the binding after reformatting to full-length IgG1. 
Briefly, antibodies were immobilized on anti-human Fc (AHC) biosensor tips and association as well 
as dissociation of the h-OX40L were monitored. Exemplary sensorgrams of the analysis of all 
reformatted antibodies are depicted in Figure 28. The data indicate a wavelength shift in nm for all 
antibodies when captured by the AHC biosensors. No shifts in the association step with the h-OX40L 
were detected. That means that the antibodies may lose their ability to bind the h-OX40L after the 
reformatting process to full-length IgG1 or the antibodies are low affinity antibodies with affinity below 
the assay limit of detection.  
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Figure 28: Binding analysis of h-OX40L to reformatted full-length IgG1 mAbs by BLI. 
Antibodies were immobilized on AHC biosensors (mAb loading). Then, association of the h-OX40L (200nM) was monitored. There 
was no interference pattern shift observed for none of the antibodies in the association steps, indicating low affinity antibodies or non-
binders antibodies. The mouse anti-OX40L used as a control bound to the h-OX40L recombinant protein.  
 
To determine whether the antibodies are low affinity antibodies or non-binders antibodies, BLI binding 
analysis using the streptavidin biosensors was applied. In brief, biotinylated h-OX40L was captured on 
streptavidin biosensor tips. Then, antibodies were associated (200 nM). Exemplary sensorgrams of the 
analysis are depicted in Figure 29. The wavelength shifts of the association of the antibodies with the 
biotinylated h-OX40L indicate specific binding. The control mouse anti-OX40L bound to the h-OX40L 
with a high nm shift, while the non-related isotype antibody (anti-CEACAM5) did not bind to the h-
OX40L. The data confirmed specific binding of the antibodies but with low affinity.    
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Figure 29: Binding analysis of h-OX40L to reformatted full-length IgG1 mAbs by BLI using SA biosensors. 
Biotinylated h-OX40L were immobilized on streptavidin biosensors. Then, association of the different antibodies was monitored. 
Exemplary sensorgrams of the association steps show an interference pattern shift that indicates specificity of the antibodies to the h-
OX40L. The control mouse anti-OX40L bound to the h-OX40L with a high nm shift, while the non-related isotype antibody (anti-
CEACAM5) did not bind to the h-OX40L. The data confirmed specific binding of the antibodies but with low affinity. 
 
5.5.2. Evaluation of re-formatted full-length IgG1 h-LRP6 targeting antibodies  
After sequence verification of the cloned constructs of the heavy and light chain, the 2 unique clones 
were confirmed with correct sequence for transient transfection to the HEK293-EBNA cells. Five days 
post transfection antibodies were harvested and purified by protein A HP SpinTrap column (chapter 
4.34) according to manufacturer’s instructions. To evaluate their kinetic parameters antibodies were 
analyzed by biolayer interferometry (BLI) to assess the binding after reformatting to full-length IgG1. 
Briefly, antibodies were immobilized on anti-human Fc (AHC) biosensor tips and association as well 
as dissociation of the h-LRP6 E3:E4 domain were monitored. Exemplary sensorgrams of the analysis 
of all reformatted antibodies are depicted in Figure 30. The data indicate a wavelength shift in nm for 
all antibodies when capture to the AHC biosensors. No shifts in the association step with the h-LRP6 
were detected. That means that the antibodies may lose their ability to bind the h-LRP6 after the 
reformatting process to full-length IgG1 or the antibodies are low affinity antibodies with affinity below 
the assay limit of detection. 
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Figure 30: Binding analysis of h-LRP6 to reformatted full-length IgG1 mAbs by BLI. 
Antibodies were immobilized on AHC biosensors (mAb loading). Then, association of the h-LRP6 (200nM) was monitored. There 
was no interference pattern shift observed for none of the antibodies in the association steps, indicating low affinity antibodies or non-
binders antibodies. The anti-LRP6 mAb used as a control bound to the h-LRP6 recombinant protein.  
 
To determine whether the antibodies are low affinity antibodies or non-binders antibodies, BLI binding 
analysis using the streptavidin biosensors was applied. In brief, biotinylated h-LRP6 was captured on 
streptavidin biosensor tips. Then, antibodies were associated (200 nM). Exemplary sensorgrams of the 
analysis are depicted in Figure 31. The wavelength shifts of the association of the antibodies with the 
biotinylated h-OX40L indicate specific binding. The control anti- h-LRP6 mAb bound to the h-LRP6 with 
a high nm shift, while the non-related isotype antibody (anti-CEACAM5) did not bind to the h-LRP6. The 
data confirmed specific binding of the antibodies but with low affinity.    
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Figure 31: Binding analysis of h-LRP6 to reformatted full-length IgG1 antibodies by BLI using SA biosensors. 
Biotinylated h-LRP6 were immobilized on streptavidin biosensors. Then, association of the different antibodies was monitored. 
Exemplary sensorgrams of the association steps show an interference pattern shift that indicates specificity of the antibodies to the h-
LRP6. The control anti-LRP6 mAb bound to the h-LRP6 with a high nm shift, while the non-related isotype antibody (anti-
CEACAM5) did not bind to the h-LRP6. The data confirmed specific binding of the antibodies but with low affinity. 
 
5.5.3. Evaluation of re-formatted full-length IgG1 h-LAG3 targeting antibodies  
After sequence verification of the cloned constructs of the heavy and light chain, only 10 clones were 
confirmed with correct sequence for transient transfection to the HEK293-EBNA cells. Five days post 
transfection antibodies were harvested and purified by protein A HP SpinTrap column (chapter 4.3.4) 
according to the manufacturer’s instructions. To evaluate their kinetic parameters the antibodies were 
analyzed by biolayer interferometry (BLI) to assess the binding after reformatting to full-length IgG1. 
Briefly, antibodies were immobilized on anti-human Fc (AHC) biosensor tips and association as well 
as dissociation of the h-LAG3 were monitored. Exemplary sensorgrams of the analysis of all 
reformatted antibodies are depicted in Figure 32. The data indicate a wavelength shift in nm for all 
antibodies when captured by the AHC biosensors. No shifts in the association step with the h-LAG3 
were detected. That means that the antibodies may lose their ability to bind the h-LAG3 after the 
reformatting process to full-length IgG1 or the antibodies are low affinity antibodies with affinity below 
the assay limit of detection.  
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Figure 32: Binding analysis of h-LAG3 to reformatted full-length IgG1 antibodies by BLI. 
Antibodies were immobilized on AHC biosensors (mAb loading). Then, association of the h-LAG3 (200nM) was monitored. There 
was no interference pattern shift observed for none of the antibodies in the association steps, indicating low affinity antibodies or non-
binders antibodies. The anti-LAG3 mAb used as a control bound to the h-LAG3 recombinant protein.  
 
To determine whether the antibodies are low affinity antibodies or non-binders antibodies, BLI binding 
analysis using the streptavidin biosensors was applied. In brief, biotinylated h-LAG3 was captured on 
streptavidin biosensor tips. Then, antibodies were associated (200 nM). Exemplary sensorgrams of the 
analysis are depicted in Figure 33. The wavelength shifts of the association of the antibodies with the 
biotinylated h-LAG3 indicate specific binding. The control anti-LAG3 bound to the h-LAG3 with a high 
nm shift, while the non-related isotype antibody (anti-CEACAM5) did not bind to the h-LAG3. The data 
confirmed specific binding of the antibodies but with low affinity.    
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Figure 33: Binding analysis of h-LAG3 to reformatted full-length IgG1 antibodies by BLI using SA biosensors. 
Biotinylated h-LAG3 were immobilized on streptavidin biosensors. Then, association of the different antibodies was monitored. 
Exemplary sensorgrams of the association steps show an interference pattern shift that indicates specificity of the antibodies to the h-
LAG3. The control anti-LAG3 mAb bound to the h-LAG3 with a high nm shift, while the non-related isotype antibody (anti-
CEACAM5) did not bind to the h-LAG3. The data confirmed specific binding of the antibodies but with low affinity. 
 
5.5.4. Evaluation of re-formatted full-length IgG1 h-CEACAM5 targeting antibodies  
After sequence verification of the cloned constructs of the heavy and light chain. The 2 unique clones 
were confirmed with correct sequence for transient transfection to the HEK293-EBNA cells. Five days 
post transfection antibodies were harvested and purified by protein A HP SpinTrap column (chapter 
4.3.4) according to the manufacturer’s instructions. To evaluate their kinetic parameters the antibodies 
were analyzed by biolayer interferometry (BLI) to assess the binding after reformatting to full-length 
IgG1. Briefly, antibodies were immobilized on anti-human Fc (AHC) biosensor tips and association as 
well as dissociation of the h-CEACAM5 were monitored. Exemplary sensorgrams of the analysis of all 
reformatted antibodies are depicted in Figure 34. The data indicate a wavelength shift in nm for all 
antibodies when captured by the AHC biosensors. No shifts in the association step with the h-
CEACAM5 were detected. That means that the antibodies may lose their ability to bind the h-
CEACAM5 after the reformatting process to full-length IgG1 or the antibodies are low affinity antibodies 
with affinity below the assay limit of detection. 
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Figure 34: Binding analysis of h-CEACAM5 to reformatted full-length IgG1 antibodies by BLI. 
Antibodies were immobilized on AHC biosensors (mAb loading). Then, association of the h-CEACAM5 (200nM) was monitored. 
There was no interference pattern shift observed for none of the antibodies in the association steps, indicating low affinity antibodies 
or non-binders antibodies. The anti-CEACAM5 mAb used as a control bound to the h-CEACAM5 recombinant protein.  
 
To determine whether the antibodies are low affinity antibodies or non-binders antibodies, BLI binding 
analysis using the streptavidin biosensors was applied. In brief, biotinylated h-CEACAM5 was captured 
on streptavidin biosensor tips. Then, antibodies were associated (200 nM). Exemplary sensorgrams of 
the analysis are depicted in Figure 35. The wavelength shifts of the association of the antibodies with the 
biotinylated h-CEACAM5 indicate specific binding. The control anti-CEACAM5 mAb bound to the h-
CEACAM5 with a high nm shift, while the non-related isotype antibody (anti-LRP6) did not bind to the 
h-CEACAM5. The data confirmed specific binding of the antibodies but with low affinity.    
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Figure 35: Binding analysis of h-CEACAM5 to reformatted full-length IgG1 antibodies by BLI using SA biosensors. 
Biotinylated h-CEACAM5 were immobilized on streptavidin biosensors. Then, association of the different antibodies was monitored. 
Exemplary sensorgrams of the association steps show an interference pattern shift that indicates specificity of the antibodies to the h-
CEACAM5. The control anti-CEACAM5 mAb bound to the h-CEACAM5 with a high nm shift, while the non-related isotype 
antibody (anti-LRP6) did not bind to the h-lrp6. The data confirmed specific binding of the antibodies but with low affinity. 
 
5.6. Selection of colon cancer cells targeting antibodies using yeast biopanning of the yeast 
display antibody libraries derived from tumor infiltrating B cells of colon cancer patients 
The approach to select antibodies from the yeast display antibody libraries derived from tumor 
infiltrating B cells of colon cancer patients (TIL-B) targeting the cancer associated antigens (LRP6 and 
CEACAM5) and immune chokepoint (OX40L and LAG3) revealed specific but low affinity full-length 
IgG1 antibodies. Here, the aim was to evaluate the TIL-B libraries for selection of binders to “unknown” 
targets on colon cancer cell lines by performing biopanning selection on live cells. Yeast display 
biopanning cell-based screening of antibody libraries was described previously to successfully identify 
antibodies targeting cell surface antigens (Tillotson et al., 2013). Here, biopanning with the TIL-B kappa 
library against 3 different colon cancer cell lines was performed, while normal colon fibroblast cells 
were used as negative cells for depletion of non-related cancer target binders. The cell lines selected for 
the screening were: HCT 116 (colorectal carcinoma derived), HT-29 (colorectal adenocarcinoma 
derived) and SW620 (colorectal adenocarcinoma derived from a metastatic lymph node site), as the 
libraries had been derived from tumor infiltrating B cells of colon cancer patients. A normal CCD-18Co 
colon fibroblast cell line was used as negative cells for depletion. 
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5.6.1. Biopanning of the TIL-B kappa library against HCT 116 cell line 
For the biopanning selection of the TIL-B kappa library against HCT 116 cell line surface targets, the 
Fab fragment display of the library was induced with a SG–Trp–Leu + peptone medium at 20ºC for 48 
hr. Post induction, 4x109 yeast-cells were panned against the confluent HCT 116 cells. After the panning 
yeast-cells were washed and removed using EDTA. Panned cells were re-grown in a SD–Trp–Leu and 
utilized for the inoculation of a SG–Trp–Leu + peptone medium for induction of the Fab fragment 
between all subsequent biopanning rounds (chapter 4.2.9). In the second biopanning round yeast-cells 
were panned first against the confluent CCD-18CO normal colon fibroblast cell line for 2 hours at RT 
and then the non-binders to the CCD-18CO yeast-cells were immediately panned against the confluent 
HCT 116 cells. After three rounds of binding, washing, clone recovery and amplification there was a 
clear enrichment in the number of yeast cells Fab display binding to the HCT 116 cells, observed under 
the light microscopy imaging (Figure 36A). While panning on the depletion cells only few yeast-cell 
binders were observed (Figure 36B). 
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Figure 36: TIL-B kappa library biopanning rounds against HCT 116 cell line and depletion rounds on normal colon CCD-
18CO cell line (B).   
(A) Light microscopic imagining of enrichment of the TIL-B kappa library yeast cells after each round of biopanning against a 
confluent HCT 116 monolayer. (B) TIL-B kappa library yeast-cells after each round of depletion against a confluent CCD-18CO cells 
monolayer. Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells. Enrichment can be observed after 
three rounds, while few binders can be observed on the normal CCD-18CO colon cells used for depletion. 
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5.6.2. Biopanning of the TIL-B kappa library against HT-29 cell line 
For the biopanning selection of the TIL-B kappa library against HT-29 cell line surface targets, the Fab 
fragment display of the library was induced with a SG–Trp–Leu + peptone medium at 20ºC for 48 hr. 
Post induction, 4x109 yeast-cells were panned against the confluent HT-29 cells. After the panning 
yeast-cells were washed and removed using EDTA. Panned cells were re-grown in a SD–Trp–Leu and 
utilized for the inoculation of a SG–Trp–Leu + peptone medium for induction of the Fab fragment 
between all subsequent biopanning rounds (chapter 4.2.9). In the second biopanning round yeast-cells 
were panned first against the confluent CCD-18CO normal colon fibroblast cell line for 2 hours at RT 
and then the non-binders to the CCD-18CO yeast-cells were immediately panned against the confluent 
HT-29 cells. After three rounds of binding, washing, clone recovery and amplification there was a clear 
enrichment in the number of yeast cells Fab display binding to the HT-29 cells, observed under the light 
microscopy imaging (Figure 37A). While panning on the depletion cells only few yeast-cell binders 
were observed (Figure 37B). 
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Figure 37: TIL-B kappa library biopanning rounds against HT-29 cell line and depletion rounds on colon normal CCD-
18CO cell line.   
(A) Light microscopic imagining of enrichment of the TIL-B kappa library yeast cells after each round of biopanning against a 
confluent HT-29 monolayer. (B) TIL-B kappa library yeast-cells after each round of depletion against a confluent CCD-18CO cells 
monolayer. Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells. Enrichment can be observed after 
three rounds, while few binders can be observed on the normal CCD-18CO colon cells used for depletion. 
 
 
 
5. Results 98 
 
 
 
 
 
5.6.3. Biopanning of the TIL-B kappa library against SW620 cell line 
For the biopanning selection of the TIL-B kappa library against SW620 cell line surface targets, the 
Fab fragment display of the library was induced with a SG–Trp–Leu + peptone medium at 20ºC for 48 
hr. Post induction, 4x109 yeast-cells were panned against the confluent SW620 cells. After the panning 
yeast-cells were washed and removed using EDTA. Panned cells were re-grown in a SD–Trp–Leu and 
utilized for the inoculation of a SG–Trp–Leu + peptone medium for induction of the Fab fragment 
between all subsequent biopanning rounds (chapter 4.2.9). In the second biopanning round yeast-cells 
were panned first against the confluent CCD-18CO normal colon fibroblast cell line for 2 hours at RT 
and then the non-binders to the CCD-18CO yeast-cells were immediately panned against the confluent 
SW620 cells. After three rounds of binding, washing, clone recovery and amplification there was a clear 
enrichment in the number of yeast cells Fab display binding to the SW620cells, observed under the 
light microscopy imaging (Figure 37A). While panning on the depletion cells only few yeast-cell 
binders were observed (Figure 37B). 
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Figure 38: TIL-B kappa library biopanning rounds against SW620 cell line and depletion rounds on colon normal CCD-
18CO cell line.   
(A) Light microscopic imagining of enrichment of the TIL-B kappa library yeast cells after each round of biopanning against a 
confluent SW620 monolayer. (B) TIL-B kappa library yeast-cells after each round of depletion against a confluent CCD-18CO cells 
monolayer. Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells. Enrichment can be observed after 
three rounds, while few binders can be observed on the normal CCD-18CO colon cells used for depletion. 
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5.7. Binding analysis of the enriched biopanning yeast-cells to panel of cancer and normal cell 
line  
After rapid enrichment during three biopanning rounds, evaluation of the colon cancer cell-enriched 
Fab-displaying yeast-cell pools from the fourth final biopanning round against the three-colon cancer 
cell line HCT 116, HT-29 and SW620 were performed. To assess the binding profile of the 3 enriched 
pools, each was evaluated by binding analysis of the yeast-cell Fab display to 10 distinct cell lines 
representing the colon cancer cell lines which the yeast-cells were panned on, other cancer type cell 
lines, the normal colon fibroblast cell line (CCD-18CO) and the Chinese hamster ovary derived cell 
line (CHO-S1) as non-cancer cell lines. The yeast-cell binding analysis was performed with the goal of 
verifying selective enrichment to colon cancer cell lines and to rule out enrichment to the non-cancer 
cell lines. 
 
5.7.1. Binding analysis of the enriched biopanning yeast-cells against the HCT 116 cell line 
To evaluate the binding profile of the enriched yeast-cell pool that was panned against the HCT 116 cell 
line, the yeast-cell pool from the forth biopanning round was induced with a SG–Trp–Leu + peptone 
medium at 20ºC for 48 hr for a Fab fragment display. Post induction, 1 x 107 yeast-cells were incubated 
on each confluent cell line in a 12 well-plate. After 2 hr the incubated yeast-cells were washed, and non-
binders yeast-cells were removed. Light microscopy was then used to assess the binding capacity of the 
Fab displayed HCT 116 binders enriched yeast-cell pool to each cell line and given a qualitative score 
from 0 to 4 (no binding to high binding). The light microscopy images of each cell line are depicted in 
Figure 39. The imaging data confirmed that the Fab displayed HCT 116 binders enriched yeast-cell 
pool demonstrated high selectivity to the colon cancer derived cell line (HCT 116 and HT-29), lower 
but also high selectivity was also observed to the gastric adenocarcinoma derived cell line (MKN-45). 
No binding to the non-cancer cell lines, including the normal colon fibroblast cell line (CCD-18CO) 
and the Chinese hamster ovary derived cell line (CHO-S1), was observed.       
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Figure 39: Binding analysis of the enriched biopanning yeast-cells against HCT 116 cell line to panel of cancer and normal 
cell line.    
Light microscopic imagining binding profile of Fab displayed HCT 116 binders enriched yeast-cell pool to 12 distinct cell lines. 
Qualitative scoring of Fab displayed HCT 116 binders enriched yeast-cell pool binding with various intensity, from 0 (no observed 
binding) to 4 (significant yeast binding). High binding to the colon cancer derived cell line observed while no-binding observed to the 
non-cancer cell lines.  Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells.  
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5.7.2. Binding analysis of the enriched biopanning yeast-cells against HT-29 cell line 
To evaluate the binding profile of the enriched yeast-cell pool that was panned against the HT-29 cell 
line, the yeast-cell pool from the forth biopanning round was induced with a SG–Trp–Leu + peptone 
medium at 20ºC for 48 hr for a Fab fragment display. Post induction, 1 x 107 yeast-cells were incubated 
on each confluent cell line in a 12 well-plate. After 2 hr the incubated yeast-cells were washed, and non-
binders yeast-cells were removed. Light microscopy was then used to assess the binding capacity of the 
Fab displayed HT-29 binders enriched yeast-cell pool to each cell line and given a qualitative score 
from 0 to 4 (no binding to high binding). The light microscopy images of each cell line are depicted in 
Figure 40. The imaging data confirmed that the Fab displayed HT-29 binders enriched yeast-cell pool 
demonstrated high selectivity to the colon cancer derived cell line (HCT 116 and HT-29) lower but also 
high selectivity was observed also to the gastric adenocarcinoma derived cells line (MKN-45) and the 
metastatic colorectal derived cell line (SW620). No binding to the non-cancer cell lines, including the 
normal colon fibroblast cell line (CCD-18CO) and the Chinese hamster ovary derived cell line (CHO-
S1), was observed. 
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Figure 40: Binding analysis of the enriched biopanning yeast-cells against HT-29 cell line to panel of cancer and normal 
cell line.    
Light microscopic imagining binding profile of Fab displayed HCT 116 binders enriched yeast-cell pool to 12 distinct cell lines. 
Qualitative scoring of Fab displayed HT-29 binders enriched yeast-cell pool binding with various intensity, from 0 (no observed 
binding) to 4 (significant yeast binding). High binding to the colon cancer derived cell line observed while no-binding observed to the 
non-cancer cell lines.  Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells.  
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5.7.3. Binding analysis of the enriched biopanning yeast-cells against SW620 cell line 
To evaluate the binding profile of the enriched yeast-cell pool that was panned against the SW620 cell 
line, the yeast-cell pool from the forth biopanning round was induced with a SG–Trp–Leu + peptone 
medium at 20ºC for 48 hr for a Fab fragment display. Post induction, 1 x 107 yeast-cells were incubated 
on each confluent cell line in a 12 well-plate. After 2 hr the incubated yeast-cells were washed, and non-
binders yeast-cells were removed. Light microscopy was then used to assess the binding capacity of the 
Fab displayed SW620 binders enriched yeast-cell pool to each cell line and given a qualitative score 
from 0 to 4 (no binding to high binding). The light microscopy images of each cell line are depicted in 
Figure 41. The imaging data confirmed that the Fab displayed SW620 binders enriched yeast-cell pool 
demonstrated high selectivity to the metastatic colorectal adenocarcinoma derived. Here different 
profile binding was observed to the other cell line, as high selectivity was observed to the metastatic 
mammary gland adenocarcinoma derived cells lines (MCF7, MB468, SKBR3), binding to the colorectal 
derived cells and to the gastric derived cells was also observed but with lower intensity No binding to 
the non-cancer cell lines, including the normal colon fibroblast cell line (CCD-18CO) and the Chinese 
hamster ovary derived cell line (CHO-S1), was observed.       
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Figure 41: Binding analysis of the enriched biopanning yeast-cells against SW620 cell line to panel of cancer and normal 
cell line.    
Light microscopic imagining binding profile of Fab displayed HCT 116 binders enriched yeast-cell pool to 12 distinct cell lines. 
Qualitative scoring of Fab displayed SW620 binders enriched yeast-cell pool binding with various intensity, from 0 (no observed 
binding) to 4 (significant yeast binding). High binding to the colon cancer derived cell line observed while no-binding observed to the 
non-cancer cell lines.  Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells.  
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5.8. Evaluation of biopanning enriched individual Fab display yeast-clones 
After the assessment of selective enrichment of Fab display yeast-cells from the TIL-B kappa library to 
antigens expressed specifically on the colorectal cancer derived cell line through the biopanning process (cf. 
chapter 5.6.1-3), further evaluation of individual yeast cells clones was performed on the enriched clones that 
panned against the colorectal cancer derived cell lines only (HCT 116 and HT-29). For that, single cells from 
the forth (last) biopanning round were plated on SD–Trp–Leu agar plates and individual yeast-cell clones 
were picked. From each biopanning approach (HCT 116 and HT-29) 48 single clones from the 4th round were 
analyzed by sequencing their variable region frameworks and complementary determining region (CDR) 
diversities within the heavy and light-chain and then analyzed by Salsa analysis (Merck). Then a clustering 
strategy was applied, where sequences with ≥ 90% identical CDR residues were allocated to the same cluster 
for identification of unique clones. Functionality of the heavy and the light chain for correct expression was 
tasted and the heavy or light chain were removed from subsequent analyses if the third complementarity 
determining region (CDR3) was of indeterminate length, stop codons were present, or the amino acid 
translation was out of frame. The analysis identified 13 unique yeast clones from the enriched HCT 116 cell 
line binder yeast-cell clones and 10 unique yeast clones from the enriched HT-29 cell line binder yeast-cell 
clones. Interestingly, 3 unique yeast clones were isolated from the two biopanning approaches (HCT 116 and 
HT-29) identified as the same clones. Table 10 summarizes the unique clones that were identified by their ID 
name, germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage from 
the germline. 
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Clone ID 
VH-region 
identity 
(%) 
VH gene DH gene JH gene 
VL-region 
identity (%) 
VL gene VJ gene 
TILB-HCT116/HT29 A06 91 
IGHV3-
15*01 
IGHD2-
15*01 
IGHJ4*02 91 IGKV4-1*01 IGKJ2*01 
TILB-HCT116/HT29 A17 89 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 87 IGKV1-33*01 IGKJ1*01 
TILB-HCT116/HT/29 B24 90 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 90 IGKV3-20*01 IGKJ1*01 
TILB-HCT116 A02 90 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 97 IGKV3-11*01 IGKJ3*01 
TILB-HCT116 A03 94 
IGHV3-
15*01 
IGHD2-
15*01 
IGHJ4*02 87 
IGKV3/OR2-
268*02 
IGKJ2*01 
TILB-HCT116 A04 93 
IGHV3-
15*01 
IGHD2-
15*01 
IGHJ4*02 94 IGKV4-1*01 IGKJ2*01 
TILB-HCT116 A05 90 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 96 IGKV3-15*01 IGKJ2*01 
TILB-HCT116 A07 94 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 85 IGKV1-6*01 IGKJ1*01 
TILB-HCT116 A11 91 
IGHV3-
15*01 
IGHD2-
15*01 
IGHJ4*02 91 IGKV1-39*01 IGKJ2*01 
TILB-HCT116 A14 80 
IGHV1-
3*01 
IGHD1-
26*01 
IGHJ4*02 92 IGKV3-20*01 IGKJ1*01 
TILB-HCT116 B06 90 
IGHV3-
15*01 
IGHD2-
15*01 
IGHJ4*02 88 IGKV3-20*01 IGKJ5*01 
TILB-HCT116 B08 93 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 82 IGKV1-39*01 IGKJ4*01 
TILB-HCT116 B10 93 
IGHV3-
33*01 
IGHD3-
22*01 
IGHJ6*03 96 IGKV2-30*02 IGKJ2*01 
TILB-HT29 A05 84 
IGHV3-
23*01 
IGHD4-
23*01 
IGHJ5*02 90 IGKV2-30*01 IGKJ2*01 
TILB-HT29 A08 88 
IGHV3-
15*07 
IGHD2-
15*01 
IGHJ4*02 92 IGKV1-5*01 IGKJ4*01 
TILB-HT29 A14 91 
IGHV1-
3*01 
IGHD2-
2*01 
IGHJ6*02 80 IGKV1-12*01 IGKJ4*01 
TILB-HT29 A16 92 
IGHV3-
15*01 
IGHD6-
13*01 
IGHJ4*02 97 IGKV4-1*01 IGKJ1*01 
TILB-HT29 A20 95 
IGHV1-
3*01 
IGHD3-
10*01 
IGHJ5*02 85 IGKV4-1*01 IGKJ2*01 
TILB-HT29 B04 78 
IGHV1-
2*02 
 IGHJ4*03 97 IGKV4-1*01 IGKJ4*01 
TILB-HT29 B24 92 
IGHV1-
3*01 
IGHD2-
2*01 
IGHJ6*02 96 IGKV1-39*01 IGKJ2*02 
 
Table 10: Isolated unique clones with their germline diversity from biopanning against HCT116 and HT-29 cell lines.  
Summary of the sequence clustering analysis for the individual yeast-cell clones that bind to HCT 116 and HT-29 cell lines. Clone 
ID name represent the cell line which the clones were panned against. Clones TILB-HCT116/HT29 A06 A17 B24 found to be 
same clones that minded from the HCT 116 and HT-29 biopanning. After clustering, 20 clones from 96 were identified as unique. 
The 20 clustered sequences were verified for functional expression for both heavy and light chain to generate functional Fab 
fragment. Germline diversity of the heavy (VDJ) and light (VJ) gene segments with their identity percentage from the germline 
are presented.      
 
5.8.1. Binding analysis to different cancer and normal cell liens 
To evaluate specific binding of the unique clones to antigens expressed on colorectal cancer cells and not 
to the normal colon cell line, binding analysis of all the unique yeast-cell clones was performed. To assess 
the binding profile of the 20-unique yeast-clones, each was evaluated by analysis of binding of the yeast-
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cell Fab display to the colorectal carcinoma derived cell line (HCT 116), the mammary gland metastatic 
adenocarcinoma derived cell line (MCF7), the normal colon fibroblast cell line (CCD-18CO) and the 
Chinese hamster ovary derived cell line (CHO-S1) as non-cancer cell lines. For that, the yeast-cell 
unique clones were induced with a SG–Trp–Leu + peptone medium at 20ºC for 48 hr to obtain a Fab 
fragment display. Post induction, 1 x 107 yeast-cells were incubated on each confluent cell line in a 12 
well-plate. After 2 hr incubation yeast-cells were washed and non-binders yeast-cells were removed. 
Light microscopy was then used to assess the binding capacity of the Fab display of the unique clones 
to each cell line by giving a qualitative score for binding or no binding to the monolayer cell lines. A 
representative example of 3 unique yeast-cells binding profiles are depicted using light microscopy 
imaging in Figure 42. Clone A01 and A02 images represent unique clones with specific binding to the 
HCT 116 cells and no binding observed to the MCF7 cell line or to the non-cancer cell lines, CCD-
18Co and CHO-S1. The clone A03 image represents a unique clone with unspecific binding, as there 
was binding both to the CCD-18Co and CHO-S1 cells. Table 11 summarizes the binding profile of all 
20 unique clones based on the light microscopy imaging. Twelve clones from the 20 unique clones 
showed specific binding to the HCT-116 cell line and were used for further evaluation.     
 
Figure 42: Example of TILB-HCT116/HT29  unique yeast-cell binding profile on the light microscopy imaging. 
Light microscopic images representing examples of 3 unique yeast-cell binding profiles. Clones A01 and A02 images represent unique 
clones with specific binding to the HCT 116 cells and no binding observed to the MCF7 cell line or to the non-cancer CCD-18Co and 
CHO-S1 cell lines. The clone A03 image represents a unique clone with unspecific binding, as binding was observed both to the CCD-
18Co and CHO-S1 cells.  Scale bar, 100 µm. Yeast are the small objects (~5 µm) residing on the monolayer cells.  
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Table 11: Binding profile summary of TILB-HCT116/HT29 unique yeast-cells. 
Binding profile of all 20 unique clones based on the light microscopy imaging (example in Figure 42). Twelve clones from the 
20 unique clones showed specific binding to the HCT-116 cell line and were used for further evaluation. 
 
5.8.2. Cellular binding of re-formatted full-length IgG1 colorectal derived cells targeting 
antibodies 
The 12 VH an VL regions of the unique clones of IgG molecules that showed specific binding to the HCT 116 
cell line were subcloned into pTT5 plasmids. After sequence verification of the cloned constructs of the heavy 
and light chain, the 12 clones were confirmed by a correct sequence for transient transfection to the HEK293-
EBNA cells. Five days post transfection, antibodies were harvested and purified with a protein A HP SpinTrap 
column, as described before (chapter 5.4). Then, crude harvests were quantified by BLI. To evaluate the binding 
of the unique clones after reformatting to full-length IgG1, binding analysis to HCT 116 cells was performed 
using flow cytometry.  Therefore, 1 x 106 HCT 116 cells were incubated together with 200 nM of the antibodies 
followed by labelling with secondary Alexa Fluor 488 -conjugated antibody and flow cytometry (chapter 4.4.3). 
Unstained cells or cells only treated with secondary Alexa Fluor 488 -conjugated antibody served as controls 
to reveal the amount of cellular autofluorescence. Exemplary histograms of relative mean fluorescence 
intensities are depicted in Figure 43. Half of the antibodies exhibited fluorescence intensities same as the 
background level after reformatting to full-length IgG1 (A). This can be explained by low affinity antibodies 
Clone ref number HCT116 MCF7 CCD-18CO CHO-S1 
TILB-HCT116 A06 + - - - 
TILB-HCT116 A17 + - - - 
TILB-HCT116 B24 + - - - 
TILB-HCT116 A02 + - - - 
TILB-HCT116 A03 + - - - 
TILB-HCT116 A04 + - - + 
TILB-HCT116 A05 + - - - 
TILB-HCT116 A07 + - - - 
TILB-HCT116 A11 + - - - 
TILB-HCT116 A14 + - - - 
TILB-HCT116 B06 + - - - 
TILB-HCT116 B08 + - - - 
TILB-HCT116 B10 + - + + 
TILB-HT29 A05 + - + + 
TILB-HT29 A08 + - - - 
TILB-HT29 A14 + + + + 
TILB-HT29 A16 + + + - 
TILB-HT29 A20 + + + + 
TILB-HT29 B04 + + + - 
TILB-HT29 B24 + + + + 
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or by losing the binding during the reformatting process. While, the other half of the antibodies exhibited 
positive mean fluorescence intensities and binding of the antibodies to the HCT 116 cells(B).       
 
Figure 43: Cellular binding of unique mAbs to HCT116 cell line. 
HCT116 cell lines were incubated with 200 nM antibodies (crude harvest) and binding was revealed with anti-human Fc antibody-
Alexa Fluor 488 conjugate via flow cytometry (5,000 counts). (A) Six antibodies displayed fluorescence intensities same as the 
background level (gray) after reformatting to full-length IgG1. (B) The remaining 6 of the antibodies exhibited positive mean 
fluorescence intensities by binding to the HCT 116 cells.  
 
5.8.3. Multiple sequence alignment for the heavy and light variable regions of the unique 
clones 
As some of the selected unique clones after reformatting to full-length IgG1were demonstrated to bind to 
the HCT 116 cell line, while the other half was not found to bind (cf. chapter 5.8.2), further evaluation at 
the level of the heavy and light variable regions sequences of the unique clones was performed. For that, 
multiple sequence alignment of all unique heavy and light chain variable region sequences was performed. 
The alignment analysis (Figure 44) indicated high similarity between heavy chain variable region 
sequences: most of the variance occurred in the framework region one (FR1) and complementarity 
determining region one (CDR1), while the CDR3 region was identical across all clones excluding clone 
A24. In the light chain variable region sequences an opposite finding was observed as low similarity 
between the clones was identified with all frameworks and CDR sequences. Moreover, very low similarity 
was observed between CDR3’s of the light chain sequences. Hence, as some of the clones were 
demonstrated binding and some not, and all clones (excluding A24) shared almost the same HC sequences,  
this may indicate the same target specificity determined by the heavy chain variable region. Changes in 
the affinity binding levels between the different unique clones were therefore determined by their light 
chain variable region. 
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Figure 44: Multiple sequence alignment for the heavy and light variable regions of TIL-B HCT116 unique clones. 
(A) Multiple sequence alignment of the heavy chain of the unique isolated TILB-HCT116 clones.  (B) Multiple sequence alignment of 
the light chain of the unique isolated TILB-HCT116 clones. The analysis shows that all clones (excluding A24) share almost the same 
HC sequences, while between the LC sequences variation can be observed. This may indicate the same target specificity determined 
by the heavy chain variable region. Changes in the affinity binding levels between the different unique clones were therefore 
determined by their light chain variable region. 
 
5.8.4. Cellular binding of re-formatted full-length IgG1 purified colorectal derived cells 
targeting clone TILB-HCT116-B24 by flow cytometry 
 
For further evaluation, clone TILB-HCT116 B24 that showed binding to the HCT 116 cell line as full-
length IgG1 crude harvest mAb was chosen (cf. chapter 5.8.2). This clone was purified by a protein A HP 
SpinTrap column (chapter 4.3.4) and subjected to cellular binding analysis with the HCT 116 cells by 
flow cytometry (chapter 4.4.3). A two-fold serial dilution of the mAb (2000 nM-0.98 nM) was applied for 
binding to HCT 116 cells. Exemplary histograms of relative mean fluorescence intensities are depicted in 
Figure 45. The TILB-HCT116-B24 mAb exhibited cellular binding to HCT 116 cells with an EC50 value 
of  569 nM. 
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Figure 45: Cellular binding of clone TILB-HCT116-B24 mAb to the HCT116 cell line. 
HCT 116 cell lines were incubated with a two-fold serial dilution (2000 nM-0.98 nM) of purified full-length IgG1 TILB-HCT116-
B24 mAb. Binding was revealed with anti-human Fc antibody-Alexa Fluor 488 conjugate via flow cytometry (10,000 counts). MFI 
values were plotted against the logarithm of antibody concentration. The TILB-HCT116-B24 mAb exhibited cellular binding to 
HCT 116 cells with an EC50 value of 569 nM. 
 
5.8.5. Cellular binding of re-formatted full-length IgG1 purified colorectal cancer derived 
cells targeting clone TILB-HCT116-B24 by fluorescence microscopy 
 
After the binding analysis using TILB-HCT116-B24 mAb indicated binding to HCT 116 cells by flow 
cytometry, the aim was to confirm specific binding to the colorectal carcinoma derived cells and not to 
normal fibroblast colon derived cells. Cellular binding assay using fluorescence microscopy was 
performed (chapter 4.4.4). For that, HCT 116 cells and the CCD-18Co normal colon fibroblast cells, were 
incubated on coverslips together with the TILB-HCT 116-B24 mAb (500 nM). TILB-HCT116-A06 mAb 
that did not exhibit binding to HCT 116 cells was used as isotype control antibody. As HCT 116 cells and 
the CCD-18Co cells are both known as surface epidermal growth factor receptor (EGFR) expressed cells, 
the human-murine chimeric IgG1 cetuximab which is a therapeutic mAb for colorectal cancer and binds 
to domain III of the EGFR ECD (Li et al, 2005), was used here as a positive control antibody (50 nM). 
The antibody binding was followed by addition of a secondary antibody fragment, the anti-human Fc 
AlexaFluor488 conjugate.  Cell nuclei were stained with Hoechst stain solution. Detection was carried out 
by fluorescence microscopy. The fluorescence microscopy images obtained for each cell line are depicted 
in Figure 46. Labeling the cells only with the anti-human Fc-AlexaFluor488 conjugate and the Hoechst 
stain solution was used as setup for the fluorescence background, so that the cell nuclei (blue) can be 
observed. As expected, the cetuximab mAb bound to EGFR expressed in both HCT 116 and CCD-18Co 
cells. The imaging data confirmed that TILB-HCT116-B24 mAb bind specifically to HCT 116 colorectal 
cancer derived cells but not to the CCD-18Co normal colon fibroblast cells. TILB-HCT116-A06 that 
served as an isotype control non-binder antibody, as expected, was not found to bind to both cells.    
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Figure 46: Cellular binding of TILB-HCT116-B24 to HCT 116 cells by fluorescence microscopy. 
HCT 116 and CCD-18Co cells were plated on coverslips and incubated with 500 nM TILB-HCT116-B24, 500 nM TILB-HCT116-
A06 (isotype control antibody) and 50 nM cetuximab mAb (positive control). Subsequently labeling with the anti-human Fc-Alexa 
Fluor488 conjugate was performed (green). Cell nuclei were stained with Hoechst stain solution (blue). Detection was carried out 
by fluorescence microscopy. Scale bar: 20 µm. TILB-HCT116-B24 showed specific binding to the HCT 116 cells while there was 
no binding observed for the CCD-18Co cells.     
 
5.8.6. Binding analysis of TILB-HCT116-B24 mAb to different TAA by BLI 
In order to evaluate if the isolated mAb, TILB-HCT116-B24, binds to one of the TAA which expressed 
on the surface of HCT 116 cells, the 4 ECD recombinant proteins: h-EGFR, h-CEACAM5, h-5T4 and h-
LRP6 (E3:E4) were tested for binding to TILB-HCT-116-B24 mAb by biolayer interferometry (BLI).  
Briefly, TILB-HCT-116-B24 mAb was immobilized on anti-human Fc (AHC) biosensor tips and 
association as well as dissociation of the different ECD proteins were monitored. Reference antibodies to 
the corresponding ECD protein were tested in the same condition.  Exemplary sensorgrams of the analysis 
are depicted in Figure 47. The data indicate a wavelength shift in nm of all antibodies captured by the 
AHC biosensors. A shift of the reference antibodies was observed in the association step with all the 
corresponding ECD proteins (Figure 47A). For TILB-HCT-116-B24 mAb, no wavelength shift was 
detected in the association step with h-CEACAM5 and h-5T4. A small shift was detected with h- EGFR 
and h-LRP6, although this shift was confirmed to be non-specific to the antibodies (data not shown) 
(Figure 47B). 
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Figure 47:Binding analysis of TILB-HCT116-B24 mAb to different TAA by BLI. 
(A) Reference antibodies were immobilized on AHC biosensors (Ab loading). Then, association and dissociation of the different 
corresponding TAA (200nM) were monitored. For all antibodies association steps an interference pattern shift was observed. (B) 
When TILB-HCT116-B24 mAb was immobilized on AHC biosensors, no wavelength shift was detected in the association step with 
h-CEACAM5 and h-5T4. A small shift was detected with h- EGFR and h-LRP6, although this shift was confirmed to be non-specific 
to the antibodies (data not shown). 
 
5.9. NGS analysis of patient libraries (HV, VK, VL) 
An NGS analysis was performed based on paired-end reads for the variable region frameworks and 
complementary determining region (CDR) diversities within the heavy and light-chain of yeast-cells 
clones of patient libraries (HV, VK, VL). The raw sequencing data was subjected to data quality control 
and filtering which indicated that sequence quality was very high which allowed for a reliable overlap of 
the forward and reverse reads (data not shown). Next, data was searched against the IMGT database to 
find the best match of germline V(D)J genes and to delineate the CDR sequences for each antibody 
variable domain sequence. After filtering, sequences with aligned V genes that did not contain a stop 
codon were considered functional sequences and defined as the total read. The V segments that were 
identical were combined into equivalence clusters and defined as unique. The number of the total reads, 
the unique sequences and their percentage in the total reads are summarized in Table 12 for each VH, VK 
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and VL patient library. This NGS data indicate small diversity of V segments in all patient libraries. 
Analysis of top ten distribution frequencies NGS reads according to V gene families (VH, VK, VL) and 
CDR3 for each individual patient sample are depicted in Figure 48 (only V gene families are presented). 
The analysis indicated high frequencies of the top sequence in most of the patients’ sequences.  
Table 12: Summary of NGS result for the Patients’ libraries V gene sequence reads. 
The number of total V genes reads (VH, VL and Vk), unique sequences and their percentage in the total reads obtained from the 
NGS analysis. The NGS data indicate small diversity of V segments in all patients’ libraries  
 
 
 
 
 
 
 
 
 
Patient 
ref 
number 
VH 
Total 
VH 
Unique 
% VH 
Unique 
VK 
Total 
VK 
Unique 
% VK 
Unique 
VL 
Total 
VL 
Unique 
% VL 
Unique 
P-20055T 34189
 
9152 3% 6092
 
22249 4% 43347
 
8778 2% 
P-20066T 43038
 
12211 3% 4880
 
24772 5% 51836
 
9249 2% 
P-20116T 29626
 
3407 1% 6287
 
18257 3% 50783
 
12134 2% 
P-20671T 37307
 
3363 1% 3308
 
14351 4% 53003
 
13634 3% 
P-20829T 97325 5150 5% 5329
 
14094 3% 51523
 
9451 2% 
P-21548T 16934
 
7365 4% 2944
 
5525 2% 50828
 
15114 3% 
P-21574T 11798
 
10095 9% 4708
 
14581 3% 47460
 
5919 1% 
P-22017T 15364
 
10206 7% 2143
 
9681 5% 96564
 
12623 1% 
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Figure 48: Summary of the NGS results for the patients’ libraries top ten distribution frequencies reads. 
Analysis of top ten distribution frequencies according to V gene families. (A)VH, (B)VK, (C)VL for each individual patient sample 
NGS reads. The NGS analysis indicates high frequencies of top sequences in most of the patients’ sequences. 
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5.9.1. NGS analysis for mated libraries (TIL-B κ and TIL-B λ) 
The NGS analysis was performed based on paired-end reads for the variable region frameworks and 
complementary determining region (CDR) diversities within the heavy and light-chain of yeast-cells 
clones of the mated libraries TIL-B κ and TIL-B λ (Appendix, Figure 53 and 54), same as described 
before (chapter 5.9). The number of total reads, unique sequences and unique sequences with a total read 
count greater than 1 are summarized in Table 13 for each VH, VK and VL of the mated libraries. This 
NGS data show more diversity of the unique sequences reads, as a result of the patients’ libraries mixing 
before the yeast mating. 
 
 
 
 
Table 13: Summary of NGS result for the mated libraries V gene sequence reads. 
The number of total V genes reads (VH, VL and Vk), unique sequences from the NGS analysis. The number of unique chains with 
a total read count greater than 1 is shown as Unique gt1.  
 
An overlap analysis of the two mated libraries showed high correlation of the HV sequence reads between 
the TIL-B κ and TIL-B λ libraries (Figure 49). This data confirms high mating efficiency, as most of the 
HV sequences reads were found present in both libraries. Moreover, the analysis of the VH gene family 
distribution of the 2 libraries showed similar distribution of the VH gene families in both libraries (Figure 
50) 
 
 
Figure 49: Overlap between V genes of mated TIL-B κ and TIL-B λ libraries. 
Overlap graphs between the 2 mated libraries TIL-B κ and TIL-B λ of V gene sequences reads. (A) An overlap between VH genes 
sequence reads showing very high correlation. (B) An overlap between VK and VL; no correlation was observed as expected. 
Library Total reads Unique Unique gt1 
TIL-B λ VH 1205657 19302 8143 
TIL-B λ VL 1873336 27642 13490 
TIL-B κ VH 1980034 33517 13724 
TIL-B κ VK 2666160 51933 29192 
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Figure 50: NGS analysis of the VH gene family distribution of mated TIL-B κ and TIL-B λ libraries. 
(A)  Analysis of the VH gene family distribution of the mated TIL-B κ library. (B) Analysis of the VH gene family distribution 
of the mated TIL-B λ library. Similar distribution of the VH gene families can be observed in both libraries. 
 
5.10. NGS analysis for the enriched biopanning yeast-cells 
The next NGS analysis was performed in order to assess the biopanning selection process, for better 
understanding the clone enrichment profile after the biopanning rounds and to evaluate the ability of 
mining the yeast libraries for potential cell-binding antibodies by cell biopanning. The NGS analysis 
included the variable region frameworks and complementary determining region (CDR) diversities within 
the heavy and light-chain of yeast-cells clones of the last biopanning round against the three cell lines 
(HCT 116, HT-29 and SW620). The raw sequencing data was subjected to data quality control and 
filtering which indicated that sequence quality was very high which allowed for reliable overlap of the 
forward and reverse reads (data not shown). Next, data was searched against the IMGT database to find 
the best match of germline V(D)J genes and to delineate the CDR sequences for each antibody variable 
domain sequence. The frequency of each germline gene usage was calculated, and a statistical analysis 
was done to characterize the CDR3 sequence profile for a given sample, as well as to identify the top 
enriched CDR3 sequences and sequence clusters in a sample (Appendix, Figures 55-57). 
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5.11. Unique V gene segment and CDR3 combination analysis 
In order to analyse the clone enrichment through the biopanning process and to assess the number of the 
unique clones after the forth biopanning round, the latter was compared to the initial library for all three 
approaches (HCT 116, HT-29 and SW620). An analysis of the number of unique V gene segments and 
CDR3 combinations was performed. The total diversity of the variable domain of the heavy chain and the 
light chain kappa together with the number of chains with a total read count greater than 1 are summarized 
in Table 14. The NGS data analysis confirmed enriched diversity of the clones, as compared to the initial 
library (Table 13) by 1-fold (from ~ 104 to ~103). Moreover, this NGS analysis revealed that the strategy 
to pick up 48 clones after the final biopanning round which resulted with identification of 10 unique clones 
is about 1% of the clones’ diversity.  
 
 
 
 
Table 14: Number of unique V gene segments and CDR3 combinations.  
The number of unique V gene segments and CDR3 combinations obtained from the NGS analysis. The number of chains with a 
total read count greater than 1 is shown as VHgt1, VKgt1 and VLgt1. The diversity after the biopanning enrichment is significantly 
lower than the initial library diversity.    
 
   
5.12. Overlap between unique clones from biopanning against HCT 116, HT-29 and SW620 
Next, the overlap between the three biopanning outcome sequence reads (TILB-HCT116, TILB-HT29 
and TILB-SW620) was examined. The unique sequences were defined by their V gene segments and 
CDR3 combination sequences. The overlap analysis between the VH unique sequences of the different 
biopanning approaches is depicted in Figure 51. Interestingly, the data indicated a strong correlation 
between the enriched unique VH clones that panned against the HCT 116 cell line and the HT-29 cell line. 
One is the colorectal carcinoma derived cell line and the other one is the colorectal adenocarcinoma cell 
line, respectively. A lower correlation was observed within the VK clone overlaps (Figure 52). These 
results may confirm that the enrichment of clones during the biopanning process is specific to the target 
expressed uniquely on those colorectal cancer derived cells. A significantly lower correlation was 
observed comparing the clones panned against the HCT-116 and the  HT-29 cell lines to the SW620 
colorectal adenocarcinoma metastatic derived cells, which observation supports the claim of the 
enrichment to specific targets expressed on the different cancer type cells through the biopanning process.  
    
Pool VH VK VHgt1 VKgt1 
TILB-HCT116 3018 1737 777 894 
TILB-HT29 3231 2291 982 1198 
TILB-SW620 1892 2102 676 1080 
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Figure 51: Overlap between unique clones from biopanning against HCT 116, HT-29 and SW620. 
Overlap graphs between the three biopanning outcome VH gene segments and the CDR3 combination unique sequences of TILB-
HCT116, TILB-HT29 and TILB-SW620. (A) The overlap between TILB-HCT116 and TILB-HT29 indicates very high 
correlation between the enriched clones. (B) The overlap between TILB-HT29 and TILB-SW620 indicates some correlation 
between the enriched clones. (C) The overlap between TILB-HCT116 and TILB-SW620 indicates low correlation between the 
enriched clones. The data may be indicative of enrichment to specific targets expressed on the different cancer type cells through 
the biopanning process.    
 
 
 
Figure 52: Overlap between unique clones from biopanning against HCT 116, HT-29 and SW620. 
Overlap graphs between the three biopanning outcome VK gene segments and the CDR3 combination unique sequences of TILB-
HCT116, TILB-HT29 and TILB-SW620. (A) The overlap between TILB-HCT116 and TILB-HT29 indicates some correlation 
between the enriched clones. (B) The overlap between TILB-HT29 and TILB-SW620 indicates some correlation between the 
enriched clones. (C) The overlap between TILB-HCT116 and TILB-SW620 indicates low correlation between the enriched 
clones.  
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5.13. V gene distribution, CDR3 length distribution, V gene and CDR3 combination top 
sequences 
A further analysis of the V gene distribution, the CDR3 length distribution, as well as the V gene and 
CDR3 combination top sequences was performed for the three biopanning outcome sequences (TILB-
HCT116, TILB-HT29 and TILB-SW620). The analyses are depicted in the appendix (Figure 55-57). The 
data confirmed very high selective enrichment within the heavy chain. In the TILB-HCT116 enriched 
pool there was selection during the biopanning  of the IGHV3-15 VH gene with the CDR3 amino acid 
sequence: TTGRHYCSGGSCHLSFFDY with 92.6 % from all sequences reads. In the TILB-HT29 the 
same family gene with the CDR3 amino acid was selected with 25.9% from all sequence reads. For the 
TILB-SW620 enriched pool a different profile of enrichment was observed, as here most VH gene 
frequencies were IGHV1-18 and IGHV3-15,21,23 and 48. For the VL genes a wider distribution within 
the enriched clones was observed in all pools. For the TILB-HCT116 most of the VL gene frequencies 
were IGKV1-33, IGKV3-15, IGKV3-20, IGKV4-1. For the TILB-HT29 most of the VL gene frequencies 
were the same as for the TILB-HCT116, i.e. IGKV3-15, IGKV3-20, IGKV4-1. A different enrichment 
profile was observed for the TILB-SW620, as most of the VL gene frequencies were IGKV1-12, IGKV3-
11, IGKV3-20, IGKV3-15 and IGKV4-1. This data also indicated that the enrichment of clones during 
the biopanning process is specific for a target expressed uniquely on the colorectal cancer derived cells 
(HCT116 and HT-29), as a different enrichment V genes distribution profile was observed from the 
SW620 enriched clones. 
 
5.14. Frequency of V gene and CDR3 combination of selected clones 
Finally, the frequency of the V gene and the CDR3 combinations of the selected clones was analyzed. 
The V genes of the heavy and the light chains with the combination of the CDR3 amino acid sequence, 
with their frequency within the NGS reads of the last biopanning round pools, TILB-HCT116 and TILB-
HT29, are summarized in Table 15. The data indicate the same VH gene and CDR3 combination in 11 
from the 12 selected unique clones that were identified as the IGHV3-15 VH gene and with the CDR3 
amino acid sequence TTGRHYCSGGSCHLSFFDY. The results are consistent with the fact that this 
clone was identified as 96% of all the reads within the TILB-HCT116 pool and 50% of all the reads within 
the TILB-HT29 pool. The VL gene and the CDR3 combination for the selected clones appeared in both 
pools but with lower frequency than VH and with high distribution between clones. The data here again 
indicate selective enrichment in the biopanning process for a specific target that expressed uniquely on 
the derived colorectal cancer cell lines with specificity determined by the heavy chain domain.   
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Table 15: Frequency of the V gene and the CDR3 combination of the biopanning selected clones. 
Frequency of V gene and CDR3 combination of selected clones were analyzed. V genes of the heavy and the light chains with 
the combination of the CDR3 amino acid sequence, with their frequency in the NGS analysis of the biopanning outcome pools, 
TILB-HCT116 and TILB-HT29, are summarized. 
 
Clone ID 
VH 
gene 
VH CDR3 AA 
Frequency  
TILB-
HCT116 
Frequency 
TILB-
HT29 
VL gene VL CDR3 AA 
Frequency 
TILB-
HCT116 
Frequency 
TILB-
HT29 
TILB-
HCT116/HT29 
A06 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV4-1 QQYYTTPQT 16.3% 28.4% 
TILB-
HCT116/HT29 
A17 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV1-33 QQYGMSPRT 14.5% 1.3% 
TILB-
HCT116/HT/29 
B24 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV3-20 QQYGMSPRT 6.5% 18.3% 
TILB-HCT116 
A02 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV3-11 QQRSGWPLT <0.5% <0.5% 
TILB-HCT116 
A03 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% 
IGKV3/OR2-
268 
QQYYNSPPAYT <0.5% <0.5% 
TILB-HCT116 
A05 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV3-15 QQYNNWPDT 25.9% 3.8% 
TILB-HCT116 
A07 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV1-6 QQYYNTPWT 1% <0.5% 
TILB-HCT116 
A11 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV1-39 QQSYSAPYT 0.6% <0.5% 
TILB-HCT116 
A14 
IGHV1-
3 
ARARSGVGATRSLWNFDY 0.9% 0.7% IGKV3-20 QHSGSSPGT <0.5% <0.5% 
TILB-HCT116 
B06 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV3-20 QQYVSSRIT <0.5% <0.5% 
TILB-HCT116 
B08 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV1-39 QQSYSTPLLT <0.5% <0.5% 
TILB-HT29 
A08 
IGHV3-
15 
TTGRHYCSGGSCHLSFFDY 92.6% 49.9% IGKV1-5 QQRSYWRT <0.5% 1.3% 
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6. Discussion 
 
 
6.1. Generating Fab YSD libraries derived from colon cancer patients’ tumor infiltrating B cells 
From the first FDA approval of the monoclonal antibody (Mab) Rituximab, targeting CD20 in non-Hodgkin's 
lymphoma patients about 20 years ago, until recent years approval of monoclonal antibodies that act by 
blocking checkpoint molecules such as PD-1, PD-L1 and CTLA-4, which enhance the immune system to 
fight against cancer cells. Monoclonal antibodies have been considered as breakthrough therapies in 
oncology. Still, cancer therapy by monoclonal antibodies has its limitations, and there is much space for better 
therapeutics to come. Historically, the success rate of monoclonal antibodies from Phase I clinical studies to 
clinical approval is low and can be estimated at 10 to 15% without considering many failures in preclinical 
studies  (A. L. Nelson & Reichert, 2009; Workman et al., 2017). Currently there are relatively few tumor-
associated antigens for antibody targeting in oncology that are approved for clinical therapy. This could be a 
result of lack in technologies enabling  antigen profiling in intact tumors, to identify tumor markers targetable 
with antibodies, which raises the need for new strategies that may be used to overcome these limitations 
(Sánchez-Martín et al., 2015). In addition, a better understanding of the antitumor immune responses in cancer 
patients can be an important key for advancing the field of monoclonal antibodies in cancer therapy. This 
may result in better mAbs, successful targeting of new tumor-associated antigens and even finding novel 
mechanisms of action. This study aims to investigate part of the antitumor immune responses by generating 
yeast display libraries representing the immunoglobins of B cells infiltrating to the tumor of colon cancer 
patients. At a later stage, screening by traditional and emerging technologies such as deep sequencing (NGS) 
and phenotypic screening by yeast display biopanning, may lead to revealing new antibodies and targets for 
cancer therapy. 
Previous reports indicate that tumor infiltrating  B cells from patient’s tissue can be a rich source of tumor-
binding antibodies. (Novinger et al., 2015; Pavoni et al., 2007). These studies isolated the antibodies from a 
TIL B phage display library derived from the patients’ tumors. To our knowledge, our work is the first study 
to construct YSD Fab libraries derived from colon cancer patients with high density of B cells infiltration (cf. 
Figure 6). The 8-patients showed diversity in gender, age, colon section and tumor grade (cf. Table 3). A 
standardized protocol developed with the hospital personnel insured snap freezing of the tissues less than an 
hour post surgery, to maintain mRNA integrity(Grizzlea et al., 2012). The RNAs isolated separately from 
each tissue, were adequate for continuous processes in terms of RNA quantity, purity and quality (cf. Table 
4, Figure 7). cDNA was prepared, and the quality of the RNA and PCR was assessed by analyzing two 
known B-cell expressed genes (CD19 and CD20) (cf. Figure 8 and 9). Heavy and light chain 
hypervariable regions (VH,VL) were PCR amplified  successfully from cDNA using VH and VL  kappa 
and lambda primers and gel purified (cf. Figure 10 ,11 and 12). Sequences for these were adapted from 
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previously described methods (Hust & Dübel, 2010). A strategy to select the class-switched B cell 
population was applied by designing a reverse primer for VH amplification starting at IgG constant 
regions. A second PCR reaction was performed to flank 5′ and 3′ overhangs for gap repair cloning and 
amplification of DNA amount was carried out  in a third PCR. After purification of the VH,VL kappa 
and lambda products and digestion of the corresponded YSD plasmids, cloning was carried out by gap 
repair according to  Benatuil et. al.(Benatuil et al., 2010)  to generate successfully heavy and light chain 
(kappa and lambda ) libraries for each of the 8 patients. Library size was calculated to be approximately 
1.4 to 5.6 x 107 clones for each VH and VL libraries with good transfection efficiency (cf. Table 5). All 
8 VH libraries that were transformed into haploid EBY100 strain yeast and were united to one pool. The 
same pooling was carried out for  the VL libraries (kappa and lambda ) that were transformed into a 
haploid  BJ5464 strain.   Functional Fab YSD libraries were obtained after fusion of haploid cells  
EBY100 and BJ5464 by yeast mating, according to a previously described method (Weaver-Feldhaus et 
al., 2004) resulting in final library sizes of approximately 4.1×108 clones for the HC-LC kappa library (TIL-B 
kappa) and approximately 2.5×108 clones for the HC-LC Lambda library (TIL-B lambda).   
 
6.1.1. Deep sequencing analysis of TIL-B derived libraries 
TIL-B phage antibody display libraries have been analyzed in previous studies by isolation of around 
102  clones in combination with Sanger sequencing (Coronella et al., 2002; Novinger et al., 2015). To 
our knowledge, this is the first study to use next-generation sequencing (NGS) to provide a high-
throughput sequencing of clones derived from patients’ TIL-B cells, allowing for far greater insights 
into library diversity by providing up to ~106 sequences reads per library. Comprehensive NGS analysis 
was run based on paired-end reads for each of the 8 patients libraries (HV, VL κ, VL λ) and for the mated 
Fab displayed TIL-B kappa and TIL-B lambda libraries. After filtering, sequences with aligned  V genes 
that did not contain a stop codon were considered functional sequences and defined as total reads. V 
segments that were identical were combined into equivalence clusters and defined as unique. 
Interestingly, looking at the number of V unique segments percentage out of the total reads, revealed a 
narrow diversity of V segments in all patients’ libraries (cf. Table 12) that could be due to a small 
number of the initial source of infiltrating B cells in the tumor. This is consistent with a previous study 
with phage display libraries, comparing sequencing of VH CDR3 of synthetic libraries and donor-
derived libraries with high and low number of donors, using the Illumina platform (That also have been 
used in this study). That study revealed that the synthetic libraries had many more unique clones 
compared with donor-derived libraries. In the donor libraries, the higher amount of donors lead to the 
higher amount of unique clones. (Ravn et al., 2013).  
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In this study, we analyzed the top ten distribution frequencies according to V genes and CDR3 for each 
individual patient sample. This revealed V gene sequences that were present in high copy number at 
high percentages from all sequences (cf. Figure 48).   In some patients there are V genes and CDR3 that 
are present in more than 40% of all sequences, and these are observed for HC and LC (κ & λ). Although, 
amplification biases during antibody library construction and during the NGS platform should always 
been considered (Fantini et al., 2017), this  distribution with dominant V genes over all unique genes 
that occurred in all patients could suggest clonal expansion within the infiltrated B cells source rater then 
a bias. This case, of high frequency of a single sequence as V gene or CDR3  fits to libraries after 
selection, as shown in previous studies (Ravn et al., 2013).  
Mated libraries TIL-B kappa and TIL-B lambda were also analyzed by NGS. As expected, both libraries 
presented more diversity as result of the patients’ libraries mixing before the yeast mating (cf. Appendix 
Figure 53 and 54). Interestingly, the V gene distribution after 2 distinct yeast mattings of the HC library 
once with the LCκ and once with the LC λ, resulted in quite similar patterns of distribution (cf. Figure 
50). This can be seen also in the strong linear correlation between the 2 HC V genes overlap plot (cf. 
Figure 49), indicating also for high efficiency of the mating process.  
6.2. Evaluation of the YSD TIL-B libraries with target-based screening and selection 
Although previous studies have demonstrated successful isolation of tumor infiltrating B derived 
antibodies binding to autologous tumor targets on cancer cells (Novinger et al., 2015; Pavoni et al., 
2007), only one study reported isolation of a ScFv anti-GD3 antibody fragment from phage display 
tumor infiltrating B cells derived library based on target-based screening to GD3 ganglioside (Kotlan 
et al., 2014) . Additionally, two studies demonstrated target-based screening of phage display libraries 
derived from invaded lymph nodes of a breast cancer patient, resulting in isolation of antibodies 
targeting Her-2 and CEA (Ayat et al., 2013b; Belimezi et al., 2006). In this study, comprehensive target-
based screening of two yeast Fab display TIL-B derived libraries (κ& λ) against a broad panel of defined 
tumor associated antigens (TAA) and immune checkpoint proteins was performed. Biotinylated 
recombinant soluble targets were incubated with the Fab displayed yeast cells, followed by staining 
with streptavidin allophycocyanin (APC) conjugate and were subjected to flow cytometry for binding 
evaluation. The tumor associated antigens panel were selected based on antigens that are overexpressed 
in colon cancer, such as EGFR (Harari, 2004), CEACAM5,6,1 (Heine et al., 2011), LRP6 (Rismani et 
al., 2017), DLK-1 (Yanai et al., 2010), C-MET (Su Jin Lee et al., 2018) and 5T4 (Starzynska et al., 
1994). The panel included also HER-2 that has low expression in colon cancer (Nathanson et al., 2003) 
and other antigens as TEM1 that displays elevated expression during tumor angiogenesis (Carson-
Walter et al., 2001) or membrane  GRP78 that is overexpressed under stress conditions of the tumor 
microenvironment (Ni, Zhang, & Lee, 2011). The panel of immune checkpoint molecules included 
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targets that are expressed on T cells such as PD-1, LAG3, CTL-4 and TIM3 and ones that are expressed 
on antigen-presenting cells and tumors such as PDL-1,CD200,OX40L and B7-H3 (Pardoll, 2012). 
Interestingly, the screening of both TIL-B libraries kappa and lambda indicated Fab displayed yeast-
cell binders to all tumor associated antigens resulting in total MFI above the background level (cf. 
Figure 12). Significant total MFI was observed from binders to 5T4 and LRP6 antigens in the TIL-B 
kappa library while in the TIL-B lambda library the most significant total MFI was observed with 
CEACAM5 and LRP6. These results align with the reported relatively high overexpression of 5T4, 
LRP6 and CEACAM5 in colon cancer. Conversely, screening for Her-2, which is known for its low 
expression in colon cancer, resulted in low total MFI in both libraries. Screening both libraries with 
immune checkpoint antigen targets resulted in in total MFI close to the background (cf. Figure 13). 
Here, significant total MFI was observed only from binders to OX40L and LAG-3 when screening the 
TIL-B kappa library. In the TIL-B lambda library most significant total MFI were observed from 
OX40L (LAG-3 was not screened). These are interesting observations, as LAG-3 is an immune 
checkpoint that is expressed on tumor infiltrating immune cells and was found to be significantly 
associated with a better disease-free survival (Soo Jung Lee et al., 2018). OX40L expression is 
upregulated in response to antigen presentation on multiple antigen-presenting cells (Webb, 
Hirschfield, & Lane, 2016).  
Based on the screening results, the two cancer associated antigens LRP6 and CEACAM5, as well the 
two immune checkpoints proteins OX40L and LAG3 were chosen for further high-throughput selection 
by fluorescence-activated cell sorting applying a multiparameter screening strategy  based on antigen 
binding and Fab display levels, to isolate human mAbs from the YSD TIL-B derived libraries. This 
YSD selection strategy has been reported in previous studies for isolation of high affinity mAbs to RTK 
, CEACAM5 and 6, where it was based on immune repertoires of transgenic rodents after immunization 
with the targeted antigen (Krah et al., 2017; Schröter et al., 2018). For all targets, enrichment was 
achieved during the sorting rounds. When monitoring binding of YSD clones during sorting rounds 
without adding the biotinylated antigen but only the SA-APC marker, enrichment of YSD clones to the 
SA-APC marker was observed. This binding explained previously as binding to the APC fluorophore 
is likely related to the presence of multiple epitopes on this large multimeric protein (Pape, Taylor, 
Maul, Gearhart, & Jenkins, 2011). The APC binders were eliminated by different strategies such as: 
replacing the secondary marker to SA-PE or SA-DyLight 633 during the sorting rounds. Selection of 
hOX40L-targeting antibodies was performed by five sorting rounds starting with 6.3 % YSD binders 
using 1µM hOX40L. The fifth round resulted with enrichment of YSD binders to 27.7 % using 0.25 
µM hOX40L (cf. Figure 14 and 15). From 95 enriched picked clones after sequencing and clustering, 
13 clones were identified as unique binders (cf. Table 6) . Selection of  LRP6-targeting antibodies was 
performed by five sorting rounds starting with 6.7 % YSD binders using 1µM hLRP6, the fifth round 
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resulted with enrichment of YSD binders to 41.1 % using 0.1 µM hLRP6 (cf. Figure 16 and 17). From 
20 clones after sequencing and clustering, 2 clones were identified as unique binders (cf. Table 7). 
Selection of hLAG3-targeting antibodies was performed by three sorting rounds starting with 0.5 % 
YSD binders using 1µM hLAG3.  The third round resulted in enrichment of YSD binders to 59.5 % 
using 0.25 µM hLAG3 (cf. Figure 18 and 19). From 95 clones after sequencing and clustering, 18 
clones were identified as unique binders (cf. Table 8).  
The Selection of hCEACAM5-targeting antibodies was performed using a different strategy: here prior 
to selection with FACS, selection by YSD biopanning was performed (cf. Figure 20), applying a YSD 
biopanning technique which was developed and described previously (Tillotson et al., 2013) (cf. Figure 
3) .The advantage here is the number of YSD cells that can be taken for the first round of selection,  
which is grater by one fold (~109) compared to the FACS sorting approach. The human gastric cancer 
derived cell line MKN-45, is known for its high expression of CEACAM5 on the cell surface (Alonso-
Camino et al., 2009). For depletion of non CEACAM5 binders, CEACAM5 CRISPR-Cas9 knockout 
MKN45 cells were constructed at ITL labs (data not shown ) using the CRISPR-Cas9 knockout 
technology (Ran et al., 2013) . Hence, depletion was conducted on cells that are identical to the selection 
strain, with the elimination of the target itself. After 5 rounds of YSD biopanning only 4.6 % of YSD 
cells were enriched for CEACAM5 binding indicating for insufficient depletion of non-CEACAM5 
binders. The biopanning enriched YSD then was subjected to selection by FACS. Here, selection of 
hCECAM5-targeting antibodies was performed in four sorting rounds starting with 8.7 % YSD binders 
using 1µM hCEACAM5, the fifth round resulting in enrichment of YSD binders to 12.1 % when using 
0.25 µM hCEACAM5 (cf. Figure 22). From 10 clones after sequencing and clustering, 2 clones were 
identified as unique binders (cf. Table 9). 
The variable regions of the unique Fab displayed clones from all four campaigns were subcloned into 
mammalian expression DNA vectors, to obtain soluble expression of full-length IgG1. Using biolayer 
interferometry (BLI) assay, the full-length IgG1 antibody is first captured on anti-human Fc biosensors 
followed by association of the corresponding soluble recombinant antigen protein (OX40L, 
LAG3,LRP6 and CEACAM5) resulted in no wavelength shift at the association step in all campaigns 
(cf. Figure 28,30,32 and 34). This can be due to loss of binding to the corresponding antigen while 
reformatting from yeast to mammalian expression, or due to the fact that the antibodies are low affinity 
antibodies with affinity below the assay’s limit of detection.  As the full-length IgG1antibody is 
bivalent, in solution it can potentially interact with two antigen molecules that are immobilized to a 
surface leading to an “avidity affect“ which may result in artificially higher affinity measurements 
(Tobias & Kumaraswamy, 2013). Therefore, using BLI in a different orientation, where a biotinylated 
antigen is immobilized to the streptavidin biosensors surface, followed by adding the antibodies in 
solution, may reveal low affinity antibodies. Using this BLI strategy, a wavelength shift was detected 
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at the association step when adding the corresponded antibodies to the biotinylated immobilized 
antigens in all campaigns, indicating specific binding of the antibodies but with low affinity to the 
antigen that can be estimated in a range of micromolar (cf. Figure 29,31,33 and 35). 
As the study confirms specific binding of the isolated reformatted IgG1 antibodies, the reason for their 
low affinity antibody is interesting. Enrichment of low affinity antibody clones from a yeast display 
library during selection with FACS was reported previously (Feldhaus et al., 2003). Yeast display 
library cells can display approximately 104 – 105 fusion proteins on each yeast cell surface. Multi-copy 
display of Fab fragments on yeast surface could enable multivalent interactions, and an increased 
propensity for multivalent binding by some library clones could lead to recovery of high avidity binders 
lacking high affinity to the antigen (Boder et al., 2012). While considering the immunoglobulin source 
in tumor infiltrating B cells, it is still debatable if those autoantibodies against self-antigens (like those 
screen in this study) can show very high affinity binding and be involved with the killing of tumor cells 
or their occurrence in the tumor microenvironment is due to antigen presentation but does not lead to 
generation of high affinity antibodies (Coronella-Wood & Hersh, 2003; Iglesia et al., 2014; Tsou, 
Katayama, Ostrin, & Hanash, 2016). On the other hand, as specificity was identified with all the isolated 
antibodies, it may be argued that the low affinity antibodies are a result of the YSD libraries construction 
strategy. As the heavy and light chains are shuffled in the antibody yeast display libraries, displayed 
antibodies may not recapitulate the original B cell heavy and light chain combinations. In this study the 
heavy chain immunoglobulin source for constructing the libraries was restricted to be only IgG isotope 
by amplifying the variable regions starting from IgG constant regions in order to select the IgG class-
switched B cell population. The light chain immunoglobulin source cannot be restricted to IgG class 
and could be selected with any type of B cell including ones that did not undergo antigen mediated 
selection. Moreover, before yeast mating, heavy chain libraries from all patients were mixed. This was 
also done for the light chain libraries, lowering the probability for original paring of heavy and light 
chains (Marks et al., 1991).     
6.3.   Evaluation of the YSD TIL-B libraries using biopanning on colon cancer derived cell lines 
Evaluation of the YSD TIL-B libraries by target-based screening resulted in isolation of specific but 
low affinity antibodies to the screened targets. This strategy is limited to the target we select for the 
screening. Moreover, screening of targets as soluble recombinant proteins when actually they are 
membrane bound in their native state in the tumor, could lead to missing out on antibodies that only 
bind effectively to targets expressed on the intact cells in their  native conformation  (Stern et al., 
2016).Therefore, phenotypic screening on intact mammalian cancer cells which present a broad 
repertoire of cancer associated antigens on their surface in their native confirmation could be a better 
strategy for evaluation of the TIL-B derived libraries. Due to this, in this study, we also evaluated the 
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colon cancer patients’ TIL-B derived YSD libraries by using the YSD biopanning method on human 
colon cancer derived cell lines. While  previous studies have been reported to isolate successful 
antibodies from naïve YSD libraries targeting a verity of  mammalian cell lines (Dangaj et al., 2013; 
Wang et al., 2007; Williams et al., 2014; Zorniak et al., 2017), this is the first study to our knowledge 
to  use TIL-B YSD libraries with the biopanning method.    
As the immunoglobulin sources of the YSD libraries are derived from tumor infiltrating B cells of colon 
cancer patients, the strategy for the libraries evaluation was to use the YSD biopanning platform against 
corresponded colon cancer derived cell lines. For that, 3 distinct colon cancer derived cell lines were 
chosen: The colorectal carcinoma derived cell line HCT 116, which are a colorectal adenocarcinoma 
derived cell line HT-29, and SW620 which is colorectal adenocarcinoma derived cell line from a 
metastatic lymph node site. To isolate antibodies to cancer associated antigens, the CCD-18Co normal 
colon fibroblast cell line was used as negative cells for depletion of colon normal cell binders. Increased 
binding of YSD to all HCT 116, HT-29 and SW620 cell surface was microscopically observed after 3 
rounds of biopanning (cf. Figure 36, 37, and 38). Next, a binding profile analysis of the biopanning 
enriched YSD clones of the three biopanning approaches was done on a broad panel of 12 distinct cell 
lines. This included the cell line the YSD cells were panned against, cells from other cancer types, the 
normal colon cell line and the Chinese hamster ovary derived cell line (CHO-S1). Interestingly, after 4 
biopanning rounds the YSD clones that were enriched on the colorectal carcinoma derived cell line 
HCT116, showed high binding also to the colorectal adenocarcinoma derived cell line HT-29 and to the 
gastric adenocarcinoma derived cell line MKN45. YSD clones that were enriched on HT-29 cell line 
showed high binding to the HCT 116 cell line and MKN 45 cell line. In both biopanning schemes, 
binding to other cancer derived cell lines was negative or low. No binding was observed to the normal 
colon cell line and the CHO-S1 cell line which is as we expected. These results indicate that the binding 
profile is selective when clones from the same library were enriched for epitope targets that are 
expressed only on colorectal cancer derived cell lines (HCT116 and HT-29) and on the gastric cancer 
derived cell line (MKN45). Moreover, YSD clones that were enriched on the colorectal adenocarcinoma 
metastatic lymph node site cell line SW620 showed a different profile of binding with high binding 
observed on all mammary gland adenocarcinoma derived cell lines (MB468 ,MCF7 and  SKBR3) and 
to the HT-29 cell line. As the SW620 colorectal adenocarcinoma are metastatic derived cells they may 
display a different membrane protein expression. The different binding profile of the enriched YSD that 
was observed indicates again for selective enrichment. 
As the biopanning enriched clones on HCT 116 and HT-29 shared the same binding profile, for further 
characterization 48 YSD clones were picked and clustered by their VH and VL sequences. The 
clustering analysis reviled 13 unique YSD clones from the biopanning enriched HCT 116 cell line 
clones and 10 unique yeast clones from the biopanning enriched HT-29 clones. Interestingly, 3 unique 
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yeast clones selected from the two distinct biopanning approaches (HCT 116 and HT-29) were found 
to be the same clones (cf. Table 10). Binding analysis of the 20 unique clones resulted in 12 clones that 
specifically bound to the colorectal carcinoma derived HCT 116 cells. No binding was observed to 
MCF7, CHO-S1 cells and to normal colon fibroblasts cells (cf. Figure 42 and Table 11) .Variable 
region subcloning of the unique YSD clones resulted in soluble expression of full-length IgG1 
antibodies. Cellular binding analysis by flow cytometry resulted in 6 antibodies that bind to the HCT 
116 cells (cf. Figure 43). When looking at the 12 antibody sequences by multiple alignment analysis 
(cf. Figure 44) the reason for the variation in binding of the antibodies could be hypothesized. The VH 
sequence multiple alignment reviled that out of 12 antibodies 11 have the same CDR3 and very high 
identity to each other. On the other hand, multiple alignment of the VL sequences showed high variation 
in CDR3 and in other segments of the different antibodies variable region (such as framework regions). 
It has been reported previously, that the heavy chain CDR3 is the region responsible for antigen 
recognition (Wine et al., 2013) and it is well known from affinity maturation experiments that the 
affinities of antibodies with identical HCDR3s may differ by up to 100-fold when they have different 
light chains (Marks et al., 1991; Schier et al., 1996; Yang et al., 1995). Consequently, it can be 
concluded that probably all selected antibodies share the same epitope binding, directed by the heavy 
chain, but the binding affinity is determined by the light chain.  
As discussed previously, the phenomenon in which binding of antibodies to cells observed in YSD Fab 
format but not as soluble full-length IgG1 antibodies, is due to an avidity effect of the YSD fab clones 
(Boder et al., 2012). The multivalent binding resulted in our incapability to differentiate between 
binding affinity of the selected YSD Fab clones, as all seemed phenotypically to be strong binders under 
the microscope (cf. Figure 42). This aspect should be considered in further studies involving YSD 
biopanning. 
For further characterization, TILB-HCT116-B24 mAb which shows positive binding to HCT 116 cells 
in crude medium was purified. A cellular binding assay to HCT 116 cells using flow cytometry with a 
two-fold serial dilution of the mAb (2000 nM-0.98 nM) resulted in a dose response curve with EC50 
value of 569 nM (cf. Figure 44). A cellular binding assay using fluorescence microscopy with TILB-
HCT116-B24 mAb to HCT 116 cells and normal colon fibroblast cells (CCD-18Co) showed specific 
binding to HCT 116 cells and no binding to the normal cells were observed (cf. Figure 45). This result 
supports the hypothesis of this study, that tumor infiltrating B cells can be a source for selective 
antibodies to antigens expressed on cancer cells.   
6.4. Combining high-throughput sequencing and YSD biopanning screening    
In order to comprehensively access the full potential of a given natural or recombinant antibody library 
usually in the range of 106–1011 clones, diversity has to be significantly reduced for high‐throughput 
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sequencing to be able to provide a meaningful in‐depth view of potential antigen‐specific library 
variants (Glanville et al., 2015). Hence, the YSD biopanning process could be ideal for combining with 
new generation sequencing (NGS). After few biopanning rounds of the YSD library all antibody 
sequences based on phenotypic binding to the antigen should ideally be observed multiple times in the 
sequencing data sets (with ~ 106 reads). Therefore, when analyzing by NGS a YSD library after 
biopanning against antigens presenting on certain cell could revile an accurate selective- binding profile of 
the enriched VH and VL sequences. This tool can be used for example to compare the binding profile of a 
YSD library after biopanning against different cancer cell lines. To our knowledge, this is the first study 
to combine YSD biopanning selection with NGS analysis.  
The fourth round biopanning outcome of clones that were enriched on HCT 116, HT-29 and SW620 
were NGS analyzed for their VH VL sequences. This analysis revealed a deeper understanding of the 
biopanning and clone selection process. When we picked 48 YSD clones from each biopanning 
enrichment on HCT 116 and HT-29 cells and Sanger-sequenced them, we found 10 unique clones for 
each approach (cf. Table 15). This is about 1% of the number of unique sequences diversity obtained 
from the biopanning enriched libraries (cf. Table 14). However, looking at the unique clones that were 
identified, from 12 clones 11 shared the same VH gene combination with CDR3 in the VH sequences 
while different VL identified in all clones. This is not surprising as the NGS analysis revealed that the 
frequency of the HC sequence is 92.6 % while much more diversity in frequency was detected in the 
VL sequences (<0.5-28%) (cf. Appendix Figure 55 and 56). This reinforces the hypothesis of high 
selective enrichment through the heavy chain antigen recognition site to specific epitopes.   
Moreover, a stronger argument to this selective enrichment was revealed by overlapping the unique 
clones’ sequences of the VH and VL sequences between the 3 biopanning approaches (cf. figure 51 
and 52). Interestingly, the outcome of the 2 independent biopanning selections of the same library on 
2 colorectal epithelial derived cell lines HCT116 and HT-29 resulted with very high correlation when 
overlapping the unique VH genes combined with CDR3 sequences of both biopanning outcome. 
However, when overlapping the SW620 biopanning sequences, no significant correlation was observed 
to HCT116 and HT-29 biopanning sequences (cf. figure 52). This can be explained by the different 
source of the cells, as this cell line is derived from the lymph node metastatic site of a colorectal cancer 
patient and apparently is displaying a distinct antigen surface expression. VL genes sequences revealed 
some correlation between biopanning HCT116 and HT-29 outcomes in low frequencies but not 
significant as the VH sequences (cf. figure 53). As discussed before, this selective binding through the 
heavy chain can be a result of the library construction strategy that restricted the heavy chain to the IgG 
class-switched B cell population. 
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This study supports the hypothesis that tumor infiltrating B cells (TIL-B) derived libraries contain a 
repertoire of antibodies that can bind preferentially to cancer cells. These antibodies can help  us better 
understand the innate immunity of cancer and may be a potential source of antibodies for cancer therapy.     
 
 
 
6.5. Outlook 
Further evaluation is needed for characterization and antigen identification of the isolated TILB-HCT116-
B24 mAb. Since the YSD cells expressing multi-copies of Fab fragments bind antigens with high avidity, 
this technique can be used to capture and isolate target antigens by yeast display immunoprecipitation 
(Tillotson et al., 2013). The outcome of this study may lead to implementation of new approaches for 
constructing TIL-B derived display libraries such as utilize tumor infiltrating memory or plasma B cells as 
the source of antibody immunoglobin of the displayed library. Deep sequencing of the libraries before and 
after biopanning proved to be a useful tool for understanding the selection process and can be used for 
establishing new strategies for isolating antibodies by combining NGS with YSD biopanning. 
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8.1. Supporting Information 
The NGS analysis report for TIL-B κ and TIL-B λ libraries and biopanning enriched pools: TIL-B 
HCT116, TIL-B HT29 and TIL-B SW620 are depicted in Figure 53-57. The report includes a table 
showing the frequency distribution of the top sequences, a graph showing the V gene distribution and a 
graph showing the CDR3 read length distribution of the VH and VL or VK genes.  
 
 
Figure 53: NGS report summary for the TIL-B κ library. 
(A) Top sequences frequency distribution of VH genes and CDR3 (B) Top sequences frequency distribution of VK genes and 
CDR3 (C) VH genes distribution (D) VK genes distribution (E) CDR3 length distribution of VH genes (F) CDR3 length 
distribution of VK genes 
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Figure 54: NGS report summary for the TIL-B λ library.  
(A) Top sequences frequency distribution of VH genes and CDR3 (B) Top sequences frequency distribution of VL genes and 
CDR3 (C) VH genes distribution (D) VL genes distribution (E) CDR3 length distribution of VH genes (F) CDR3 length 
distribution of VL genes 
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Figure 55: NGS report summary for the biopanning pool TIL-B HCT 116.  
(A) Top sequences frequency distribution of VH genes and CDR3 (B) Top sequences frequency distribution of VK genes and 
CDR3 (C) VH genes distribution (D) VK genes distribution (E) CDR3 length distribution for VH genes (F) CDR3 length 
distribution of VK genes 
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Figure 56: NGS report summary for the biopanning pool TIL-B HT-29. 
(A) Top sequences frequency distribution of VH genes and CDR3 (B) Top sequences frequency distribution of VK genes and 
CDR3 (C) VH genes distribution (D) VK genes distribution (E) CDR3 length distribution of VH genes (F) CDR3 length 
distribution of VK genes 
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Figure 57: NGS report summary for the biopanning pool TIL-B SW620. 
(A) Top sequences frequency distribution of VH genes and CDR3 (B) Top sequences frequency distribution of VK genes and 
CDR3 (C) VH genes distribution (D) VK genes distribution (E) CDR3 length distribution of VH genes (F) CDR3 length 
distribution of VK genes 
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8.2. Abbreviations 
 
aa Amino acid 
ADC Antibody-drug conjugate 
ADCC antibody-dependent cellular cytotoxicity  
AHC Anti-human Fc biosensor 
AID Activation-induced cytidine deaminase  
Amp Ampicillin 
APC Allophycocyanin 
BCR B cell-receptor 
BLI Biolayer interferometry 
bp Base pair 
BSA Bovine serum albumin 
CCR4 CC chemokine receptor 4 
CDC complement-dependent cytotoxicity  
cDNA Complementary DNA 
CDR Complementary determining regions  
CEA  Carcinoembryonic antigen 
CEACAM1,5,6 Carcinoembryonic antigen-related cell adhesion molecule 1,5,6 
CH1, CH2, CH3 Constant domain 1, 2 and 3 of the heavy chain 
C-Met Tyrosine-protein kinase Met 
CTL4 Cytotoxic T-lymphocyte-associated protein 4 
Da Dalton 
dH20 Distilled water 
DLK1 Protein delta homolog 1 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleotide triphosphate 
DO  Dropout 
E. coli Escherichia coli 
EC50 Half maximal effective concentration 
ECD Extracellular domain  
EGFR Epidermal growth factor receptor 
Fab  Fragment antigen-binding 
FACS fluorescence-activated cell sorting  
FBS Fetal bovine serum 
Fc Fragment crystallizable  
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FcγR Fcγ receptor 
FDA Food and Drug Administration  
FDCs Follicular dendritic cells 
FITC Fluorescein 
FR framework regions  
GAL1 Galactose 1 promoter  
H Hour 
HC  Heavy chain 
HER2 human epidermal growth factor receptor 2 
His-tag Histidine tag, usually composed of six histidines 
HIV-1 Human immunodeficiency virus-1 
h- Human  
Ig Immunoglobulin 
KB Kinetics buffer 
LAG3 Lymphocyte-activation gene 3 
LB medium Luria-Bertani medium 
LC Light chain 
Leu Leucine 
LRP6 Low-density lipoprotein receptor-related protein 6 
mAbs Monoclonal antibodies  
MCS Multiple cloning site 
MFI Mean fluorescence intensity 
MoA Mechanisms of action  
mRNA Messenger ribonucleic acid 
MSA Multiple sequence alignment 
MWCO Molecular weight cut-off 
NGS Next-generation sequencing  
NK cells Natural killer cells 
OD Optic density 
OX40L  OX40 ligand 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD1 Programmed cell death protein 1 
PDB Protein Data Bank 
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PDGFRα Platelet-derived growth factor receptor α 
PDL-1 Programmed death-ligand 1  
PE R-phycoerythrin 
RINe RNA integrity number equivalent  
RNA Ribonucleic acid 
RNKL Receptor activator of nuclear factor kappa-Β ligand 
rpm Revolutions per minute 
RT Room temperature 
S. cerevisiae  Saccharomyces cerevisiae 
SA Streptavidin 
scFv Single-chain variable fragment 
SD Synthetic defined 
sec second 
SLAMF7 SLAM family member 7 
SN Sentinel lymph node  
TAA Tumor-associated antigens  
TCR T-cell receptor 
TIL-B Tumor infiltrating B cells  
TILs Tumor infiltrating lymphocytes 
Tim-3 T-cell immunoglobulin and mucin-domain containing-3 
TLS Tertiary lymphoid structures  
Tris Tris(hydroxymethyl)aminomethane 
Trp Tryptophan 
v/v Volume per volume 
VEGF  Vascular endothelial growth factor 
VH Variable domain of the heavy chain 
VL Variable domain of the light chain 
w/v Weight per volume 
YPD Yeast extract peptone dextrose 
YSD Yeast surface display 
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